"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOUSSN_VITTORIOEMANUELE",2000,5,4.2,2.4,0.6,0.6,1,1.09090909090909,0.75,1,0.833333333333333,0,0,2,0,0,3,0.4,0,0,0.6,2.4,0.0529439276620069,NA,0,0.6,0.257,0.167,0.167,0.15,"GIUSEPPE MORGIA;MASSIMO MADONIA;MARIO FALSAPERLA;P GANGEMI;GIUSEPPE ARENA;S. AMBROSINI;S CASCHETTO;G GAROZZO;P. SCARINGELLA;P CONSALVO;L. FATA;TORRISI AM;MAURO ABBATE;AGOSTINO DI CIAULA;NICOLA SILVESTRIS;L CARAGLIANO;ADRIENNE PRATTI LUCARELLI","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","GIUSEPPE ARENA;GIUSEPPE MORGIA;MAURO ABBATE;MASSIMO MADONIA;MARIO FALSAPERLA;P GANGEMI;S CASCHETTO;G GAROZZO;P CONSALVO;TORRISI AM;L CARAGLIANO;S. AMBROSINI;P. SCARINGELLA;L. FATA;AGOSTINO DI CIAULA;NICOLA SILVESTRIS;ADRIENNE PRATTI LUCARELLI","0.5;0.5;0.5;0.5;0.5;0.5;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17","GIUSEPPE MORGIA;MASSIMO MADONIA;MARIO FALSAPERLA;P GANGEMI;GIUSEPPE ARENA;S. AMBROSINI;G GAROZZO;P. SCARINGELLA;L. FATA;AGOSTINO DI CIAULA;ADRIENNE PRATTI LUCARELLI","2;2;2;2;1;1;1;1;1;1;1","GIUSEPPE ARENA;GIUSEPPE MORGIA;MASSIMO MADONIA;MARIO FALSAPERLA;P GANGEMI;G GAROZZO;S. AMBROSINI;P. SCARINGELLA;L. FATA;AGOSTINO DI CIAULA;ADRIENNE PRATTI LUCARELLI","0.5;0.5;0.5;0.5;0.5;0.2;0.17;0.17;0.17;0.17;0.17","GIUSEPPE ARENA;MAURO ABBATE;G GAROZZO;L CARAGLIANO;P CONSALVO;S CASCHETTO;TORRISI AM;ADRIENNE PRATTI LUCARELLI;AGOSTINO DI CIAULA;GIUSEPPE MORGIA;L. FATA;MARIO FALSAPERLA;MASSIMO MADONIA;NICOLA SILVESTRIS;P GANGEMI;P. SCARINGELLA;S. AMBROSINI","8;8;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","GIUSEPPE ARENA;G GAROZZO;ADRIENNE PRATTI LUCARELLI;AGOSTINO DI CIAULA;L. FATA;P GANGEMI;P. SCARINGELLA;S. AMBROSINI;GIUSEPPE MORGIA;MARIO FALSAPERLA;MASSIMO MADONIA","8;2;1;1;1;1;1;1;0;0;0","P GANGEMI;ADRIENNE PRATTI LUCARELLI;AGOSTINO DI CIAULA;G GAROZZO;GIUSEPPE ARENA;L. FATA;P. SCARINGELLA;S. AMBROSINI;GIUSEPPE MORGIA;MARIO FALSAPERLA;MASSIMO MADONIA","2;1;1;1;1;1;1;1;0;0;0","MEDICINE;BIOLOGY","5;1","INTERNAL MEDICINE;PATHOLOGY;ONCOLOGY;CARDIOLOGY;PALEONTOLOGY;PSYCHIATRY;SURGERY","5;4;3;1;1;1;1","CANCER;ADJUVANT;CHEMOTHERAPY;RADIATION THERAPY;SARCOMA;ANGIOGENESIS;ARTERY;ASYMPTOMATIC;CALCIUM;CARCINOMA;CENTRAL NERVOUS SYSTEM;CONSERVATIVE TREATMENT;DISEASE;IMMUNOHISTOCHEMISTRY;MALIGNANCY;MYOCARDIAL INFARCTION;NERVOUS SYSTEM;RECEPTOR;STAGE (STRATIGRAPHY)","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADJUVANT RADIOTHERAPY;BREAST CANCER;RHABDOMYOSARCOMA;ANTAGONIST;CALCIUM CHANNEL BLOCKER;CERVICAL CANCER;NEOVASCULARIZATION;RADIAL ARTERY;REVASCULARIZATION;STROMA","2;2;2;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY","2","UTERINE CERVICAL NEOPLASMS;HUMANS;;CALCIUM CHANNEL BLOCKERS;CORONARY ARTERY BYPASS;PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;POSTOPERATIVE CARE;RADIAL ARTERY;DIAGNOSIS, DIFFERENTIAL;FEMALE;NEOPLASM STAGING;NEOVASCULARIZATION, PATHOLOGIC;PROGNOSIS;SURVIVAL RATE","5;3;2;2;2;2;2;2;1;1;1;1;1;1","SARCOMA RESEARCH AND TREATMENT;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;CANCER OF UNKNOWN PRIMARY SITE;TREATMENT AND MECHANISMS OF COMPLEX PAIN SYNDROMES","2;1;1;1","ADJUVANT CHEMOTHERAPY;ADJUVANT RADIOTHERAPY;RHABDOMYOSARCOMA;ANGIOGENIC SIGNALING;ANTI-ANGIOGENIC THERAPY;CALCIUM CHANNEL BLOCKER;CARDIOVASCULAR EVALUATION;CONSERVATIVE TREATMENT;PARANEOPLASTIC SYNDROMES;TREATMENT;TUMOR ANGIOGENESIS","2;2;2;1;1;1;1;1;1;1;1","PROSTATIC RHABDOMYOSARCOMA;ANTAGONIST ADMINISTRATION;AORTOCORONARY BYPASS;CALCIUM ANTAGONIST;CENTRAL NERVOUS;CERVICAL CARCINOMA;IB-IIB CERVICAL;NERVOUS SYSTEM;PARANEOPLASTIC SYNDROMES;RADIAL ARTERY;STAGE IB-IIB","2;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2001,3,6.33333333333333,2.66666666666667,0.666666666666667,0.333333333333333,0.666666666666667,1,0.666666666666667,0.5,0.666666666666667,0.333333333333333,0,0,0,0,2,0,0,0,0.67,3,0.0656563913148538,NA,0,0.333333333333333,0.016,0,0,0,"ROBERTO PERRIS;ROSARIO FOTI;GAETANO MAGRO;ROSALIA LEONARDI;GIOVINETTO RM;MARIA MARCELLO;PIETRO CASTELLINO;CAMERON INCOGNITO;G BENFATTO;S FAGONE;A GIOVINETTO;MARIA MANUEL LOPES;L BONINCONTRO;ROSA ROMEO;F CATALANO;LICARI;G CATANIA;SEBASTIANO GRASSO;ENRICO VASQUEZ","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ROSARIO FOTI;ROSALIA LEONARDI;GIOVINETTO RM;PIETRO CASTELLINO;CAMERON INCOGNITO;G BENFATTO;S FAGONE;A GIOVINETTO;L BONINCONTRO;F CATALANO;LICARI;G CATANIA;ROBERTO PERRIS;GAETANO MAGRO;MARIA MARCELLO;MARIA MANUEL LOPES;ROSA ROMEO;SEBASTIANO GRASSO;ENRICO VASQUEZ","0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.14","ROSARIO FOTI;ROSALIA LEONARDI;PIETRO CASTELLINO;CAMERON INCOGNITO;G BENFATTO;S FAGONE;MARIA MANUEL LOPES;L BONINCONTRO","1;1;1;1;1;1;1;1","ROSARIO FOTI;ROSALIA LEONARDI;PIETRO CASTELLINO;CAMERON INCOGNITO;G BENFATTO;S FAGONE;L BONINCONTRO;MARIA MANUEL LOPES","0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14","ENRICO VASQUEZ;GAETANO MAGRO;MARIA MANUEL LOPES;MARIA MARCELLO;ROBERTO PERRIS;ROSA ROMEO;SEBASTIANO GRASSO;A GIOVINETTO;CAMERON INCOGNITO;F CATALANO;G BENFATTO;G CATANIA;GIOVINETTO RM;L BONINCONTRO;LICARI;PIETRO CASTELLINO;ROSALIA LEONARDI;ROSARIO FOTI;S FAGONE","9;9;9;9;9;9;9;0;0;0;0;0;0;0;0;0;0;0;0","MARIA MANUEL LOPES;CAMERON INCOGNITO;G BENFATTO;L BONINCONTRO;PIETRO CASTELLINO;ROSALIA LEONARDI;ROSARIO FOTI;S FAGONE","9;0;0;0;0;0;0;0","MARIA MANUEL LOPES;CAMERON INCOGNITO;G BENFATTO;L BONINCONTRO;PIETRO CASTELLINO;ROSALIA LEONARDI;ROSARIO FOTI;S FAGONE","1;0;0;0;0;0;0;0","MEDICINE;BIOLOGY","2;1","ANATOMY;SURGERY;CELL BIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;INTERNAL MEDICINE","2;2;1;1;1;1;1;1","ABDOMINAL PAIN;ADRENAL INSUFFICIENCY;APONEUROSIS;CELL;FASCIA;GENE;HERNIA;IMMUNOHISTOCHEMISTRY;KIDNEY;LUMBAR;MEDIUS;PALPITATIONS;THROMBOSIS;THYROID;VOMITING","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIPHOSPHOLIPID SYNDROME;CYTOSKELETON;EMBRYONIC STEM CELL;EUTHYROID;GLOMERULUS;MESONEPHRIC DUCT;VIMENTIN;ZEBRAFISH","1;1;1;1;1;1;1;1","INTERMEDIATE FILAMENT;MESONEPHROS;PRONEPHROS","1;1;1","KIDNEY GLOMERULUS;KIDNEY TUBULES, DISTAL;KIDNEY TUBULES, PROXIMAL;MESONEPHROS;MUSCLE, SMOOTH;NEPHRONS;ACTINS;ADULT;HUMANS;KERATINS;LUMBOSACRAL REGION;VIMENTIN;;FEMALE;HERNIORRHAPHY;IMMUNOHISTOCHEMISTRY;MALE;PHENOTYPE;PREGNANCY;RECURRENCE","3;3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","GENETIC BASIS OF NEUTROPENIA DISORDERS;HERNIA REPAIR TECHNIQUES AND MATERIALS;SEX DETERMINATION AND DIFFERENTIATION IN ORGANISMS","1;1;1","ADRENAL INSUFFICIENCY;APONEUROSIS;FETAL TESTOSTERONE;GLOMERULUS;HERNIA REPAIR;HYPOTHALAMIC-PITUITARY-ADRENAL AXIS DYSFUNCTION;INTERMEDIATE FILAMENT PROTEIN;MEDIUS;MESONEPHRIC DUCT;MESONEPHROS;PALPITATIONS;PRONEPHROS;PROSTHETIC MESH","1;1;1;1;1;1;1;1;1;1;1;1;1","AB ADRENAL;ADRENAL INSUFFICIENCY;ALPHA-SMOOTH MUSCLE;ANTIBODY SYNDROME;ANTIPHOSPHOLIPID ANTIBODY;AUTOIMMUNE HYPOTHYROIDISM;COMPARATIVE IMMUNOHISTOCHEMICAL;CYTOKERATINS VIMENTIN;FOETAL MESONEPHROS;HUMAN FOETAL;IMMUNOHISTOCHEMICAL ANALYSIS;INSUFFICIENCY PRIMARY;MUSCLE ACTIN;PETITS TRIANGLE;PRIMARY ANTIPHOSPHOLIPID;RECURRENT HERNIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADRENAL INSUFFICIENCY;CONNECTIVE TISSUE;FEMORAL VEIN;TISSUE DISEASE;ABDOMINAL PAIN;ACTH CONCENTRATION;ACTH TEST;ADRENAL CORTEX;ADRENAL FAILURE;ADRENAL GLAND;ADRENAL GLANDS;ADRENAL INFARCTION;ADRENAL VEIN;AI SECONDARY;ALDOSTERONE LT;ANA DSDNA;ANOREXIA VOMITING;ANTHIPOSPHOLIPID SYNDROME;ANTIBODIES IGG;ANTIBODY SYNDROME;ANTIPHOSPHOLIPID ANTIBODIES;ANTIPHOSPHOLIPID ANTIBODY;AUTOIMMUNE HYPOTHYROIDISM;AUTOIMMUNE THYROID;BILATERAL ADRENAL;BILATERAL ENLARGED;BIOCHEMICAL STATUS;BLOOD PRESSURE;CHEST RADIOGRAPH;CONCENTRATION MGDL","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2002,1,4,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0.0181262166658808,NA,1,1,0,0,0,0,"M. CUMO;FRANCESCO D’ANNIBALE;GIAN PIERO CELATA;AKIO TOMIYAMA","1;1;1;1","M. CUMO;FRANCESCO D’ANNIBALE;GIAN PIERO CELATA;AKIO TOMIYAMA","0.25;0.25;0.25;0.25","M. CUMO","1","M. CUMO","0.25","AKIO TOMIYAMA;FRANCESCO D’ANNIBALE;GIAN PIERO CELATA;M. CUMO","1;1;1;1","M. CUMO","1","M. CUMO","1","COMPUTER SCIENCE;PHYSICS","1;1","MECHANICS;THERMODYNAMICS","1;1","BUBBLE;COMPONENT (THERMODYNAMICS);WAKE","1;1;1","","","","","","1","TURBULENT INTERACTIONS WITH DISPERSED PARTICLES AND DROPLETS","1","BUBBLE COLUMN REACTORS;COMPONENT (THERMODYNAMICS);MIXING EFFICIENCY;SCALE-UP;TURBULENCE;TWO-PHASE FLOW","1;1;1;1;1;1","BUBBLE RISING;ONE-COMPONENT SYSTEMS;RISING VELOCITY;WAKE EFFECT","1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2003,8,6.75,1.625,0.5,0.5,0.375,1.3,0.8,1,0.75,0,0,1,1,4,2,0.12,0.12,0.5,0.25,21.88,0.413298077040549,NA,0,0.625,0.366,0.15,0.167,0,"GAETANO MAGRO;MARCO COSENTINO;VIVIANA COSENTINO;MARIA MANUEL LOPES;DALLA PP;GUERRINO ZUIN;CARMELO MADIA;SALVATORE PENNISI;A CIRCO;A L DISTEFANO;EGARTER VIGL E;P CAGLIÀ;DAVIDE D’AMICO;S CASCHETTO;MASSIMO RAPATI;F CASASSA;FULVIO BELLOCCI;P. PENNISI;MASSIMILIANO VEROUX;CESARE RUFFOLO","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GAETANO MAGRO;FRANCESCO FIORINO;MARCO COSENTINO;VITTORIO COLLETTI;VIVIANA COSENTINO;MARIA MANUEL LOPES;A L DISTEFANO;S CASCHETTO;P. PENNISI;STEFANIA RICCOBENE;C. E. FIORE;SALVATORE PENNISI;ALFIO LA FERLA;BENEDETTA XIMENES;ROSAMARIA ROSSO;VIVIANA FRONTINI;MARIA GABRIELLA FERRO;TURIDDU LOMBARDO;CARMELO MADIA;P CAGLIÀ","0.5;0.5;0.5;0.5;0.5;0.5;0.2;0.2;0.2;0.2;0.2;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.11;0.11","MARCO COSENTINO;VIVIANA COSENTINO;MARIA MANUEL LOPES;SALVATORE PENNISI;A CIRCO;MASSIMILIANO VEROUX;A QUACECI;VITTORIO COLLETTI;C. E. FIORE;P GANGEMI","2;2;2;1;1;1;1;1;1;1","MARCO COSENTINO;VITTORIO COLLETTI;VIVIANA COSENTINO;MARIA MANUEL LOPES;C. E. FIORE;SALVATORE PENNISI;MASSIMILIANO VEROUX;A CIRCO;A QUACECI;P GANGEMI","0.5;0.5;0.5;0.5;0.2;0.14;0.11;0.09;0.08;0.08","A CIRCO;ATTILIO MASERI;FRANCESCO DI PEDE;FULVIO BELLOCCI;GAETANO ANTONIO LANZA;GUERRINO ZUIN;MASSIMO RAPATI;MASSIMO ROMANÒ;MASSIMO SANTINI;OTTAVIO ALFIERI;PAOLA CARDANO;FRANCESCO FIORINO;VITTORIO COLLETTI;A BUFFONE;CARMELO MADIA;CESARE RUFFOLO;DAVIDE D’AMICO;IMERIO ANGRIMAN;MASSIMILIANO VEROUX;MICHELA BAROLLO","85;85;85;85;85;85;85;85;85;85;85;44;44;18;18;18;18;18;18;18","A CIRCO;VITTORIO COLLETTI;MASSIMILIANO VEROUX;C. E. FIORE;SALVATORE PENNISI;A QUACECI;MARCO COSENTINO;MARIA MANUEL LOPES;P GANGEMI;VIVIANA COSENTINO","85;44;18;15;13;0;0;0;0;0","A CIRCO;C. E. FIORE;MASSIMILIANO VEROUX;SALVATORE PENNISI;VITTORIO COLLETTI;A QUACECI;MARCO COSENTINO;MARIA MANUEL LOPES;P GANGEMI;VIVIANA COSENTINO","1;1;1;1;1;0;0;0;0;0","MEDICINE;BIOLOGY;BUSINESS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;GEOGRAPHY;PHYSICS;POLITICAL SCIENCE","8;2;1;1;1;1;1;1;1","SURGERY;INTERNAL MEDICINE;PATHOLOGY;RADIOLOGY;ANATOMY;ASTROBIOLOGY;AUDIOLOGY;CARDIOLOGY;CARTOGRAPHY;ENDOCRINOLOGY;FINANCE;GASTROENTEROLOGY;GENETICS;LAW;MANAGEMENT;MECHANICAL ENGINEERING;MEDICAL PHYSICS;OBSTETRICS;OPERATING SYSTEM;OPERATIONS MANAGEMENT;PALEONTOLOGY;PEDIATRICS","4;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DISEASE;ACOUSTIC NEUROMA;AUDITORY CANAL;BENCHMARK (SURVEYING);BENCHMARKING;BLOOD TRANSFUSION;BONE REMODELING;BONE RESORPTION;CALCANEUS;CANCER;CONTEXT (ARCHAEOLOGY);CORONARY ARTERY DISEASE;DIFFERENTIAL DIAGNOSIS;ENDOSCOPY;EXCHANGE TRANSFUSION;FACIAL NERVE;GASTROINTESTINAL BLEEDING;HEMATOCRIT;HYPERPLASIA;ILEOSTOMY;IMMUNOHISTOCHEMISTRY;INSTITUTION;MAGNETIC RESONANCE IMAGING;MEDICAL RECORD;MESOTHELIAL CELL;MIDDLE CRANIAL FOSSA;MYOCARDIAL INFARCTION;ORDER (EXCHANGE);OSTEOPOROSIS;PATHOLOGICAL ANATOMY;PREGNANCY;PROSPECTIVE COHORT STUDY;PULMONARY HYPERTENSION;REFRACTORY (PLANETARY SCIENCE);SCHWANNOMA;SPERMATIC CORD;TEMPORAL BONE;TUNICA VAGINALIS;ULTRASOUND;VESTIBULAR SYSTEM;WORK (PHYSICS);WORKLOAD","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANGINA;BONE DENSITY;BONE MINERAL;CEREBELLOPONTINE ANGLE;COLORECTAL CANCER;CROHN'S DISEASE;ENTEROSCOPY;FEMORAL NECK;INTERNAL AUDITORY MEATUS;REVASCULARIZATION;SICKLE CELL ANEMIA;TRANSFUSION THERAPY;ULCERATIVE COLITIS;VESTIBULAR NERVE","1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE CHEST SYNDROME;CANADIAN CARDIOVASCULAR SOCIETY;COLECTOMY;COLONOSCOPY","1;1;1;1","FEMALE;HUMANS;GASTROINTESTINAL HEMORRHAGE;MALE;NEUROMA, ACOUSTIC;ADULT;ANGINA PECTORIS;AUTOPSY;BONE AND BONES;CROHN DISEASE;CYTOLOGICAL TECHNIQUES;FROZEN SECTIONS;HISTOLOGICAL TECHNIQUES;OTOLOGIC SURGICAL PROCEDURES;PATHOLOGY DEPARTMENT, HOSPITAL;PROSPECTIVE STUDIES;STAINING AND LABELING;TISSUE AND ORGAN HARVESTING;;AGED","5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS;EVOLUTION AND USAGE OF ANATOMICAL NOMENCLATURE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;INTUSSUSCEPTION AND MECKEL'S DIVERTICULUM;OSTEOPOROSIS;PATHOGENESIS AND CLINICAL MANAGEMENT OF RHODOCOCCUS EQUI INFECTIONS;SARCOMA RESEARCH AND TREATMENT;TREATMENT AND MECHANISMS OF COMPLEX PAIN SYNDROMES","1;1;1;1;1;1;1;1","ACOUSTIC NEUROMA;ACUTE CHEST SYNDROME;BENCHMARK (SURVEYING);BENCHMARKING;BONE MINERAL DENSITY;BONE REMODELING;CANADIAN CARDIOVASCULAR SOCIETY;DIAGNOSIS;ENTEROSCOPY;EXCHANGE TRANSFUSION;FACIAL REANIMATION;GASTROINTESTINAL BLEEDING;ILEOSTOMY;INSTITUTION;INTERNAL AUDITORY MEATUS;INTERNATIONAL MYELOMA WORKING GROUP;LOWER GASTROINTESTINAL BLEEDING;MEDICAL RECORD;MEDICAL TERMINOLOGY;MIDDLE CRANIAL FOSSA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE CHEST;ANGINA PECTORISSEE;BONE DENSITY;BONE TURNOVER;CELL DISEASE;CHEST SYNDROME;CLINICAL OUTCOME;CORD STIMULATION;CROHNS DISEASE;DIAGNOSTIC PITFALL;FIBROUS HISTIOCYTOMA;FOSSA VERSUS;GASTROINTESTINAL BLEEDING;LONG-TERM CLINICAL;MALIGNANT FIBROUS;MESOTHELIAL HYPERPLASIA;MIDDLE FOSSA;PARTICIPATING CENTERS;PATHOLOGICAL ANATOMY;PLEOMORPHIC MALIGNANT;POTENTIAL DIAGNOSTIC;PROSPECTIVE DATA;PROSPECTIVE STUDY;PSEUDO-GLANDULAR MESOTHELIAL;REACTIVE PSEUDO-GLANDULAR;REFRACTORY STABLE;RETROSIGMOID-TRANSMEATAL APPROACH;SCHWANNOMA SURGERY;SEVERE GASTROINTESTINAL;SICKLE CELL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",1,0.12,3,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,51,51,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2004,6,10.1666666666667,1.33333333333333,0,0.333333333333333,0,1,0,0.666666666666667,0,0.166666666666667,0,2,2,1,0,0.33,0.33,0.17,0,20.5,0.43567323887843,NA,0.166666666666667,0.833333333333333,0.378,0,0,0,"GABRIELLA CELOTTA;G. MINALDI;E. NAPOLI;S. RAFFINO;PIETRO PEPE;GIUSEPPE MARCHESE;GREGORY ALEXANDER RACITI;GAETANO MAGRO;DANIELE DIGRANDI;S CASCHETTO;SALVATORE BAIANO;CARMELITA SANTANGELO;GIULIA DI BENEDETTO;C. ARAGONA;NUNZIATA CASSIBBA;IDA DURO;GIORGIA RIZZA;MARIA PIA COSTA;DANIELA NICOLOSI;P. LA ROSA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GAETANO MAGRO;MARIA MANUEL LOPES;E. NAPOLI;SALVATORE BAIANO;CARMELITA SANTANGELO;IDA DURO;ANNA GIAMMANCO;VITTORIO ELIA;MARCELLA NICCOLI;FRANCINE GRIMONT;L. NONATELLI;PATRICK A. D. GRIMONT;GIUSEPPE GIAMMANCO;SARINA PIGNATO;A PRIVITERA;GIUSEPPE SANFILIPPO;ANTONIO MAGNANO;ANTONIO BIONDI;G CALOGERO;LUIGI NANFIT","0.5;0.5;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14","E. NAPOLI;CARMELITA SANTANGELO;GIORGIA RIZZA;VITO BORZÌ;ANTONIO BIONDI;CONCETTA LIBERTINI;MARIA MANUEL LOPES;FRANCESCO BASILE","1;1;1;1;1;1;1;1","MARIA MANUEL LOPES;E. NAPOLI;CARMELITA SANTANGELO;ANTONIO BIONDI;FRANCESCO BASILE;VITO BORZÌ;CONCETTA LIBERTINI;GIORGIA RIZZA","0.5;0.17;0.17;0.14;0.14;0.08;0.08;0.04","E. NAPOLI;IDA DURO;L. NONATELLI;MARCELLA NICCOLI;SALVATORE BAIANO;VITTORIO ELIA;A PRIVITERA;ANTONIO BIONDI;ANTONIO MAGNANO;FRANCESCO BASILE;G CALOGERO;GIUSEPPE SANFILIPPO;LUIGI NANFIT;A. DAMMINO;A. SERRAO;ALBERTO SAITA;ALESSANDRO CALARCO;C. ARAGONA;C. IURATO;DANIELA NICOLOSI","57;57;57;57;57;57;25;25;25;25;25;25;25;23;23;23;23;23;23;23","E. NAPOLI;ANTONIO BIONDI;FRANCESCO BASILE;GIORGIA RIZZA;CARMELITA SANTANGELO;CONCETTA LIBERTINI;VITO BORZÌ;MARIA MANUEL LOPES","57;25;25;23;17;1;1;0","ANTONIO BIONDI;CARMELITA SANTANGELO;CONCETTA LIBERTINI;E. NAPOLI;FRANCESCO BASILE;GIORGIA RIZZA;VITO BORZÌ;MARIA MANUEL LOPES","1;1;1;1;1;1;1;0","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;PHYSICS","5;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;GENETICS;GEOMETRY;GYNECOLOGY;MICROBIOLOGY;ONCOLOGY;OPTICS;ORGANIC CHEMISTRY;RADIOLOGY;SURGERY;TRADITIONAL MEDICINE;VIROLOGY","4;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALTERNATIVE MEDICINE;CANCER;ANGIODYSPLASIA;AQUEOUS SOLUTION;BLOODSTREAM INFECTION;BODY MASS INDEX;CAPSULE ENDOSCOPY;CAROTID ARTERIES;CORRELATION;DIABETES MELLITUS;ENDOSCOPY;GASTROINTESTINAL BLEEDING;GENE;HORMONE;ILEUM;INCIDENCE (GEOMETRY);INSULIN;JEJUNUM;KIDNEY;MENOPAUSE;MULTIVARIATE ANALYSIS;PATHOLOGICAL;POSTMENOPAUSAL WOMEN;RANDOMIZED CONTROLLED TRIAL;RENAL CELL CARCINOMA;STROMAL CELL;TESTOSTERONE (PATCH);TYPING","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;COMMON CAROTID ARTERY;GENOTYPE;HOMEOPATHY;HORMONE REPLACEMENT THERAPY (FEMALE-TO-MALE);INTIMA-MEDIA THICKNESS;LIPID PROFILE;MULTICENTER STUDY;NEPHRECTOMY;OBSCURE GASTROINTESTINAL BLEEDING;PROSTATE;PROSTATE CANCER;PROTOCOL (SCIENCE);TRANSFORMATION (GENETICS)","1;1;1;1;1;1;1;1;1;1;1;1;1;1","AGROBACTERIUM;AGROBACTERIUM TUMEFACIENS;COLONOSCOPY;HOMEOPATHIC MEDICINE;PULSED-FIELD GEL ELECTROPHORESIS;RENAL TUMOR","1;1;1;1;1;1","HUMANS;MIDDLE AGED;PROSTATIC NEOPLASMS;ADULT;AGING;CARDIOVASCULAR DISEASES;HOMEOPATHY;MALE;PROSTATE;2,4-DICHLOROPHENOXYACETIC ACID;ADENOCARCINOMA;AGED;ANEMIA;ANGIODYSPLASIA;ARSENICALS;BACTEREMIA;BIOMARKERS;CAROTID ARTERIES;CATHETERIZATION;CROHN DISEASE","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;INTERFACIAL WATER AND BIOLOGICAL EFFECTS;MOLECULAR MECHANISMS OF KIDNEY DEVELOPMENT AND DISEASE;NOSOCOMIAL PATHOGENS: STENOTROPHOMONAS MALTOPHILIA AND RELATED BACTERIA;PROSTATE CANCER RESEARCH AND TREATMENT","1;1;1;1;1;1","ANGIODYSPLASIA;BACTEREMIA;BLOODSTREAM INFECTION;CAPSULE ENDOSCOPY;CAROTID INTIMA-MEDIA THICKNESS;DIABETES;DOUBLE-BALLOON ENTEROSCOPY;EFFICACY EVALUATION;GASTROINTESTINAL BLEEDING;HOMEOPATHIC MEDICINE;INCIDENCE;INSULIN RESISTANCE;INTIMA-MEDIA THICKNESS;JEJUNUM;KIDNEY ORGANOIDS;LIPID PROFILE;OBSCURE GASTROINTESTINAL BLEEDING;RENAL TUMOR;UPPER GASTROINTESTINAL BLEEDING","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AQUEOUS SOLUTIONS;ARTERY INTIMA-MEDIA;BLOODSTREAM INFECTIONS;CAPSULE ENDOSCOPY;CAROTID ARTERY;CASE-FINDINGS PROTOCOL;CATHETER-RELATED BLOODSTREAM;CYSTIC TUMORS;DILUTED AQUEOUS;EXTREMELY DILUTED;GASTROINTESTINAL BLEEDING;HOMEOPATHIC MEDICINES;INTIMA-MEDIA THICKNESS;KIDNEY REVISION;METABOLIC MARKERS;MOLECULAR TYPING;MULTICENTER CASE-FINDINGS;OBSCURE GASTROINTESTINAL;OFIAGROBACTERIUMISPECIES ISOLATES;PERMANENT PHYSICO-CHEMICAL;PHYSICO-CHEMICAL PROPERTIES;POSTMENOPAUSAL WOMEN;PROSTATE CANCER;SICILY RESULTS;TYPING OFIAGROBACTERIUMISPECIES;VASCULAR RISK","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ASSURE PATIENT;AUTHORS REPORT;CARCINOMA CYSTIC;CELL CARCINOMA;CLINICO-PATHOLOGIC ENTITIES;CLINICO-PATHOLOGICAL FEATURES;CORRECT TREATMENT;CYSTIC MULTILOCULAR;CYSTIC NEPHROMA;CYSTIC PARTIALLY;CYSTIC TUMORS;DETAIL CYSTIC;DIFFERENTIATED NEPHROBLASTOMA;DISCUSSING DATA;ENGLISH LITERATURE;EPITHELIALSTROMAL TUMOR;HISTOLOGICALLY ILLUSTRATIONS;KIDNEY DISCUSSING;MALIGNANT EPITHELIALSTROMAL;MIXED BENIGN;MULTILOCULAR RENAL;NEPHROMA CYSTIC;PARTIALLY DIFFERENTIATED;PROGNOSTIC INFORMATIONS;PROVIDING GROSSLY;RENAL CELL;SO-CALLED CYSTIC;TUMOR ENTITIES","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.17,4.35,8,2,0,0,0,0,0,0,13,0,0,6,0,0,0,2,3,1,0,0,36,36,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2005,10,6.2,2.3,0.7,0.4,0.7,1,0.875,0.8,0.875,0.2,0,3,2,1,4,0.3,0.2,0.1,0.4,27.1,0.511864213166454,NA,0,0.6,0.126,0,0,0,"DANIELA LETO;CARMELO MAZZA;ROSSELLA CACCIOLA;SEBASTIANA SAGLIMBENE;L. TIEPOLO;GUIDO LA ROSA;ROSARIO VECCHIO;CHIARA POLINO;MARIA RITA NASCA;RICCARDO VIGNERI;G CICCIARELLA;MARIO MOTTA;MAURIZIO BURRELLO;SANDRINE IMBEAUD;GIOVANNA CAMERINO;E CACCIOLA;F SARNATARO;VICENTE VANACLOCHA;A PRIVITERA;A BUFFONE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GUIDO LA ROSA;F SARNATARO;R. A. MANGIAFICO;TULLIO RUSSO;FABIO GIUDICE;MARCO MANGIAFICO;R. VARSALONA;CARMELO ERIO FIORE;SEBASTIANA SAGLIMBENE;G CICCIARELLA;A BUFFONE;E PANASCIA;GIACOMO CASTIGLIONE;DI MARI P;GUIDO BASILE;BIAGIO PANASCIA;P CALABRESE;E CIRINO;ROSSELLA CACCIOLA;ROSARIO VECCHIO","0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.17","SEBASTIANA SAGLIMBENE;ROSARIO VECCHIO;F SARNATARO;A PRIVITERA;GIUSEPPE BASILE;E PANASCIA;BRUNO GIAMMUSSO;GIUSEPPE SANFILIPPO;R. A. MANGIAFICO;GIACOMO CASTIGLIONE;GUIDO BASILE;BIAGIO PANASCIA;F UCCELLATORE;ANTONIO MAGNANO;P CALABRESE;LUIGI NANFITO';TULLIO RUSSO;MARCO MANGIAFICO;R. VARSALONA;G CALOGERO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","F SARNATARO;R. A. MANGIAFICO;TULLIO RUSSO;MARCO MANGIAFICO;R. VARSALONA;CARMELO ERIO FIORE;SEBASTIANA SAGLIMBENE;E PANASCIA;GIACOMO CASTIGLIONE;GUIDO BASILE;BIAGIO PANASCIA;P CALABRESE;ROSARIO VECCHIO;A PRIVITERA;GIUSEPPE BASILE;GIUSEPPE SANFILIPPO;ANTONIO MAGNANO;LUIGI NANFITO';G CALOGERO;BRUNO GIAMMUSSO","0.25;0.25;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14","ANNA CARTA;CLAUDIA SCOLLO;ETTORE C. DEGLI UBERTI;MARIA ROSARIA AMBROSIO;MARTA BONDANELLI;PATRIZIA TITA;PIETRO GANGEMI;RICCARDO VIGNERI;V. PEZZINO;CARMELO ERIO FIORE;F SARNATARO;MARCO MANGIAFICO;R. A. MANGIAFICO;F UCCELLATORE;GIOVANNA CAMERINO;GIUSEPPE MICALI;L. TIEPOLO;MARIA RITA NASCA;ORIETTA RADI;P MARASCHIO","100;100;100;100;100;100;100;100;100;56;56;56;56;41;41;41;41;41;41;41","PIETRO GANGEMI;CARMELO ERIO FIORE;F SARNATARO;MARCO MANGIAFICO;R. A. MANGIAFICO;F UCCELLATORE;A PRIVITERA;ANTONIO MAGNANO;G CALOGERO;GIUSEPPE BASILE;GIUSEPPE SANFILIPPO;LUIGI NANFITO';ROSARIO VECCHIO;LICIA LAROCCA;R. VARSALONA;TULLIO RUSSO;GUIDO BASILE;BRUNO GIAMMUSSO;BIAGIO PANASCIA;E PANASCIA","100;56;56;56;56;41;34;34;34;34;34;34;22;7;6;6;3;2;0;0","A PRIVITERA;ANTONIO MAGNANO;BRUNO GIAMMUSSO;CARMELO ERIO FIORE;F SARNATARO;F UCCELLATORE;G CALOGERO;GIUSEPPE BASILE;GIUSEPPE SANFILIPPO;GUIDO BASILE;LICIA LAROCCA;LUIGI NANFITO';MARCO MANGIAFICO;PIETRO GANGEMI;R. A. MANGIAFICO;R. VARSALONA;ROSARIO VECCHIO;TULLIO RUSSO;BIAGIO PANASCIA;E PANASCIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;0;0","MEDICINE;BIOLOGY;ENGINEERING;COMPUTER SCIENCE;MATERIALS SCIENCE;PHYSICS","9;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ENVIRONMENTAL HEALTH;PATHOLOGY;RADIOLOGY;ANATOMY;ANESTHESIA;BIOMEDICAL ENGINEERING;BOTANY;CARDIOLOGY;ELECTRICAL ENGINEERING;ENDOCRINOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;MECHANICAL ENGINEERING;OPTICS;ORTHODONTICS;PSYCHIATRY;UROLOGY;VIROLOGY","6;5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ASYMPTOMATIC;BIOPSY;DISEASE;POPULATION;VASCULAR DISEASE;ADRENAL GLAND;ADRENALECTOMY;ANTIBODY;CANCER;CAPSULE;CAPSULE ENDOSCOPY;COGNITION;D-DIMER;DIFFERENTIAL DIAGNOSIS;ENDOSCOPY;EPIDEMIOLOGY;ERECTILE DYSFUNCTION;GENE;HEMANGIOMA;HORMONE;HYPERKERATOSIS;ILEUM;IMMUNOHISTOCHEMISTRY;IMPLANT;INCIDENCE (GEOMETRY);INTRAMEDULLARY ROD;LAPAROSCOPY;LUMBAR;MEDULLARY CAVITY;NEUROVASCULAR BUNDLE;PERCUTANEOUS;PERIOPERATIVE;PERIPHERAL;PHYSICAL EXAMINATION;PLATELET;PROPRANOLOL;PYELOGRAM;SMALL INTESTINE;SPLEEN;STROKE (ENGINE);SUBCLINICAL INFECTION;THYROID;TRANSMISSION (TELECOMMUNICATIONS)","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANGIOMA;ARTERIAL DISEASE;CAPILLARY HEMANGIOMA;GENETIC LINKAGE;GENETIC PREDISPOSITION;GROWTH HORMONE;KERATODERMA;NEUROPSYCHOLOGY;OBSCURE GASTROINTESTINAL BLEEDING;PALMOPLANTAR KERATODERMA;PHENOTYPE;PHENTOLAMINE;PRIMARY EFFUSION LYMPHOMA;SEROLOGY;SPLENECTOMY;THROMBOCYTOPENIC PURPURA;THYROID CANCER;THYROID CARCINOMA;THYROID FUNCTION;THYROID FUNCTION TESTS;THYROID NODULES;THYROIDECTOMY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACROMEGALY;PAPILLARY THYROID CANCER;SEROPREVALENCE","1;1;1","HUMANS;MALE;FEMALE;ADRENAL GLAND DISEASES;ADULT;CYSTS;ATHEROSCLEROSIS;COGNITION DISORDERS;HERPESVIRIDAE INFECTIONS;RETROSPECTIVE STUDIES;ACROMEGALY;ADENOMA;AGED;ANTIBODIES, VIRAL;CARCINOMA, PAPILLARY;ERECTILE DYSFUNCTION;GOITER;HEMANGIOMA, CAVERNOUS;HEMORRHAGE;HUMERAL FRACTURES","9;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;MANAGEMENT OF SPLEEN TRAUMA IN POLYTRAUMA PATIENTS;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;SEX DETERMINATION AND DIFFERENTIATION IN ORGANISMS;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;THERAPEUTIC APPLICATIONS OF BEE VENOM THERAPY;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","1;1;1;1;1;1;1;1;1;1","ACROMEGALY;ADRENAL VEIN SAMPLING;ANGIOMA;APOPTOSIS INDUCTION;CAPILLARY HEMANGIOMA;CAPSULE;CAPSULE ENDOSCOPY;D-DIMER;DIFFERENTIATED THYROID CANCER;ERECTILE DYSFUNCTION;GENETIC LINKAGE;GENETIC PREDISPOSITION;HUMAN HERPESVIRUS 8;INTERNAL FIXATION;KERATODERMA;NEUROVASCULAR BUNDLE;OBSCURE GASTROINTESTINAL BLEEDING;PALMOPLANTAR KERATODERMA;PERIPHERAL ARTERIAL DISEASE;PHENTOLAMINE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADRENAL PSEUDOCYST;ADRENERGIC HYPERTONE;ARTERIAL DISEASE;ASYMPTOMATIC PERIPHERAL;BLEEDING DIAGNOSED;BLOOD-BORNE INFECTIONS;BONE-IMPLANT CONTACT;C-REACTIVE PROTEIN;CAPSULE ENDOSCOPY;CARCINOMA GENETIC;CATANIA EASTERN;CAVERNOUS ADRENERGIC;CELL CARCINOMA;COGNITIVE PERFORMANCE;D-DIMER LEVELS;DIFFERENTIATED THYROID;DISEASE RELATION;DYSFUNCTION SECONDARY;EASTERN SICILY;ERECTILE DYSFUNCTION;GENETIC ANALYSIS;HEMORRHAGIC ADRENAL;HUMERAL NAIL;HYPERTONE INITIAL;IDIOPATHIC THROMBOCYTOPENIC;IMPAIRED COGNITIVE;INITIAL RESULTS;LAPAROSCOPIC SPLENECTOMY;LUMBAR SYMPATHECTOMY;NUMERICALEXPERIMENTAL ANALYSIS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACTIVATED PROTEIN;ARTERIAL DISEASE;ASYMPTOMATIC PERIPHERAL;ATTACK-FREE PATIENTS;CEREBRAL ATHEROSCLEROSIS;CEREBROVASCULAR EVENTS;CO-EXISTING CLINICAL;COGNITIVE FUNCTION;DISEASE APAD;HAEMOSTATIC MARKERS;HIGHLY PREVALENT;INCREASED RISK;INCREASES FIBRINOLYSIS;INFUSION INCREASES;ISCHAEMIC ATTACK-FREE;NEUROPSYCHOLOGICAL PERFORMANCE;PERIPHERAL ARTERIAL;PREVALENT CONDITION;PURPOSE ASYMPTOMATIC;RHAPC INFUSION;STANDARD TESTS;SUBCLINICAL CEREBRAL;TRANSIENT ISCHAEMIC","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",1,0.1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,48,48,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2006,18,8.72222222222222,2.05555555555556,0.444444444444444,0.333333333333333,0.444444444444444,1.19354838709677,1,0.857142857142857,1,0.388888888888889,0,8,7,0,3,0.44,0.39,0,0.17,23.17,0.453552854446012,NA,0.166666666666667,0.777777777777778,0.262,0.229,0.3,0.229,"ROBERTO BORDONARO;ANTONIO GRANATA;VALENTINA BEVELACQUA;VITTORIO GEBBIA;MASSIMO LIBRA;MARÍA CLORINDA MAZZARINO;GRAZIA MALAPONTE;FRANCESCO FERRAÙ;PAOLO TRALONGO;ANTONIO BASILE;FRANCESCO VERDERAME;MICHELE FIGUERA;PIETRO GANGEMI;ANGELA MARIA CALLARI;EMANUELA RIZZIOLI;FRANCA STIVALA;MARINELLA ZINGALE;DONATELLA GRECO;GIUSEPPE BATTAGLIA;DARIO GIUFFRIDA","4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ANTONIO GRANATA;ROBERTO BORDONARO;GIUSEPPE BATTAGLIA;N GIUSTOLISI;D PULVIRENTI;MONACA;SERGIO NERI;ROSARIO TRINGALE;ANTONIO BASILE;MICHELE FIGUERA;DOMENICO SANTORO;MANUELA STELLA;STEPHEN CASTELLINO;FRANCESCO LOGIAS;SHARON M. CASTELLINO;VALENTINA BEVELACQUA;MASSIMO LIBRA;MARÍA CLORINDA MAZZARINO;GRAZIA MALAPONTE;VITTORIO GEBBIA","0.54;0.39;0.33;0.33;0.33;0.33;0.33;0.33;0.29;0.29;0.25;0.25;0.25;0.2;0.2;0.18;0.18;0.18;0.18;0.17","ROBERTO BORDONARO;ANTONIO GRANATA;GRAZIA MALAPONTE;ANTONIO BASILE;MICHELE FIGUERA;PIETRO GANGEMI;EMANUELA RIZZIOLI;GIUSEPPE BATTAGLIA;N GIUSTOLISI;NUNZIO RESTUCCIA;MARIO MOTTA;C. BOVO;GIUSEPPE LUIGI BANNA;FERDINANDO D’AMICO;R. A. MANGIAFICO;DANIELE MUNARO;MARCELLA NORMANNO;CARMELO PRIVITERA;SERENELLA MORANA;ALESSANDRO MALAGOLI","4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTONIO GRANATA;ROBERTO BORDONARO;GIUSEPPE BATTAGLIA;N GIUSTOLISI;ANTONIO BASILE;MICHELE FIGUERA;GRAZIA MALAPONTE;EMANUELA RIZZIOLI;MARIO MOTTA;C. BOVO;DANIELE MUNARO;MARCELLA NORMANNO;SERENELLA MORANA;ALESSANDRO MALAGOLI;ASTRID BONACCORSI;VIRGINIO MEREGALLI;FRANCESCO P. MARCHESE;P. CONZ;FERDINANDO D’AMICO;R. A. MANGIAFICO","0.54;0.39;0.33;0.33;0.29;0.29;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14","GRAZIA MALAPONTE;MARÍA CLORINDA MAZZARINO;MASSIMO LIBRA;PIETRO GANGEMI;VALENTINA BEVELACQUA;ROBERTO BORDONARO;ANTONIO PLUMARI;DANIELA MASSIMINO;F STIVALA;GIUSEPPINA NICOTRA;GUIDO VALENTE;PAOLA MERITO;SALVATORE CURATOLO;STEFANO LA GRECA;DINO AMADORI;FRANCESCO GIOTTA;GIACOMO CARTENÌ;ROBERTA RONDENA;SIMONA SCALONE;VINCENZA VINACCIA","120;120;120;120;120;109;84;84;84;84;84;84;84;84;53;53;53;53;53;53","ROBERTO BORDONARO;PIETRO GANGEMI;CARMELO ERIO FIORE;ENZO RUSSO;FERDINANDO D’AMICO;MARCO MANGIAFICO;PIETRA PENNISI;R. A. MANGIAFICO;STEFANIA RICCOBENE;GRAZIA MALAPONTE;ANTONIO GRANATA;GIUSEPPE BATTAGLIA;MICHELE FIGUERA;MARIO FALSAPERLA;SERENELLA MORANA;VIRGINIO MEREGALLI;ASTRID BONACCORSI;CARMELO PRIVITERA;FRANCESCO P. MARCHESE;MARIO MOTTA","109;84;42;42;42;42;42;42;42;36;32;31;31;23;22;22;21;21;21;21","ROBERTO BORDONARO;ANTONIO GRANATA;MICHELE FIGUERA;ANGELA RAGUSA;ANTONIO BASILE;ASTRID BONACCORSI;CARMELO ERIO FIORE;CARMELO PRIVITERA;ENZO RUSSO;FERDINANDO D’AMICO;FRANCESCO P. MARCHESE;GIUSEPPE BATTAGLIA;GRAZIA MALAPONTE;MARCO MANGIAFICO;MARIO FALSAPERLA;MARIO MOTTA;N GIUSTOLISI;NUNZIO RESTUCCIA;PIETRA PENNISI;PIETRO GANGEMI","4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;BUSINESS","17;3;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CANCER RESEARCH;GENETICS;RADIOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;OPTICS;PATHOLOGY;ASTROBIOLOGY;EMERGENCY MEDICINE;ENDOCRINOLOGY;FINANCE;GYNECOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;OBSTETRICS","10;8;4;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;CATHETER;DISEASE;GENE;INCIDENCE (GEOMETRY);OSTEOPOROSIS;POPULATION;PROSPECTIVE COHORT STUDY;VASCULAR DISEASE;VEIN;ANEMIA;ANGIOGRAPHY;ATRIAL FIBRILLATION;AZYGOS VEIN;BOLUS (DIGESTION);CLINICAL TRIAL;COMPLICATION;COMPUTED TOMOGRAPHY;CONFIDENCE INTERVAL;CONNECTIVE TISSUE;DIABETES MELLITUS;DISSECTION (MEDICAL);FIBROSIS;GLIOBLASTOMA;GLIOMA;HEMODIALYSIS;HORNER SYNDROME;IMMUNOHISTOCHEMISTRY;INFECTION CONTROL;INFLAMMATION;JUGULAR VEIN;KINASE;LUNG CANCER;MELANOMA;NEPHRITIS;OCCLUSION;ORTHOPEDIC SURGERY;OXYTOCIN;PATHOGENESIS;PERICARDIAL EFFUSION;PERIPHERAL;POPLITEAL ARTERY;POSITION (FINANCE);POSTMENOPAUSAL WOMEN;PREGNANCY;PRESENTATION (OBSTETRICS);PROSTHESIS;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REFRACTORY (PLANETARY SCIENCE);REGIMEN;RETROSPECTIVE COHORT STUDY;RIGHT ATRIUM;SCHWANNOMA;THROMBOSIS;TOMOGRAPHY;TRISOMY;URINARY SYSTEM;ZOLEDRONIC ACID","6;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ARTERIAL DISEASE;COLORECTAL CANCER;NEUTROPENIA;ANTIMETABOLITE;ATRIUM (ARCHITECTURE);BONE DENSITY;BREAST CANCER;CELL CYCLE;CENTRAL VENOUS CATHETER;CERVIX;CHEMOTHERAPY REGIMEN;CHOROIDAL MELANOMA;CHROMOGRANIN A;CHROMOSOMAL TRANSLOCATION;CHROMOSOME;CISPLATIN;FETUS;FLUOROURACIL;GESTATION;GESTATIONAL AGE;HEMODIALYSIS CATHETER;LABOR INDUCTION;LEFT ATRIUM;LUPUS NEPHRITIS;MAPK/ERK PATHWAY;MUTATION;NEPHROPATHY;PACLITAXEL;PERFORMANCE STATUS;PERINEURAL INVASION;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;PROSTATE;PROSTATE CANCER;RANDOMIZATION;RETROPERITONEAL FIBROSIS;SYNAPTOPHYSIN;TEMOZOLOMIDE;VAGINAL DELIVERY","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BISHOP SCORE;BONE DENSITY CONSERVATION AGENTS;CARBOPLATIN;CARDIOTOCOGRAPHY;CENTROMERE;CERVICAL DILATION;CETUXIMAB;CLAUDICATION;FEBRILE NEUTROPENIA;FLUORESCENCE IN SITU HYBRIDIZATION;IRINOTECAN;KARYOTYPE;LNCAP;METASTATIC BREAST CANCER;MOLECULAR MEDICINE;NEUROENDOCRINE DIFFERENTIATION;OXALIPLATIN;SUBTELOMERE;THYMIDYLATE SYNTHASE;V600E","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;ADENOCARCINOMA;MALE;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MIDDLE AGED;ADULT;COLORECTAL NEOPLASMS;BRAIN NEOPLASMS;CHOROID NEOPLASMS;GLIOMA;INFLAMMATION;MELANOMA;PROSTATIC HYPERPLASIA;PROSTATIC NEOPLASMS;PSORIASIS;AGED, 80 AND OVER;ARTHRITIS, PSORIATIC;BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS","16;14;10;9;8;8;8;7;6;4;4;4;4;4;4;4;4;3;3;3","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;ADVANCEMENTS IN LUNG CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE;EPIDEMIOLOGY AND TREATMENT OF URINARY TRACT INFECTIONS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;GLIOMAS;MATERNAL AND NEONATAL OUTCOMES OF CESAREAN SECTION;OCULAR CANCER RESEARCH AND TREATMENT;PREVALENCE AND TREATMENT OF HYPERHIDROSIS;ROLE OF PENTRAXINS IN INNATE IMMUNITY AND INFLAMMATION;STRUCTURE AND FUNCTION OF G PROTEIN-COUPLED RECEPTORS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CENTRAL VENOUS CATHETERIZATION;METASTATIC COLORECTAL CANCER;PERIPHERALLY INSERTED CENTRAL CATHETERS;ANKLE-BRACHIAL INDEX;ATRIUM (ARCHITECTURE);AUTISM;AZYGOS VEIN;BISHOP SCORE;BOLUS (DIGESTION);BONE METASTASIS;BRAF GENE;CARBOPLATIN;CARDIAC OUTPUT;CARDIOTOCOGRAPHY;CATHETER-RELATED BLOODSTREAM INFECTIONS;CENTRAL VENOUS CATHETER;CERVICAL DILATION;CETUXIMAB;CHEMOTHERAPY REGIMEN;CHOROIDAL MELANOMA","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ELDERLY PATIENTS;ACTIVE SURVEILLANCE;ACUTE RENAL;ADVANCED COLORECTAL;ADVANCED NON-SMALL;ARCH CANNULATION;ARTERIAL DISEASE;AUTISTIC DISORDER;AZYGOS ARCH;BIWEEKLY SCHEDULE;BOLUSCONTINUOUS INFUSION;BONDED EPTFE;BREAST CANCER;BYPASS IMPLICATIONS;CANCER METASTATIC;CANCER NSCLC;CATHETER TIP;CELL LUNG;CENTRAL VENOUS;CERVICAL GEL;CERVICAL PRIMING;CERVICAL SYMPATHETIC;CHAIN SCHWANNOMA;CHEMOTHERAPY-REFRACTORY METASTATIC;CHOROIDAL MELANOMA;CLINICAL PRACTICE;CLINICAL TRIAL;COLORECTAL ADENOCARCINOMAS;COLORECTAL CARCINOMAS;DETECTION OFIBRAFIGENE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VAGINAL INSERT;CELL LINES;ZOLEDRONIC ACID;BONE METASTASES;CERVICAL GEL;CHROMOGRANIN-A SYNAPTOPHYSIN;ABNORMAL CARDIOTOCOGRAPHY;ACID COMBINATION;ACUTE PHASE;BISHOP SCORE;BRAF MUTATION;BRAF MUTATIONS;BREAST CANCER;CANCER PATIENTS;CHOROIDAL MELANOMA;DIAGNOSED BONE;DINOPROSTONE VAGINAL;DISEASE ACTIVITY;ELDERLY PATIENTS;HUMAN PROSTATE;LABOR VERSUS;MEDIAN TIME;MICROSCOPIC PERINEURAL;NEUROD EXPRESSION;NEUROENDOCRINE DIFFERENTIATION;NEWLY DIAGNOSED;PASI SCORE;PERINEURAL INVASION;PROSTATE CELL;RAFMEKERK PATHWAY","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",2,0.11,3.19,2.5,0,0,0,0,0,0,1,2.75,0,0,1,0,2,1,0,0,0,0,0,27.5,27.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,5,168,3.45,0,0,3,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","1;1","ATHEROSCLEROSIS;BIOMEDICAL IMAGING;CARDIOVASCULAR;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;HYPERTENSION;KIDNEY DISEASE;PREVENTION","1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR","1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING","1;1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2007,21,8.52380952380952,1.85714285714286,0.333333333333333,0.285714285714286,0.380952380952381,1.11428571428571,0.875,1,0.888888888888889,0.19047619047619,0,8,5,5,3,0.38,0.24,0.24,0.14,38.19,0.72363352180181,NA,0.380952380952381,0.761904761904762,0.259,0.257,0.3,0.239,"ANTONIO GRANATA;MARIA TERESA PATTI;DIMITRIOS TSETIS;E. SICUREZZA;GIOVANNI CARLO ETTORRE;MARIO CUCCIA;STEFANO PULEO;SEBASTIANO RINNONE;GIACOMO CALCARA;ANTONIO BASILE;FRANCESCO SCARAVILLI;MICHELE FIGUERA;EMANUELE PANZA;EZIO ZANON;TERESA IUVONE;M. CUMO;PAOLO GRESELE;ARINDAM PAUL;ROBERTO BORDONARO;NÚRIA PUJOL‐MOIX","4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","ANTONIO GRANATA;FRANCESCO SCARAVILLI;MARIA TERESA PATTI;DIMITRIOS TSETIS;GIUSEPPE ZARBO;TANIA GIANNONE;L COCO;GIACOMO CALCARA;ANTONIO BASILE;MICHELE FIGUERA;GIOVANNI CARLO ETTORRE;STEFANO PULEO;M. CUMO;G. ZUMMO;M. GERVASI;GIAN PIERO CELATA;RAGAZZI SALVATORE;PIAZZA DIEGO;VIRZÌ GIUSEPPE;E. SICUREZZA","0.43;0.39;0.38;0.38;0.33;0.33;0.33;0.27;0.27;0.27;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.25;0.24","ANTONIO GRANATA;E. SICUREZZA;STEFANO PULEO;FRANCESCO SCARAVILLI;MICHELE FIGUERA;EZIO ZANON;M. CUMO;ROBERTO BORDONARO;SALVATORE RAGAZZI;LUCA STEARDO;GIUSEPPE ESPOSITO;R. A. MANGIAFICO;VINCENZA PARLA;FRANCESCO BUSSICHELLA;EDVIGE SALOMONE;CARMELA SANTANGELO;ALIDA IMBRIANI;KATERINA CECHALOVA;G BENFATTO;MARIA TERESA XIBILIA","4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTONIO GRANATA;FRANCESCO SCARAVILLI;L COCO;MICHELE FIGUERA;STEFANO PULEO;M. CUMO;RAGAZZI SALVATORE;PIAZZA DIEGO;VIRZÌ GIUSEPPE;E. SICUREZZA;VITO BORZÌ;G TORRISI;SALVATORE RAGAZZI;R. A. MANGIAFICO;FRANCESCO BUSSICHELLA;EDVIGE SALOMONE;GIUSEPPE VIRZÌ;SERGIO LO CAPUTO;PLACIDO D’AGATI;MARIO FALSAPERLA","0.43;0.39;0.33;0.27;0.25;0.25;0.25;0.25;0.25;0.24;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.14","ANTONIO GRANATA;JANUSZ GUMPRECHT;P. VALENSI;ROBERT J. LIGTHELM;RYUZO KAWAMORI;VITO BORZÌ;YANG WEN-YING;ACHILLE IOLASCON;ALESSANDRO PECCI;ANNA SAVOIA;BIANCA ROCCA;CARLO DUFOUR;CARLO L. BALDUINI;CARMINE PECORARO;CATHERINE KLERSY;DIRK SCHWABE;EMANUELE PANZA;ERICA DE CANDIA;FABRIZIO FABRIS;FILOMENA DI BARI","232;178;178;178;178;178;178;173;173;173;173;173;173;173;173;173;173;173;173;173","ANTONIO GRANATA;VITO BORZÌ;ALIDA IMBRIANI;CARMELA SANTANGELO;MARIA TERESA XIBILIA;GIUSEPPE ESPOSITO;LUCA STEARDO;KATERINA CECHALOVA;LUCIANO SASO;PETYA DIMITROVA;Z ŘEHÁKOVÁ;L COCO;E. SICUREZZA;STEFANO PULEO;VINCENZA PARLA;R. A. MANGIAFICO;FRANCESCO SCARAVILLI;M. CUMO;DIEGO PIAZZA;FRANCESCO BUSSICHELLA","232;178;87;87;87;62;62;36;36;36;36;33;32;32;32;27;24;24;21;21","ANTONIO GRANATA;FRANCESCO SCARAVILLI;ALIDA IMBRIANI;CARMELA SANTANGELO;DIEGO PIAZZA;E. SICUREZZA;EDVIGE SALOMONE;FRANCESCO BUSSICHELLA;G BENFATTO;G TORRISI;GIUSEPPE ESPOSITO;GIUSEPPE VIRZÌ;KATERINA CECHALOVA;L COCO;LUCA STEARDO;LUCIANO SASO;M. CUMO;MARIA TERESA XIBILIA;MICHELE FIGUERA;PETYA DIMITROVA","4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ART;ENGINEERING;GEOLOGY;MATERIALS SCIENCE;PHYSICS;POLITICAL SCIENCE","19;9;2;1;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;GENETICS;PATHOLOGY;BIOCHEMISTRY;CARDIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;MICROBIOLOGY;OBSTETRICS;VIROLOGY;ANATOMY;CANCER RESEARCH;CELL BIOLOGY;ELECTRICAL ENGINEERING;GASTROENTEROLOGY;GENERAL SURGERY;GEOMORPHOLOGY;GYNECOLOGY;HUMANITIES;INTENSIVE CARE MEDICINE;LAW;MECHANICS;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;PHYSIOLOGY;THERMODYNAMICS","15;9;5;4;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENE;INFERIOR VENA CAVA;CARCINOMA;DISEASE;IMMUNOHISTOCHEMISTRY;KIDNEY;PREGNANCY;STENOSIS;VEIN;ALTERNATIVE MEDICINE;ANTIBIOTICS;AORTA;ASYMPTOMATIC;BLOOD PRESSURE;BOILING;BRUCELLOSIS;CANCER;CATARACTS;CHEMOTHERAPY;COHORT;COMPLICATION;CONCOMITANT;CONFIDENCE INTERVAL;DIABETES INSIPIDUS;DIABETES MELLITUS;DIALYSIS;EMBOLIZATION;ENZYME;EPIDEMIOLOGY;FLANK PAIN;FLOW (MATHEMATICS);FLOW MEASUREMENT;GROSS HEMATURIA;HAMARTOMA;HEMARTHROSIS;HEMODIALYSIS;HEPATITIS C;HEPATOCELLULAR CARCINOMA;HERNIA;HORMONE;HYPOPITUITARISM;HYSTERECTOMY;INFLAMMATION;INLET;LAPAROSCOPY;LEIOMYOMA;LIPOPOLYSACCHARIDE;LOGISTIC REGRESSION;LUNG CANCER;MASS FLOW;MEDLINE;MELATONIN;MOTILITY;MULTIVARIATE ANALYSIS;NEPHRITIS;OBSERVATIONAL STUDY;OSTEOPOROSIS;OUTBREAK;OXIDATIVE STRESS;PALPITATIONS;PANCREAS;PELVIC FLOOR;PERCUTANEOUS;PLUG FLOW;PULMONARY ARTERY;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;REGIMEN;RETROSPECTIVE COHORT STUDY;SECONDARY PROPHYLAXIS;SELLA TURCICA;SEPSIS;STAGE (STRATIGRAPHY);STENT;STOMA (MEDICINE);STOMACH;SUPERIOR MESENTERIC ARTERY;TRANSMISSION (TELECOMMUNICATIONS);TYPING;ULTRASOUND;URINARY INCONTINENCE;VIRUS;VOLUMETRIC FLOW RATE;YOUNG ADULT","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GENOTYPE;LEFT RENAL VEIN;RENAL VEIN;16S RIBOSOMAL RNA;ABDOMINAL AORTA;ACINUS;ACTIVATOR (GENETICS);ANTIBIOTIC RESISTANCE;ARTERIAL STIFFNESS;BIOVAR;BONE MINERAL;BRUCELLA;CHEMORADIOTHERAPY;CHROMOGRANIN A;CISPLATIN;DEHYDROGENASE;FETUS;FLOW COEFFICIENT;GESTATION;HEPATITIS C VIRUS;HERNIA REPAIR;HIGH RISK PREGNANCY;INDUCTION CHEMOTHERAPY;LAPAROSCOPIC SURGERY;LEIOMYOMATOSIS;LIPID PEROXIDATION;MASS FLOW METER;MYOEPITHELIAL CELL;OPEN-CHANNEL FLOW;PACLITAXEL;PHASES OF CLINICAL RESEARCH;PITUITARY GLAND;POLYURIA;PROSTATE;PROSTATE CANCER;PROTEINURIA;PULSE PRESSURE;PULSE WAVE VELOCITY;RENAL ARTERY;STRESS INCONTINENCE;SURGICAL MESH;SYNAPTOPHYSIN;TOLERABILITY;TRANSCRIPTION FACTOR;UNIVARIATE ANALYSIS;UTERINE LEIOMYOMA;VAGINAL DELIVERY;VIRAL DISEASE","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MOLECULAR EPIDEMIOLOGY;NUTCRACKER SYNDROME;BRUCELLA MELITENSIS;CARBOPLATIN;FLAVIVIRIDAE;GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE;HEPACIVIRUS;ISOTHERMAL FLOW;MICROHEMATURIA;MULTILOCUS SEQUENCE TYPING;NEUROENDOCRINE DIFFERENTIATION;OSTEOPROTEGERIN;POSTERIOR PITUITARY;RENAL ARTERY STENOSIS;RIGHT RENAL ARTERY;RPOB;VARIABLE NUMBER TANDEM REPEAT","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;HEMATURIA;LUNG NEOPLASMS;PROTEINURIA;RENAL VEINS;ADULT;BRUCELLA MELITENSIS;CONSTRICTION, PATHOLOGIC;GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES;LIPOPOLYSACCHARIDES;MIDDLE AGED;AGED;AMYLOID BETA-PEPTIDES;CARCINOMA, NON-SMALL-CELL LUNG;HEPACIVIRUS;HEPATITIS C;PEPTIDE FRAGMENTS;PUERPERAL DISORDERS","17;10;9;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4","VENOUS ANOMALIES AND SYNDROMES IN VASCULAR SYSTEM;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BRUCELLOSIS: A RE-EMERGING ZOONOSIS;COMPLICATIONS AND MANAGEMENT OF STOMA-RELATED ISSUES;CRYOGENIC FLUID STORAGE AND MANAGEMENT;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;HERNIA REPAIR TECHNIQUES AND MATERIALS;IMPACT OF CHRONIC STRESS ON CANCER PROGRESSION;IMPACT OF GESTATIONAL DIABETES MELLITUS ON PREGNANCY;INTUSSUSCEPTION AND MECKEL'S DIVERTICULUM;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;MECHANISMS OF ALZHEIMER'S DISEASE;PELVIC FLOOR DISORDERS;PLATELET DISORDERS AND THROMBOSIS MECHANISMS;UTERINE CONDITIONS AND TREATMENTS","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HERNIA REPAIR;MOLECULAR EPIDEMIOLOGY;NUTCRACKER SYNDROME;PROSTHETIC MESH;RENAL NUTCRACKER SYNDROME;RENAL VEIN;ABDOMINAL AORTA;ACINUS;AORTIC STIFFNESS;ARTERIAL STIFFNESS;BIOVAR;BRUCELLOSIS;CARBOPLATIN;CHEMORADIOTHERAPY;CHROMOGRANIN A;CLINICAL GUIDELINES;CONCOMITANT;FECAL INCONTINENCE;FLANK PAIN;FLOW COEFFICIENT","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NUTCRACKER SYNDROME;POSTMENOPAUSAL WOMEN;ADULT ITALIAN;ADVANCED NON-SMALL-CELL;ALZHEIMERS DISEASE;ANATOMIC ASSESSMENT;ANIMAL MODELS;ANTIBIOTIC SUSCEPTIBILITY;AORTIC BLOOD;ARTERY ORIGIN;AUGMENTATION INDEX;BLOOD PRESSURE;CAVAL VEIN;CENTRAL AORTIC;CEREBRAL GLYCERALDEHYDE--PHOSPHATE;CHAIN IIA;CLINICAL PRACTICE;CONCURRENT CHEMORADIOTHERAPY;DEHYDROGENASE ACTIVITY;ELDERLY PATIENTS;FLOW BOILING;FLOW PATTERN;GASTRIC CARCINOMA;GASTROINTESTINAL MOTILITY;GLYCERALDEHYDE--PHOSPHATE DEHYDROGENASE;HEAVY CHAIN;HEMODIALYSIS UNIT;HEPATOCELLULAR CARCINOMA;HERNIA MESH;HIGHRISK PREGNANCY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INTRAVENOUS LEIOMYOMATOSIS;MELITENSIS BIOVAR;PUBMED SCOPUS;ABNORMAL VASCULAR;ANTIBIOTIC SUSCEPTIBILITY;APPROXIMATELY CM;BRUCELLA ISOLATES;CARDIOLOGY DEPARTMENT;CATANIA ITALY;COMPUTED TOMOGRAPHY;CROSSREF PUBMED;E-TEST METHOD;GI DISTURBANCES;GYNECOL OBSTET;INFERIOR VENA;INTRACARDIAC LEIOMYOMATOSIS;INTRAVASCULAR LESION;ITALY DR;KW-K LAU;LAU T-K;LITERATURE REVIEWARCH;MUSCLE TUMOR;OBSTET -CROSSREF;PROGESTERONE RECEPTORS;PULMONARY ARTERY;RARE BENIGN;REVIEWARCH GYNECOL;RPOB NUCLEOTIDE;SEVERE THROMBOCYTOPENIA;SMOOTH MUSCLE","5;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",4,0.19,6.25,3.5,0,0,0,0,1,0,1,3.75,0,0,3,0,1,0,0,2.5,1,0.75,0,90.5,91.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2008,24,8.29166666666667,1.95833333333333,0.458333333333333,0.291666666666667,0.666666666666667,1.27027027027027,1.1,1,1.06666666666667,0.208333333333333,0,15,0,4,4,0.62,0,0.17,0.17,28.71,0.523188529448742,NA,0.208333333333333,0.75,0.43,0.296,0.3,0.289,"GRAZIA GUZZETTA;CARMELO PRIVITERA;PIETRO GANGEMI;D. SAPIENZA;ROBERTO BORDONARO;SALVATORE RAGAZZI;L TENAGLIA;D. LAURETTA;E MINONA;RICCARDO POLOSA;STEFANO PULEO;ANTONIO GRANATA;ELISA MINONA;DIEGO PIAZZA;TERESA ROSANNA PORTALE;MARIA ANTONIETTA TROVATO;C. DI MAGGIO;MARCO LUCHETTI;ALFONSO FAUSTO;EUGENIO INGLESE","4;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","GRAZIA GUZZETTA;CARMELO PRIVITERA;D. SAPIENZA;D. LAURETTA;ANTONIO GRANATA;SALVATORE RAGAZZI;DIEGO PIAZZA;PIETRO GANGEMI;ROBERTO BORDONARO;STEFANO PULEO;ELISA MINONA;TERESA ROSANNA PORTALE;MARIA ANTONIETTA TROVATO;MARCO LUCHETTI;MASSIMO CANELLA;RICCARDO MASSEI;ALESSANDRO PECCI;MARCO ZOPPI;CARLO L. BALDUINI;C. E. FIORE","1.5;1.5;0.5;0.5;0.39;0.29;0.29;0.29;0.29;0.29;0.29;0.29;0.29;0.25;0.25;0.25;0.25;0.25;0.25;0.25","GRAZIA GUZZETTA;CARMELO PRIVITERA;PIETRO GANGEMI;ROBERTO BORDONARO;SALVATORE RAGAZZI;L TENAGLIA;RICCARDO POLOSA;STEFANO PULEO;ANTONIO GRANATA;DIEGO PIAZZA;ANNA RITA TOGNA;G. TOGNA;LUIGI CASTELLI;PAOLO NENCINI;GIUSEPPE LUIGI BANNA;LUCA ROMANELLI;MAURA PALMERY;MASSIMO CANELLA;ARTURO MONTINERI;P. PICCOLOTTI","4;4;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","GRAZIA GUZZETTA;CARMELO PRIVITERA;ANTONIO GRANATA;SALVATORE RAGAZZI;DIEGO PIAZZA;PIETRO GANGEMI;ROBERTO BORDONARO;STEFANO PULEO;MASSIMO CANELLA;C. E. FIORE;RICCARDO POLOSA;L TENAGLIA;LUCA ROMANELLI;MAURA PALMERY;ARTURO MONTINERI;P. PICCOLOTTI;ANTONIO MAGNANO;P. VALERI;LUIGI CASTELLI;CRISTINA RUSSO","1.5;1.5;0.39;0.29;0.29;0.29;0.29;0.29;0.25;0.25;0.24;0.21;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14","DARIO LOMBARDI;GIORGIO STASSI;GIULIO MAIRA;GIUSEPPE LUIGI BANNA;LUCIA RICCI‐VITIANI;LUIGI MARIA LAROCCA;MATILDE TODARO;MAURIZIO MARTINI;MICHELE SIGNORE;ROBERTO PALLINI;RUGGERO DE MARIA;J. SHÁBAN;JANUSZ GUMPRECHT;MARIAN BENROUBI;P. VALENSI;RYUZO KAWAMORI;SHREYAS SHAH;VITO BORZÌ;WENYING YANG;М. В. ШЕСТАКОВА","335;335;335;335;335;335;335;335;335;335;335;89;89;89;89;89;89;89;89;89","GIUSEPPE LUIGI BANNA;VITO BORZÌ;ANTONIO GRANATA;C. E. FIORE;F. PANE;PIETRO GANGEMI;RICCARDO POLOSA;MASSIMO CANELLA;DIEGO PIAZZA;SALVATORE RAGAZZI;ROBERTO BORDONARO;ARTURO MONTINERI;BARBARO SPAMPINATO;COSIMO DI MAURO;CRISTINA RUSSO;GIUSEPPE D’AMICO;LUIGI CASTELLI;LUCA ROMANELLI;MAURA PALMERY;P. PICCOLOTTI","335;89;80;69;42;41;35;16;12;12;10;9;9;9;9;9;9;8;8;8","CARMELO PRIVITERA;GRAZIA GUZZETTA;PIETRO GANGEMI;ANTONIO GRANATA;RICCARDO POLOSA;ROBERTO BORDONARO;ALDO BADIANI;ANNA RITA TOGNA;ANTONIO MAGNANO;ARTURO MONTINERI;BARBARO SPAMPINATO;C. E. FIORE;COSIMO DI MAURO;CRISTINA RUSSO;DIEGO PIAZZA;F. PANE;G. TOGNA;GIUSEPPE D’AMICO;GIUSEPPE LUIGI BANNA;GIUSEPPE VIRZÌ","4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ART;COMPUTER SCIENCE;ENGINEERING","23;6;2;1;1;1","INTERNAL MEDICINE;SURGERY;ANESTHESIA;GENETICS;PHARMACOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;DERMATOLOGY;ENVIRONMENTAL HEALTH;GENERAL SURGERY;IMMUNOLOGY;PATHOLOGY;BIOTECHNOLOGY;CANCER RESEARCH;HUMANITIES;MECHANICAL ENGINEERING;MEDICAL PHYSICS;MICROBIOLOGY;ONCOLOGY;UROLOGY;VIROLOGY","15;10;6;5;5;4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","RECEPTOR;DIABETES MELLITUS;GENE;ASCITES;BLOOD PRESSURE;CANCER;CARCINOID TUMORS;CHEMOTHERAPY;CLONIDINE;COMPLICATION;CONFIDENCE INTERVAL;MORPHINE;NEOSTIGMINE;PAIN MANAGEMENT;POPULATION;SHOULDER SURGERY;TRANSDERMAL;ANALGESIC;ANEURYSM;ANTIBIOTICS;ANTIFUNGAL;ARTERY;ARTHROPLASTY;ASYMPTOMATIC;BACTERIA;BIOPSY;CAROTID ARTERIES;CERVICAL PLEXUS;CIRRHOSIS;COLLATERAL CIRCULATION;CREATININE;D-DIMER;DIABETES INSIPIDUS;DRUG;EMBOLIZATION;ETIOLOGY;FAMILY HISTORY;FEMUR;FENTANYL;GASTROINTESTINAL TRACT;HEMODYNAMICS;HORMONE;IMMUNOHISTOCHEMISTRY;IN VITRO;IN VIVO;INFUNDIBULUM;INSULIN;INTENSIVE CARE UNIT;INTERQUARTILE RANGE;KIDNEY;LIDOCAINE;LUNG;LYMPHATIC SYSTEM;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MEDICAL IMAGING;METABOLISM;METHADONE;MYCOSIS;NITRIC OXIDE;OBSERVATIONAL STUDY;ORTHOPEDIC SURGERY;PAPAVERINE;PERIOPERATIVE;PNEUMONIA;POLYMYOSITIS;PULMONARY EMBOLISM;RADIATION THERAPY;REGIMEN;RESPIRATORY DISTRESS;RISK FACTOR;ROPIVACAINE;SELLA TURCICA;SEPSIS;SPINAL ANESTHESIA;STEM CELL;STENT;STROKE (ENGINE);VIRUS","6;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OPIOID;CHYLE;CHYLOUS ASCITES;ACUTE RESPIRATORY DISTRESS;AGONIST;ALLELE;AMPHOTERICIN B;BACTEREMIA;BLOCKADE;BREAST CANCER;CANCER STEM CELL;CAPSAICIN;CAROTID ENDARTERECTOMY;CHROMOSOMAL TRANSLOCATION;ENDARTERECTOMY;FEMORAL FRACTURE;FUNGEMIA;GASTRODUODENAL ARTERY;GLUCURONIDE;HAZARD RATIO;HEART RATE;HEPATITIS C VIRUS;HEROIN;HYPERHOMOCYSTEINEMIA;LEVOBUPIVACAINE;MALT LYMPHOMA;MICROSOME;NEPHROPATHY;OPIATE;PITUITARY GLAND;POLYMERASE CHAIN REACTION;POLYURIA;POSTPRANDIAL;PROBIOTIC;PROTEINURIA;PSEUDOANEURYSM;RECEPTOR TYROSINE KINASE;RENIN–ANGIOTENSIN SYSTEM;RNA;STEREOTACTIC BIOPSY;TEMOZOLOMIDE;TYPE 2 DIABETES","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BUPRENORPHINE;(+)-NALOXONE;BREAST CARCINOMA;GAS6;GLUCURONIDATION;INSULIN ASPART;MAMMOGRAPHY;MEAN ARTERIAL PRESSURE;METHYLENETETRAHYDROFOLATE REDUCTASE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NALTREXONE;OPIOID RECEPTOR;POSTERIOR PITUITARY;TRANSFER RNA","2;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;GASTROINTESTINAL NEOPLASMS;ANALGESICS, OPIOID;TREATMENT OUTCOME;;AGED;LIVER CIRRHOSIS, ALCOHOLIC;ADULT;BIOMARKERS, TUMOR;BRAIN;CARCINOID TUMOR;CARCINOMA, NEUROENDOCRINE;DIABETES MELLITUS, TYPE 2;GALLBLADDER NEOPLASMS;LUNG DISEASES, FUNGAL;MORPHINE;POLYMYOSITIS","18;11;11;9;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4","EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT OF POSTOPERATIVE PAIN AND COMPLICATIONS;OPIOID EPIDEMIC IN THE UNITED STATES;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CANCER OF UNKNOWN PRIMARY SITE;CANCER STEM CELLS AND TUMOR METASTASIS;DIAGNOSIS AND MANAGEMENT OF CELIAC DISEASE;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DRUG METABOLISM AND PHARMACOGENOMICS;EPIDEMIOLOGY, CLASSIFICATION, AND CLINICAL FEATURES OF INFLAMMATORY MYOPATHIES;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HERNIA REPAIR TECHNIQUES AND MATERIALS;LYMPHOID NEOPLASMS;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;MANAGEMENT OF MESENTERIC ISCHEMIA AND ANEURYSMS;MECHANISMS OF APOPTOTIC CELL CLEARANCE AND IMMUNE REGULATION;PATHOPHYSIOLOGY OF GLOMERULAR DISEASES AND NEPHROTIC SYNDROMES;ROLE OF HOMOCYSTEINE IN HEALTH AND DISEASE;WOUND HEALING AND REGENERATION","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CARCINOID TUMORS;CHYLE;CHYLOUS ASCITES;PAIN MANAGEMENT;POSTOPERATIVE PAIN;REGIONAL ANESTHESIA;SHOULDER ARTHROPLASTY;SHOULDER FUNCTION;SHOULDER PATHOLOGY;SHOULDER SURGERY;AMINOACYL TRNA SYNTHETASE;BACTEREMIA;BREAST CARCINOMA;BREAST IMAGING;BREAST MRI;CANCER GENOMICS;CANCER STEM CELLS;CAPSAICIN;CARDIOVASCULAR EVALUATION;CERVICAL PLEXUS","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","BUPRENORPHINE PATCHES;CARCINOID TUMOR;CHYLOUS ASCITES;GASTROINTESTINAL CARCINOID;PAIN MANAGEMENT;POOR PROGNOSIS;POSTOPERATIVE PAIN;RARE ASSOCIATION;SHOULDER SURGERY;TDS BUPRENORPHINE;TRANSDERMAL TDS;ACUTE DYSPNEA;ACUTE RESPIRATORY;ALCOHOL-RELATED HEPATIC;ANESTHESIA VERSUS;ANTIHISTIDYL-TRNA SYNTHETASE;ARTERY COIL;ARTERY PSEUDOANEURYSM;ARTHROPLASTY SURGERY;BASELINE CHARACTERISTICS;BREAST MAGNETIC;CANCER STEM;CAROTID ENDARTERECTOMY;CELL ANALYSIS;CENTRAL DIABETES;CEREVISIAE FUNGEMIA;CLINICAL CHALLENGES;CLINICAL OUTCOME;COIL EMBOLIZATION;COMBINED REGIONAL","2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;BONE MARROW;CROSSREF PUBMED;SERUM IMMUNOFIXATION;ABNORMAL COAGULATION;AMORPHOUS MATERIAL;BOWEL MOVEMENTS;ENDOSCOPIC FINDINGS;FIGURE VIEWERDOWNLOAD;GRANULAR MUCOSA;HI-RES IMAGE;IMAGE DOWNLOAD;IMAGE FIGURE;INTESTINAL INVOLVEMENT;MALABSORPTION SYNDROME;MARROW BIOPSY;MED -CROSSREF;MONOCLONAL PROTEIN;RHEUMATOID FACTOR;SERUM ELECTROPHORESIS;SEVERE MALABSORPTION;VIEWERDOWNLOAD HI-RES;WALDENSTROMS MACROGLOBULINEMIA;YEAR-OLD WOMAN;CLINICAL CHALLENGES;LEUKOCYTE INCLUSIONS;DISORDER CHARACTERIZED;HISTOLOGIC EXAMINATION;ACUTE SIGNS;ALBUMIN GDL","15;12;12;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;5;5;4;4;3;3",1,0.04,3,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,3,1,171,175,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,5.5,512.5,5.41,0,0,15.5,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4206 PUBLIC HEALTH","2;1;1;1","CARDIOVASCULAR;CLINICAL RESEARCH;HEART DISEASE;BIOMEDICAL IMAGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIABETES;DIGESTIVE DISEASES;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;LIVER DISEASE;NUTRITION;OBESITY;PREVENTION;RARE DISEASES;TRANSPLANTATION","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;BLOOD;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL","2;1;1;1","6.1 PHARMACEUTICALS","1","LEUKEMIA / LEUKAEMIA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2009,26,8.11538461538461,1.34615384615385,0.346153846153846,0.0769230769230769,0.307692307692308,1.25,1.125,0.666666666666667,1.14285714285714,0.269230769230769,1,13,3,4,6,0.5,0.12,0.15,0.23,28.5,0.61612000528446,NA,0.384615384615385,0.769230769230769,0.396,0.308,0,0.318,"RYUZO KAWAMORI;М. В. ШЕСТАКОВА;VITO BORZÌ;J. SHÁBAN;WENYING YANG;ANTONIO GRANATA;MARIAN BENROUBI;SHREYAS SHAH;ANTONIO BIONDI;P. VALENSI;FRANCESCO BASILE;TRISTAN FERRY;J. VERHOEF;JAKUB GUMPRECHT;AD C. FLUIT;SALVATORE MOTTA;A. L. A. BLOEMENDAAL;JOSÉ MANUEL AMORIM;FRANCESCO DI RAIMONDO;STEFANIA STEFANI","4;4;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","RAFFAELE FALSAPERLA;ANTONIO GRANATA;RENZO MIGNAMI;ANTONIO BIONDI;FRANCESCO BASILE;RYUZO KAWAMORI;М. В. ШЕСТАКОВА;VITO BORZÌ;J. SHÁBAN;WENYING YANG;MARIAN BENROUBI;MATTEO SIMONELLI;GIUSEPPE LUIGI BANNA;ANGELO GAMBERA;MARCELLO PEZZINO;ARMANDO SANTORO;ANNA RITA MARUCCI;SHREYAS SHAH;P. VALENSI;SALVATORE MOTTA","1;0.83;0.5;0.49;0.49;0.42;0.42;0.42;0.42;0.42;0.42;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.32;0.29","VITO BORZÌ;ANTONIO GRANATA;ANTONIO BIONDI;STEFANIA STEFANI;PIERO PAVONE;ROBERTO BORDONARO;SALVATORE RAGAZZI;MANUELA CHIARA ACCARDI;NUNZIO RESTUCCIA;V. GAROZZO;GIUSEPPE LUIGI BANNA;VITO LEANZA;GIACOMO CASTIGLIONE;ANGELO GAMBERA;PAOLO VIGNERI;GIUSEPPE EVOLA;MICHELE VECCHIO;CARMELO PRIVITERA;ORAZIO GARRETTO;RAFFAELE FALSAPERLA","4;4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RAFFAELE FALSAPERLA;ANTONIO GRANATA;ANTONIO BIONDI;VITO BORZÌ;GIUSEPPE LUIGI BANNA;ANGELO GAMBERA;SALVATORE RAGAZZI;DAVIDE FERRARA;FRANCESCO PALAZZO;DIEGO PIAZZA;CARMELO PRIVITERA;ORAZIO GARRETTO;GIUSEPPINA DI STEFANO;MANUELA CHIARA ACCARDI;VITO LEANZA;GIUSEPPE EVOLA;MICHELE VECCHIO;FORTUNATO GENOVESE;PIERO PAVONE;STEFANIA STEFANI","1;0.83;0.49;0.42;0.33;0.33;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.15","J. SHÁBAN;MARIAN BENROUBI;RYUZO KAWAMORI;VITO BORZÌ;WENYING YANG;М. В. ШЕСТАКОВА;DAVID M. SIMPSON;DONALD J. WEISZ;JEAN‐MICHEL GRACIÈS;MARA LUGASSY;MICHELE VECCHIO;STEVEN R. FLANAGAN;P. VALENSI;SHREYAS SHAH;JAKUB GUMPRECHT;A. L. A. BLOEMENDAAL;AD C. FLUIT;J. VERHOEF;JOSÉ MANUEL AMORIM;MENNO R. VRIENS","187;187;187;187;187;187;175;175;175;175;175;175;173;173;127;74;74;74;74;74","VITO BORZÌ;MICHELE VECCHIO;GIACOMO CASTIGLIONE;ANTONIO GRANATA;GIUSEPPE EVOLA;G. NOVELLO;ROBERTO BORDONARO;V. GAROZZO;PIERO PAVONE;GIUSEPPE LUIGI BANNA;FORTUNATO GENOVESE;MANUELA CHIARA ACCARDI;VITO LEANZA;DAVIDE FERRARA;DIEGO PIAZZA;FRANCESCO PALAZZO;SALVATORE RAGAZZI;STEFANIA STEFANI;CALOGERO BUSCARINO;NUNZIO RESTUCCIA","187;175;60;54;54;52;52;45;25;21;16;16;16;14;14;14;14;14;9;9","ANTONIO GRANATA;VITO BORZÌ;ANTONIO BIONDI;CALOGERO BUSCARINO;CARMELO PRIVITERA;DAVIDE FERRARA;DIEGO PIAZZA;FORTUNATO GENOVESE;FRANCESCO PALAZZO;G. NOVELLO;GIACOMO CASTIGLIONE;GIUSEPPE EVOLA;GIUSEPPE LUIGI BANNA;GIUSEPPINA DI STEFANO;MANUELA CHIARA ACCARDI;MICHELE VECCHIO;NUNZIO RESTUCCIA;ORAZIO GARRETTO;PAOLO VIGNERI;PIERO PAVONE","4;4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATERIALS SCIENCE;CHEMISTRY;PHILOSOPHY;PHYSICS;POLITICAL SCIENCE;PSYCHOLOGY","26;5;3;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;ENDOCRINOLOGY;RADIOLOGY;GENETICS;GASTROENTEROLOGY;ANATOMY;ANESTHESIA;ENVIRONMENTAL HEALTH;GENERAL SURGERY;INTENSIVE CARE MEDICINE;METALLURGY;MICROBIOLOGY;ONCOLOGY;PHYSICAL MEDICINE AND REHABILITATION;ARTIFICIAL INTELLIGENCE;AUDIOLOGY;CARDIOLOGY;COMPUTER NETWORK;COMPUTER VISION;DERMATOLOGY;EMERGENCY MEDICINE;EPISTEMOLOGY;LAW;MEDICAL EDUCATION;NURSING;OPERATING SYSTEM;OPTICS;ORGANIC CHEMISTRY;PEDAGOGY;PEDIATRICS;PHYSICAL THERAPY;UROLOGY","16;10;9;5;5;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INSULIN;CANCER;DIABETES MELLITUS;KIDNEY;ADVERSE EFFECT;ALTERNATIVE MEDICINE;BACTERIA;BIOPSY;INTENSIVE CARE;LAPAROSCOPY;META-ANALYSIS;OBSERVATIONAL STUDY;POPULATION;SACRUM;ABDOMEN;ABDOMINAL SURGERY;ABDOMINAL WALL;ABSCESS;AGENESIS;ANALGESIC;ANASTOMOSIS;ANTIBIOTICS;ANTIMICROBIAL;ARTHROPLASTY;ASYMPTOMATIC;ASYNCHRONOUS COMMUNICATION;BICEPS;CEMENT;CEREBRAL PALSY;CHEMOTHERAPY;COLONIZATION;COMPLICATION;CONCOMITANT;CONSERVATIVE TREATMENT;CORPUS CALLOSUM;CULTURAL KNOWLEDGE;CYST;CYTOLOGY;DISEASE;DIVERTICULAR DISEASE;DIVERTICULITIS;EHLERS–DANLOS SYNDROME;ELBOW;ETHNIC GROUP;FISTULA;GENE;GIANT CELL;GROUP B;HEALTH CARE;HEARING LOSS;HEART FAILURE;HERNIA;HISTOPATHOLOGY;INCIDENCE (GEOMETRY);INTENSIVE CARE UNIT;INTERVENTION (COUNSELING);KIDNEY DISEASE;LYMPH NODE;LYMPHOMA;MAGNETIC RESONANCE IMAGING;MICROCEPHALY;MORTALITY RATE;MULTIPLE MYELOMA;MULTIVARIATE ANALYSIS;MYASTHENIA GRAVIS;MYELOID LEUKEMIA;NEPHROLOGY;PARESIS;PATTERN RECOGNITION (PSYCHOLOGY);PHYLLODES TUMOR;PREGNANCY;PRINCIPAL (COMPUTER SECURITY);PUNCHING;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;SEGMENTATION;SEROUS FLUID;SIMPLE (PHILOSOPHY);SPASTICITY;SURGICAL EMERGENCY;THYMOMA;TOTAL JOINT REPLACEMENT;TOTAL KNEE ARTHROPLASTY;TRANSPLANTATION;TUBEROUS SCLEROSIS;ULTRASONOGRAPHY;URINARY SYSTEM;UTERUS;VISUAL ANALOGUE SCALE;VISUALIZATION;WIDE LOCAL EXCISION","5;4;4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TYPE 2 DIABETES;POSTPRANDIAL;BASAL (MEDICINE);COLORECTAL CANCER;STAPHYLOCOCCUS AUREUS;SUBGROUP ANALYSIS;AGENESIS OF THE CORPUS CALLOSUM;ANGIOMYOLIPOMA;ANTIBIOTIC PROPHYLAXIS;ASYNCHRONY (COMPUTER PROGRAMMING);BACK PAIN;BONE CEMENT;BREAST CANCER;CAESAREAN SECTION;CERVICAL CANCER;CLINICAL ENDPOINT;CORPUS CALLOSUM AGENESIS;DUPLEX ULTRASONOGRAPHY;EJECTION FRACTION;ENZYME REPLACEMENT THERAPY;FABRY DISEASE;FINE-NEEDLE ASPIRATION;GENE DUPLICATION;GESTATION;HUMAN INSULIN;HYPOGLYCEMIA;IMAGE SEGMENTATION;IMATINIB;INCISIONAL HERNIA;JOINT ARTHROPLASTY;JOINT REPLACEMENT;KIDNEY TRANSPLANTATION;LAMBERT-EATON MYASTHENIC SYNDROME;LYMPH NODE BIOPSY;MICROALBUMINURIA;NEUTROPENIA;OVARIAN CYST;PERFORATION;PROTEINURIA;RENAL COLIC;RESISTIVE INDEX;SENSORINEURAL HEARING LOSS;SPASTIC;THYMECTOMY;TOLERABILITY;TRANSCULTURAL NURSING;UNIVARIATE ANALYSIS","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","INSULIN ASPART;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;STAPHYLOCOCCAL INFECTIONS;ALPHA-GALACTOSIDASE;BREAST TISSUE;CAPECITABINE;CETUXIMAB;DASATINIB;GLYCATED HEMOGLOBIN;HPV INFECTION;INSULIN GLARGINE;IRINOTECAN;MAMMOGRAPHY;MASTECTOMY;OXALIPLATIN;PAPANICOLAOU STAIN","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;INSULIN;MIDDLE AGED;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;STAPHYLOCOCCUS AUREUS;AGED;DIABETES MELLITUS, TYPE 2;CARCINOMA;HYPOGLYCEMIC AGENTS;STAPHYLOCOCCAL INFECTIONS;HYPOGLYCEMIA;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;DIVERTICULITIS, COLONIC;EUROPE;PARESIS;SACRUM","24;18;14;11;11;11;10;10;8;8;7;7;7;6;6;5;5;5;5;5","MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTIONS;ADDRESSING RACIAL AND ETHNIC DISPARITIES IN HEALTHCARE THROUGH CULTURAL COMPETENCE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF DIVERTICULITIS;DIAGNOSIS AND TREATMENT OF PROSTHETIC JOINT INFECTIONS;EFFICACY AND RESISTANCE IN CML TREATMENT;GENE THERAPY FOR SPINAL MUSCULAR ATROPHY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HERNIA REPAIR TECHNIQUES AND MATERIALS;HIRSCHSPRUNG DISEASE AND ENTERIC NERVOUS SYSTEM DEVELOPMENT;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;KIKUCHI-FUJIMOTO DISEASE ANALYSIS AND MANAGEMENT;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MANAGEMENT OF DIABETES MELLITUS AND CARDIOVASCULAR RISK;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;PATHOPHYSIOLOGY OF LUMBAR DISC DEGENERATION AND TREATMENT","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CONTINUOUS GLUCOSE MONITORING;DIABETES;INSULIN ASPART;TYPE 2 DIABETES;GLUCOSE CONTROL;INSULIN THERAPY;BASAL (MEDICINE);SUBGROUP ANALYSIS;TREATMENT;ACUTE COMPLICATIONS;AGENESIS;ALPHA-GALACTOSIDASE;ANGIOMYOLIPOMA;ASYNCHRONY (COMPUTER PROGRAMMING);BACK PAIN;BONE CEMENT;BOTULINUM TOXIN;BREAST TISSUE;BREAST TUMOURS;CARDIAC ELECTROPHYSIOLOGY","4;4;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","BIPHASIC INSULIN;INSULIN ASPART;SUBGROUP ANALYSIS;TYPE DIABETES;ASPART NOVOMIXSUPSUP;CARE UNITS;EUROPEAN INTENSIVE;GLYCAEMIC CONTROL;IMPROVE OBSERVATIONAL;INSULIN THERAPY;INTENSIVE CARE;OBSERVATIONAL STUDY;ACUTE COMPLICATED;ACUTE RENAL;ADULT HETEROZYGOUS;ADVANCED COLORECTAL;ANTI-EGFR ANTIBODY;ANTI-HU PARANEOPLASTIC;ANTIBIOTIC-LOADED BONE;ANTIBODY CETUXIMAB;ANTIDIABETICS SUBGROUP;ASPART BIASP;AUTONOMIC ANTI-HU;AVE REGISTRY;BASAL INSULINS;BENIGN GIANT;BENIGN PHYLLOIDES;BIASP NOVOMIXSUPSUP;BONE CEMENT;BOTULINUM TOXIN","3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OBSERVATIONAL STUDY;SCLEROSIS COMPLEX;TUBEROUS SCLEROSIS;ASPART BIASP;BASELINE HBAC;BIPHASIC INSULIN;DIABETES DURATION;INSULIN ASPART;INSULIN THERAPY;MAJOR HYPOGLYCAEMIA;SENSORINEURAL DEAFNESS;TREATMENT SATISFACTION;ADVERSE EVENTS;BID DAYS;CAPECITABINE MGM;CURRARINO TRIAD;DAYS QD;ELEVATED SOFT;GLYCAEMIC PARAMETERS;GYRATION PATTERN;IMPROVE OBSERVATIONAL;INCLUDING MICROCEPHALY;INSULIN OADS;IV DAYS;MGM ORALLY;NORMAL GYRATION;ORALLY BID;ORGAN DAMAGE;PHARMACEUTICAL THERAPY;RENAL VARIANT","5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",3,0.12,3.5,1.5,0,0,0,0,0,0,1,1.5,0,1,0,0,0,0,0,0,0,0,0,43.5,43.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,6,1060,11.11,2,0.67,190.67,0,0,0,0,2,0,0,1,0,3,0,0,0,0,0,0,0,2,1,0,3,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","3;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AUTOIMMUNE DISEASE;BREAST CANCER;CANCER;DIGESTIVE DISEASES;LUNG;NUTRITION;PEDIATRIC;RARE DISEASES","3;3;2;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL;RESPIRATORY","1;1;1","6.1 PHARMACEUTICALS","2","BREAST CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2010,42,7,2.04761904761905,0.642857142857143,0.357142857142857,0.69047619047619,1.40983606557377,1.42105263157895,1,1.38095238095238,0.30952380952381,2,15,10,2,9,0.36,0.24,0.05,0.21,20.1,0.44467745351404,NA,0.19047619047619,0.666666666666667,0.47,0.374,0.444,0.381,"PIERO PAVONE;FRANCESCO BASILE;GAETANO MAGRO;ANTONIO BIONDI;MARTINO RUGGIERI;PAOLO AMICO;STEFANO PALMUCCI;GIOVANNI CARLO ETTORRE;S CIUNI;ROBERTO CIUNI;MICHELA DI GIUNTA;ANTONIO GRANATA;ANTONIO CIANCI;NICOLA MUSMECI;G ZANGHÍ;ANTONIO PESCE;MARIA L. MANDALÀ;INGO KENNERKNECHT;ALESSANDRO TROPEA;WALTER MORALE","8;7;6;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","GAETANO MAGRO;PIERO PAVONE;STEFANO PALMUCCI;FRANCESCO BASILE;T AVITABILE;ANTONIO BIONDI;PAOLO AMICO;ANTONIO GRANATA;S CIUNI;ROBERTO CIUNI;MARTINO RUGGIERI;MICHELA DI GIUNTA;FULVIO FLOCCARI;ALESSANDRO TROPEA;PAOLO GRECO;PANTALEO GRECO;ANTONIO PESCE;STEFANO PULEO;TERESA ROSANNA PORTALE;MARIA ANTONIETTA TROVATO","1.49;1.33;1.27;1.21;1;0.97;0.87;0.66;0.54;0.54;0.53;0.52;0.5;0.5;0.5;0.5;0.4;0.4;0.4;0.4","PIERO PAVONE;FRANCESCO BASILE;GAETANO MAGRO;ANTONIO BIONDI;PAOLO AMICO;STEFANO PALMUCCI;GIOVANNI CARLO ETTORRE;ROBERTO CIUNI;ANTONIO GRANATA;ANTONIO CIANCI;G ZANGHÍ;ANTONIO PESCE;ALESSANDRO TROPEA;RAFFAELE FALSAPERLA;STEFANO PULEO;PIETRO MILONE;MARTINA MESSINA;ROSALBA GIORDANO;LETIZIA ANTONELLA MAURO;TERESA ROSANNA PORTALE","8;7;6;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","GAETANO MAGRO;PIERO PAVONE;STEFANO PALMUCCI;FRANCESCO BASILE;T AVITABILE;ANTONIO BIONDI;PAOLO AMICO;ANTONIO GRANATA;ROBERTO CIUNI;ALESSANDRO TROPEA;PANTALEO GRECO;ANTONIO PESCE;STEFANO PULEO;TERESA ROSANNA PORTALE;MARIA ANTONIETTA TROVATO;GIOVANNI CARLO ETTORRE;RAFFAELE FALSAPERLA;ANTONIO CIANCI;ROSALBA GIORDANO;VITO BORZÌ","1.49;1.33;1.27;1.21;1;0.97;0.87;0.66;0.54;0.5;0.5;0.4;0.4;0.4;0.4;0.38;0.37;0.36;0.36;0.33","ALESSANDRA CACCIATORE;BEATRICE LA ROSA;MATTEA ROMANO;ROSALBA GIORDANO;FRANCESCO BASILE;ANTONIO GRANATA;G ZANGHÍ;GAETANO MAGRO;A. MARVASO;ACHILLE GASPARI;ANTONIO BRESCIA;C. FRONTICELLI BALDELLI;CESARE STABILINI;E GIANETTA;EZIO FALLETTO;G COSCARELLA;G. CAMPANELLI;G. CORRADO;G. M. BUONANNO;LANDINO FEI","196;196;196;196;124;87;86;79;77;77;77;77;77;77;77;77;77;77;77;77","MATTEA ROMANO;FRANCESCO BASILE;ANTONIO GRANATA;G ZANGHÍ;STEFANO PALMUCCI;GIUSEPPE CARPINTERI;GIOVANNI CARLO ETTORRE;LETIZIA ANTONELLA MAURO;PIETRO MILONE;PIERO PAVONE;GAETANO MAGRO;ANTHONY S. BASILE;C. E. FIORE;E. SICUREZZA;MICHELE FIGUERA;RAFFAELE FALSAPERLA;ANTONIO BIONDI;GIAMBATTISTA BONANNO;S. LA SCOLA;ANDREA MUSUMECI","196;100;87;77;73;67;64;58;58;47;42;40;40;40;40;34;32;30;30;28","PIERO PAVONE;ROBERTO CIUNI;ANTONIO BIONDI;ANTONIO GRANATA;GIOVANNI CARLO ETTORRE;STEFANO PALMUCCI;ANTONIO CIANCI;FRANCESCO BASILE;GAETANO MAGRO;LETIZIA ANTONELLA MAURO;MARTINA MESSINA;PAOLO AMICO;PIETRO MILONE;RAFFAELE FALSAPERLA;A. VIGLIANESI;ALESSANDRA GURRERA;ALESSANDRO TROPEA;ANDREA MUSUMECI;ANGELA RAGUSA;ANTHONY S. BASILE","4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY","41;6;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;RADIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;PSYCHIATRY;ANATOMY;DERMATOLOGY;GENETICS;PEDIATRICS;UROLOGY;IMMUNOLOGY;OBSTETRICS;PALEONTOLOGY;PHYSICAL MEDICINE AND REHABILITATION;ANESTHESIA;BIOCHEMISTRY;CARDIOLOGY;EMERGENCY MEDICINE;GYNECOLOGY;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;NUCLEAR MEDICINE;OPHTHALMOLOGY;OPTICS;ORGANIC CHEMISTRY;PHARMACOLOGY;PHYSICAL THERAPY;PSYCHOANALYSIS","27;19;15;14;4;4;4;4;3;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;DISEASE;RETROSPECTIVE COHORT STUDY;THYROID;ALTERNATIVE MEDICINE;ASYMPTOMATIC;BLOOD PRESSURE;KIDNEY;LESION;MAGNETIC RESONANCE IMAGING;PATHOLOGICAL;ABDOMINAL PAIN;ADVERSE EFFECT;ANGIOGRAPHY;BILE DUCT;BIOPSY;CARCINOMA;CIRRHOSIS;CUTIS;DIFFERENTIAL DIAGNOSIS;EPILEPSY;HEMODIALYSIS;HERNIA;IMMUNOHISTOCHEMISTRY;KIDNEY DISEASE;LAPAROSCOPY;LAPAROTOMY;PANCREATITIS;PREDICTIVE VALUE;PREDICTIVE VALUE OF TESTS;PREGNANCY;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);URINARY INCONTINENCE;VEIN","6;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLORECTAL CANCER;POSITIVE PREDICATIVE VALUE;PROTEINURIA;THYROIDECTOMY;ABDOMINAL HERNIA;ABORTION;ACUPUNCTURE;ADENOCARCINOMA;ADJUVANT THERAPY;AMLODIPINE;ANAPLASTIC CARCINOMA;ANGIOTENSIN II;ANGIOTENSIN-CONVERTING ENZYME;ARTERIOVENOUS ANASTOMOSIS;BENAZEPRIL;BRACHIAL ARTERY;BREAST CANCER;CENTRAL VENOUS CATHETER;CEPHALIC VEIN;CERVICAL SPONDYLOSIS;CHEMORADIOTHERAPY;CHILDBIRTH;CHRONIC HEPATITIS;COMPLEMENTARY DNA;CONGENITAL HYPOTHYROIDISM;CONTRAST-ENHANCED ULTRASOUND;CORTICAL DYSPLASIA;DERMATOFIBROMA;DIALYSIS CATHETER;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;ENDOSCOPIC ULTRASONOGRAPHY;EPISIOTOMY;EPITHELIOID CELL;FIBRIN TISSUE ADHESIVE;FLUVASTATIN;GANGLIOGLIOMA;GENE EXPRESSION;GENOTYPE;GESTATION;GLOMERULONEPHRITIS;GOITER;HEMODIALYSIS CATHETER;HEPATITIS C VIRUS;HERNIA REPAIR;HYPOGLYCEMIA;INCISIONAL HERNIA;INFARCTION;INGUINAL HERNIA;INTRACTABLE EPILEPSY;IODINATED CONTRAST;LIVER CANCER;LYMPHADENECTOMY;MUTATION;MYELOPATHY;NEURONAVIGATION;NUCLEAR ATYPIA;OCCULT;PANCREATIC DUCT;PANCREATIC MASS;PARATHYROID HORMONE;PATHOGNOMONIC;PERITONEAL MESOTHELIOMA;POSTPARTUM PERIOD;POSTPRANDIAL;PSEUDOANEURYSM;RADICAL SURGERY;RARE DISEASE;RENAL BIOPSY;RETINAL DETACHMENT;SEROMA;SORAFENIB;SPLENECTOMY;SPLENIC INFARCTION;STATUS EPILEPTICUS;STROMA;THYROID CANCER;THYROID CARCINOMA;THYROID DISEASE;THYROID NODULES;TYPE 2 DIABETES;URINALYSIS;VALSARTAN;VASCULITIS;VENOGRAPHY;VIMENTIN;VITRECTOMY","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACE INHIBITOR;ALPHA-THALASSEMIA;ANTIVIRAL THERAPY;ATRX;AXILLA;DRY NEEDLING;FIBRINOID NECROSIS;GESTATIONAL SAC;LOSARTAN;MACULAR HOLE;MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY;MICROARRAY;OLIGOHYDRAMNIOS;PARS PLANA;RECTAL CARCINOMA;TOTAL MESORECTAL EXCISION;TOTAL THYROIDECTOMY;WANDERING SPLEEN","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;PIGMENTATION DISORDERS;TREATMENT OUTCOME;;AGED;PROSPECTIVE STUDIES;RECTAL NEOPLASMS;SEIZURES;ITALY;ADOLESCENT;CHILD;HEPATITIS C;PANCREATIC DISEASES;RECTUM;RETROSPECTIVE STUDIES;BRAIN NEOPLASMS","34;23;20;16;9;9;9;8;8;8;7;7;6;5;5;5;5;5;5;4","CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;GENOMIC REARRANGEMENT DISORDERS IN SKIN DISEASES;HEPATOCELLULAR CARCINOMA;HERNIA REPAIR TECHNIQUES AND MATERIALS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;PELVIC FLOOR DISORDERS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;COLORECTAL CANCER RESEARCH AND TREATMENT;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND TREATMENT OF HEART FAILURE;EPILEPSY AND SEIZURES;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS;HEPATITIS C INFECTION AND TREATMENT;HIRSCHSPRUNG DISEASE AND ENTERIC NERVOUS SYSTEM DEVELOPMENT;INTEGRIN SIGNALING IN INFLAMMATION AND CANCER;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH","3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CENTRAL VENOUS CATHETERIZATION;CLINICAL FEATURES;CUTIS;HEMODIALYSIS VASCULAR ACCESS;HERNIA REPAIR;INCISIONAL HERNIA;METASTATIC COLORECTAL CANCER;POSITIVE PREDICATIVE VALUE;THYROID NODULES;TREATMENT;ABDOMINAL HERNIA;ABNORMALITY;ADJUVANT THERAPY;ALBUMINURIA;ALPHA-THALASSEMIA;AMLODIPINE;ANAL CANCER;ANAMNESIS;ANAPLASTIC CARCINOMA;ANCA-ASSOCIATED","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;CUTIS TRICOLOR;HISTOGENETIC CONSIDERATIONS;MAGNETIC RESONANCE;RESONANCE CHOLANGIOPANCREATOGRAPHY;ABDOMINAL WALL;ACCESSORY SPLEEN;ACUTE HEART;ACUTE PYELONEPHRITIS;ADD-ON FLUVASTATIN;ADVERSE EVENTS;ALPHA THALASSEMIA;AMLODIPINE TREATMENT;ANCA-ASSOCIATED VASCULITIS;ANEURYSM MIMICKING;ANTIANGIOGENIC THERAPY;ARTERIOVENOUS FISTULAE;ARTERY ANEURYSM;ATYPICAL DERMATOFIBROMA;ATYPICAL PLACEMENT;AUTOIMMUNE HYPOTHYROIDISM;BILIARY ADENOFIBROMA;BILIARY PATHOLOGY;BNP REDUCTION;BOY BORN;BREAST MYXOMA;CANCER FOLLOW-UP;CELL COMPONENT;CENTRAL VENOUS;CERVICAL DISC","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BNP LEVEL;LT PGML;PERCENTAGE DECREASE;ANGIOTENSIN RECEPTOR;ANGIOTENSIN-CONVERTING ENZYME;BILIARY ADENOFIBROMA;BLOOD MONONUCLEAR;CDNA MICROARRAY;COMBINED ANGIOTENSIN-CONVERTING;FIBRINOID NECROSIS;KIDNEY DISEASE;MENTAL RETARDATION;MONONUCLEAR CELLS;POSITIVE SUBJECTS;ADVERSE EVENTS;ANCA-ASSOCIATED VASCULITIS;ANDOR MYELOPATHY;ANTIVIRAL TREATMENT;ARTERIAL WALL;BNP REDUCTION;CARDIOVASCULAR OUTCOMES;CERVICAL RADICULOPATHY;CHRONIC KIDNEY;CLINICAL BEHAVIOUR;COLORECTAL CANCER;DEVELOP HO;DISC REPLACEMENT;DISCHARGE COMPARED;DISEASE PATIENTS;ELDERLY PATIENTS","5;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",4,0.1,3.12,9.25,1,0,0,0,16,0,0,9.25,0,0,5.5,0,0,0,1,4,1,0,0,15,15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4.43,419.71,13.56,3,0.38,43.88,0,0,0,0,5,0,0,3,0,4,3,0,0,0,0,0,0,8,0,0,7,1,0,0,0,0,0,0,0,0,"Italy;Switzerland;United States","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","8;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;BRAIN DISORDERS;CANCER;NEURODEGENERATIVE;RARE DISEASES;HEMATOLOGY;AGING;ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD);AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;EYE DISEASE AND DISORDERS OF VISION;LYMPHOMA;MENTAL HEALTH;MULTIPLE SCLEROSIS;ORPHAN DRUG;PARKINSON'S DISEASE;PEDIATRIC;REGENERATIVE MEDICINE","7;5;4;3;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL;CANCER;EYE;INFLAMMATORY AND IMMUNE SYSTEM","3;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES","4;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;STOMACH CANCER","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2011,50,9.26,3.28,0.5,0.3,0.52,1.35537190082645,1.19047619047619,1.07142857142857,1.23809523809524,0.46,2,14,15,11,5,0.28,0.3,0.22,0.1,27.96,0.657352032590793,NA,0.2,0.76,0.405,0.332,0.205,0.332,"ANTONIO GRANATA;PIERO PAVONE;FULVIO FLOCCARI;GAETANO MAGRO;GIUSEPPE MORGIA;SALVATORE MERCURIO;FRANCESCO DI RAIMONDO;ROSARIO CALTABIANO;ANTONIO BASILE;ALBERTO SAITA;MARIO FALSAPERLA;SALVATORE LEOTTA;LUCA DI LULLO;MASSIMO POIDOMANI;FULVIO FIORINI;A. VIGLIANESI;PAOLO FIUMARA;PASQUALE CAPONNETTO;MARIO MOTTA;ANTONIO PESCE","6;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","GAETANO MAGRO;GRANATA;ANTONIO GRANATA;PIERO PAVONE;FULVIO FLOCCARI;ROSARIO CALTABIANO;ALBERTO SAITA;MARIO FALSAPERLA;GIUSEPPE MORGIA;LIDIA PUZZO;PASQUALE CAPONNETTO;MARIO MOTTA;DAVIDE CAMPAGNA;RICCARDO POLOSA;MARCO PUGLISI;ANTONINO PETRALIA;LUCA DI LULLO;FULVIO FIORINI;ANTONIO PESCE;ROBERTO SCILLETTA","1.26;1;0.88;0.73;0.7;0.48;0.46;0.46;0.4;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.32;0.32;0.31;0.31","ANTONIO GRANATA;PIERO PAVONE;GAETANO MAGRO;GIUSEPPE MORGIA;SALVATORE MERCURIO;ROSARIO CALTABIANO;ANTONIO BASILE;ALBERTO SAITA;MARIO FALSAPERLA;SALVATORE LEOTTA;MASSIMO POIDOMANI;A. VIGLIANESI;PASQUALE CAPONNETTO;MARIO MOTTA;ANTONIO PESCE;GIOVANNI CARLO ETTORRE;ANDREA SPADARO;ROBERTO SCILLETTA;ANGELA BRANCA;EUGENIO AGUGLIA","6;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","GAETANO MAGRO;GRANATA;ANTONIO GRANATA;PIERO PAVONE;ROSARIO CALTABIANO;ALBERTO SAITA;MARIO FALSAPERLA;GIUSEPPE MORGIA;LIDIA PUZZO;PASQUALE CAPONNETTO;MARIO MOTTA;DAVIDE CAMPAGNA;RICCARDO POLOSA;MARCO PUGLISI;ANTONINO PETRALIA;ANTONIO PESCE;ROBERTO SCILLETTA;ANGELA BRANCA;GUIDO BASILE;STEFANO PULEO","1.26;1;0.88;0.73;0.48;0.46;0.46;0.4;0.36;0.33;0.33;0.33;0.33;0.33;0.33;0.31;0.31;0.31;0.31;0.31","DAVIDE CAMPAGNA;PASQUALE CAPONNETTO;RICCARDO POLOSA;CRISTINA RUSSO;GABRIELLA PAPALE;JAYMIN B. MORJARIA;GAETANO MAGRO;A SCIACCA;CARLA CAIO;CARMELA SANTANGELO;D. SCIORTINO;FLORIANA GONA;MARIA LINA MEZZATESTA;STEFANIA STEFANI;V. PETROLITO;ANDREA BIONDI;ANTHONY M. FORD;ELENA MIRABILE;FREDERIK W. VAN DELFT;GIOVANNI CAZZANIGA","481;481;481;429;429;429;106;95;95;95;95;95;95;95;95;92;92;92;92;92","DAVIDE CAMPAGNA;PASQUALE CAPONNETTO;RICCARDO POLOSA;CRISTINA RUSSO;GABRIELLA PAPALE;GAETANO MAGRO;CARMELA SANTANGELO;ELENA MIRABILE;LUCA LO NIGRO;GIADA MARIA VECCHIO;ROSARIO CALTABIANO;VINCENZO GUARDABASSO;ANTONIO GRANATA;G ARCIDIACONO;SUSAN MANCUSO;EUGENIO AGUGLIA;MARIA SALVINA SIGNORELLI;A. REIBALDÍ;CORRADO SPATOLA;GABRIELA FRANCO","481;481;481;429;429;106;95;92;92;91;91;64;62;52;52;51;51;50;50;50","ANTONIO GRANATA;PIERO PAVONE;ALBERTO SAITA;GAETANO MAGRO;MARIO FALSAPERLA;ROSARIO CALTABIANO;SALVATORE MERCURIO;A. VIGLIANESI;ANDREA SPADARO;ANGELA BRANCA;ANTONELLA PRIVITERA;ANTONIO PESCE;CARLA CONSOLI;DAVIDE CAMPAGNA;GIADA MARIA VECCHIO;GIOVANNI CARLO ETTORRE;GIUSEPPE AVOLA;GIUSEPPE MILONE;MA TROVATO;MARIA GRAZIA CAMUGLIA","6;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;ECONOMICS;HISTORY;MATERIALS SCIENCE;MATHEMATICS;PHYSICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","49;16;4;3;2;2;2;2;2;2;1;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;RADIOLOGY;GENETICS;PSYCHIATRY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;PEDIATRICS;ANATOMY;CANCER RESEARCH;ENDOCRINOLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;OBSTETRICS;ARCHAEOLOGY;BIOCHEMISTRY;CHROMATOGRAPHY;CLINICAL PSYCHOLOGY;COMPOSITE MATERIAL;EMERGENCY MEDICINE;MACROECONOMICS;MEDICAL PHYSICS;MICROBIOLOGY;PALEONTOLOGY;PHARMACOLOGY;PHYSICAL THERAPY;PHYSIOLOGY;STATISTICS","34;16;16;13;7;7;5;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CANCER;DISEASE;GENE;HEART FAILURE;BIOPSY;IMMUNOHISTOCHEMISTRY;KIDNEY;LAPAROSCOPY;MAGNETIC RESONANCE IMAGING;POPULATION;PREGNANCY;ANTIBIOTICS;ANXIETY;COHORT;DEPRESSION (ECONOMICS);DOSIMETRY;EPIDEMIOLOGY;ETIOLOGY;HEMODIALYSIS;HEMODYNAMICS;LOGISTIC REGRESSION;LYMPHOMA;MOBILIZATION;NEPHROTIC SYNDROME;NICOTINE;OBSERVATIONAL STUDY;ODDS RATIO;PATHOLOGICAL;PHARMACOKINETICS;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING);SMOKING CESSATION;STEM CELL;STENOSIS;TRANSPLANTATION;URINARY SYSTEM","4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;BREAST CANCER;CD34;EJECTION FRACTION;GENOTYPE;GLOMERULONEPHRITIS;INTRAVASCULAR VOLUME STATUS;PROTEINURIA;RENAL BIOPSY;VOLUME OVERLOAD;ABDOMINAL HERNIA;ACHALASIA;AGONIST;ALLELE;ANTIPSYCHOTIC;AORTIC VALVE REPLACEMENT;AORTIC VALVE STENOSIS;APOLIPOPROTEIN E;AREA UNDER CURVE;ASTHMA ATTACK;ATOPY;BIOSTATISTICS;BONE CEMENT;BRACHYTHERAPY;BREAKPOINT CLUSTER REGION;CAESAREAN SECTION;CARDIAC MAGNETIC RESONANCE IMAGING;CARDIORENAL SYNDROME;CEMENTUM;CENTRAL VENOUS CATHETER;CHILDBIRTH;CHROMOSOMAL TRANSLOCATION;CISPLATIN;COLISTIN;CYCLOTRON;CYTOKERATIN;DIALYSIS CATHETER;DIFFUSION MRI;EFFECTIVE DIFFUSION COEFFICIENT;ELECTROSPRAY;ENDOSCOPIC ULTRASONOGRAPHY;EPIDERMAL GROWTH FACTOR RECEPTOR;ESCHERICHIA COLI;ESOPHAGEAL CANCER;FUSION GENE;GEE;GEMCITABINE;GESTATION;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEMODIALYSIS CATHETER;HERNIA REPAIR;HYDRONEPHROSIS;IMMUNOSTAINING;INFRATEMPORAL FOSSA;LAPAROSCOPIC SURGERY;LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY;LIVER FIBROSIS;LYMPHOBLASTIC LEUKEMIA;MALT LYMPHOMA;NEPHROSTOMY;NEURODEGENERATION;NICOTINE DEPENDENCE;NICOTINE REPLACEMENT THERAPY;NITRIC OXIDE SYNTHASE;OCULAR MELANOMA;PERCUTANEOUS NEPHROLITHOTOMY;PROSTHESIS IMPLANTATION;PTERYGOPALATINE FOSSA;RADIATION TREATMENT PLANNING;REFLUX;RENAL PELVIS;RISPERIDONE;SEROLOGY;SEROMA;SPLENECTOMY;SURGICAL INFECTIONS;SURGICAL MESH;TANDEM MASS SPECTROMETRY;THYROID CANCER;THYROID CARCINOMA;TRANSFERRIN RECEPTOR;UNIVARIATE ANALYSIS;UPPER URINARY TRACT;VAGINAL DELIVERY;VASCULAR ENDOTHELIAL GROWTH FACTOR;VENOGRAPHY;VIMENTIN","2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FOCAL SEGMENTAL GLOMERULOSCLEROSIS;MEMBRANOUS NEPHROPATHY;ACUTE LYMPHOCYTIC LEUKEMIA;ADENOSINE RECEPTOR;AUTONOMIC NERVOUS SYSTEM;CARBOPLATIN;CARDIAC SKELETON;DESMIN;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;ELECTROSPRAY MASS SPECTROMETRY;ENOS;ERLOTINIB;ESOPHAGEAL MOTILITY DISORDER;ESOPHAGECTOMY;EXTERNAL BEAM RADIOTHERAPY;GENOTYPING;HEART RATE VARIABILITY;HIATAL HERNIA;HORMONE RECEPTOR;KLEBSIELLA PNEUMONIAE;METAPLASTIC CARCINOMA;METHYLENETETRAHYDROFOLATE REDUCTASE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;MYOTOMY;PERIPHERAL BLOOD STEM CELLS;PHILADELPHIA CHROMOSOME;PYELOPLASTY;SINGLE-NUCLEOTIDE POLYMORPHISM;SOLITARY FIBROUS TUMOR;SPLENIC DISEASE;STAGHORN CALCULUS;TRANSIENT ELASTOGRAPHY;TRASTUZUMAB;URETEROPELVIC JUNCTION","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;ADULT;MIDDLE AGED;AGED;ITALY;LEUKEMIA, MYELOID, ACUTE;NEOPLASMS, MUSCLE TISSUE;CHILD;DEPRESSION;GLUCOCORTICOIDS;TREATMENT OUTCOME;YOUNG ADULT;CARCINOMA, NON-SMALL-CELL LUNG;LAPAROSCOPY;LUNG NEOPLASMS;RNA, MESSENGER;SMOKING CESSATION","28;24;22;20;19;18;13;8;7;7;6;6;6;6;6;5;5;5;5;5","ACUTE MYELOID LEUKEMIA;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;LYMPHOID NEOPLASMS;SMOKING CESSATION AND HEALTH EFFECTS OF TOBACCO;ADVANCEMENTS IN LUNG CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ASTHMA;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;EFFECTS OF KETOGENIC DIET ON HEALTH;EMOTION REGULATION AND PSYCHOPATHOLOGY IN CHILDREN AND ADOLESCENTS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;EPILEPSY AND SEIZURES;FORENSIC TOXICOLOGY METHODS AND ANALYSIS","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE;DEPRESSION (ECONOMICS);ETIOLOGY;INTRAVASCULAR VOLUME STATUS;MEMBRANOUS NEPHROPATHY;MINIMAL CHANGE DISEASE;MOBILIZATION;NICOTINE ADDICTION;POLYCYSTIC KIDNEY DISEASE;SMOKING CESSATION;STEM CELL MOBILIZATION;VERTEBRAL COMPRESSION FRACTURE;VERTEBROPLASTY;VOLUME OVERLOAD;ABDOMINAL HERNIA;ABDOMINAL MASS;ABDOMINAL WALL RECONSTRUCTION;ACHALASIA;ACUTE LYMPHOCYTIC LEUKEMIA","3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","AML PATIENTS;AUTOSOMAL DOMINANT;COMPLEX RENAL;DOMINANT POLYCYSTIC;ELDERLY PATIENTS;IDIOPATHIC MEMBRANOUS;KIDNEY DISEASE;MAGNETIC RESONANCE;MEMBRANOUS NEPHROPATHY;PILOT STUDY;POLYCYSTIC KIDNEY;POTENTIAL DIAGNOSTIC;UNUSUAL ASSOCIATION;ABDOMINAL WALL;ABERRANT EXPRESSION;ACCESSIBLE TOOL;ACUTE ASTHMA;ACUTE LYMPHOBLASTIC;AD-RELATED DEPRESSION;ADVANCED NSCLC;ALLOGENEIC TRANSPLANTATION;ALTERED SPERMATOGENESIS;ALZHEIMERS DISEASE;ANXIOUS-DEPRESSIVE SPECTRUM;AORTIC VALVE;ARIADNES THREAD;ATYPICAL PLACEMENT;AUTONOMIC NERVOUS;BCR-ABL FUSION;BIOMOLECULAR CHARACTERISTICS","2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CD CELL;CD CELLS;RESIDUAL GROWTH;AML PATIENTS;CD MOBILIZATION;CLONOGENIC PRECURSORS;PUBMED SCOPUS;CELL MOBILIZATION;CROSSREF PUBMED;PERIPHERAL BLOOD;ΜGML ΜGML;ACUTE MYELOID;BONE MARROW;CELL PEAK;STEM CELL;DISEASE-FREE SURVIVAL;MYELOID LEUKEMIA;MEDIAN RANGE;BLOOD STEM;CD PEAK;CFU-GM CHEMOSENSITIVITY;MINIMAL RESIDUAL;NORMAL NONLEUKEMIC;NORMALIZED RESIDUAL;VITRO CFU-GM;COMPLETE REMISSION;CONSOLIDATION CYCLE;LEUKEMIC CELLS;LIPID METABOLISM;MARROW CLONOGENIC","24;21;18;16;15;13;13;12;12;12;12;10;9;9;9;8;8;7;6;6;6;6;6;6;6;5;5;5;5;5",11,0.22,3,1.5,32.5,4,5,8,1.75,0,2,2.5,0,1,3.25,3,1.75,0,3.25,2.5,1,0,0,79,79.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,5.56,439.33,7.83,2,0.22,71.33,0,0,1,0,4,0,2,2,0,9,0,0,0,0,0,0,0,8,1,0,9,0,0,0,0,0,0,0,0,0,"Italy;United States","2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3212 OPHTHALMOLOGY AND OPTOMETRY;4207 SPORTS SCIENCE AND EXERCISE","7;3;3;2;2;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;NEUROSCIENCES;AGING;BRAIN DISORDERS;LYMPHOMA;ORPHAN DRUG;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;STROKE;TRAUMATIC HEAD AND SPINE INJURY;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;DIABETES;DIGESTIVE DISEASES;EYE DISEASE AND DISORDERS OF VISION;LIVER DISEASE;NUTRITION","7;4;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL;STROKE;CARDIOVASCULAR;EYE;METABOLIC AND ENDOCRINE","3;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","7;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;OVARIAN CANCER","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2012,55,9.05454545454545,2.34545454545455,0.490909090909091,0.327272727272727,0.509090909090909,1.41758241758242,1.22727272727273,1.2,1.27272727272727,0.363636363636364,1,16,12,11,8,0.29,0.22,0.2,0.15,20.27,0.485361155930752,3.65891472868217,0.181818181818182,0.836363636363636,0.425,0.402,0.38,0.393,"PIERO PAVONE;FRANCESCO BASILE;ANDREA D. PRATICÒ;MARTINO RUGGIERI;STEFANO PALMUCCI;FILIPPO DRAGO;GIULIA MALAGUARNERA;GIOVANNI CARLO ETTORRE;ALBERTO VERROTTI;GEMMA INCORPORA;RICCARDO POLOSA;RAFFAELE FALSAPERLA;ANTONIO BIONDI;MARCO VACANTE;PASQUALE CAPONNETTO;MICHELE MALAGUARNERA;VELIA D’AGATA;ROSARIO CUNSOLO;ROBERTO BORDONARO;GAETANO MAGRO","12;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","PIERO PAVONE;STEFANO PALMUCCI;ROBERTO CATANZARO;RICCARDO POLOSA;PASQUALE CAPONNETTO;FRANCESCO BASILE;ANDREA D. PRATICÒ;MARTINO RUGGIERI;ANGELA DIMARTINO;CRISTINA RUSSO;ANGELO ITALIA;GEMMA INCORPORA;FILIPPO DRAGO;GIULIA MALAGUARNERA;GIOVANNI CARLO ETTORRE;G ZANGHÍ;G BENFATTO;RAFFAELE FALSAPERLA;MARK F. SANDS;ALBERTO VERROTTI","1.48;1.41;1;0.83;0.83;0.82;0.71;0.67;0.5;0.5;0.5;0.43;0.42;0.42;0.41;0.4;0.4;0.35;0.33;0.33","PIERO PAVONE;FRANCESCO BASILE;ANDREA D. PRATICÒ;STEFANO PALMUCCI;GIOVANNI CARLO ETTORRE;RICCARDO POLOSA;RAFFAELE FALSAPERLA;ANTONIO BIONDI;PASQUALE CAPONNETTO;ROSARIO CUNSOLO;ROBERTO BORDONARO;GAETANO MAGRO;G ZANGHÍ;CRISTINA RUSSO;LUCIA SALVATORELLI;ANTONIO PESCE;GAETANO BERTINO;GIUSEPPE SESSA;RITA CHIARAMONTE;PIETRO VALERIO FOTI","12;6;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","PIERO PAVONE;STEFANO PALMUCCI;ROBERTO CATANZARO;RICCARDO POLOSA;PASQUALE CAPONNETTO;FRANCESCO BASILE;ANDREA D. PRATICÒ;CRISTINA RUSSO;GIOVANNI CARLO ETTORRE;G ZANGHÍ;RAFFAELE FALSAPERLA;ANTONIO BIONDI;VITO PAVONE;GIOVANNI FAILLA;ANTONIO PESCE;ROBERTO SCILLETTA;GAETANO MAGRO;LUCIA SALVATORELLI;RITA CHIARAMONTE;I. CHIARAMONTE","1.48;1.41;1;0.83;0.83;0.82;0.71;0.5;0.41;0.4;0.35;0.31;0.31;0.3;0.28;0.28;0.27;0.27;0.27;0.27","PIERO PAVONE;GAETANO MAGRO;LUCIA SALVATORELLI;FRANCESCO BASILE;FILIPPO DRAGO;GIULIA MALAGUARNERA;MICHELE MALAGUARNERA;ANTONIO BIONDI;MARCO VACANTE;MARTINO RUGGIERI;RAFFAELE FALSAPERLA;STEFANO PALMUCCI;ALBERTO RIGHI;DENISA KACEROVSKÁ;DMITRY V. KAZAKOV;LAURA CASORZO;MICHAL MICHAL;TORRISI ANTONIETTA;ANDREA D. PRATICÒ;PIETRO MILONE","326;140;140;131;128;128;128;115;115;115;109;109;103;103;103;103;103;103;94;88","PIERO PAVONE;GAETANO MAGRO;LUCIA SALVATORELLI;ANTONIO BIONDI;FRANCESCO BASILE;RAFFAELE FALSAPERLA;STEFANO PALMUCCI;GIOVANNI CARLO ETTORRE;PIETRO VALERIO FOTI;ANTONINO GULLO;CRISTINA SANTONOCITO;ANTONIO PESCE;GIOVANNI LI DESTRI;ROBERTO SCILLETTA;TERESA ROSANNA PORTALE;VINCENZO MINUTOLO;DIEGO PIAZZA;HÉCTOR SOTO PARRÀ;IRENE CONTI;A RACALBUTO","259;140;140;115;115;109;109;87;74;73;73;62;62;62;62;62;53;53;47;45","PIERO PAVONE;STEFANO PALMUCCI;ANTONIO BIONDI;FRANCESCO BASILE;GIOVANNI CARLO ETTORRE;RAFFAELE FALSAPERLA;PASQUALE CAPONNETTO;RICCARDO POLOSA;A. D'AMORE;CRISTINA RUSSO;G ZANGHÍ;GAETANO MAGRO;GIORGIO CONTE;GIOVANNI FAILLA;HÉCTOR SOTO PARRÀ;I. CHIARAMONTE;LUCIA SALVATORELLI;PIETRO VALERIO FOTI;RITA CHIARAMONTE;ROBERTO CATANZARO","10;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;ECONOMICS;PHYSICS;PSYCHOLOGY;PHILOSOPHY;POLITICAL SCIENCE;ENGINEERING;BUSINESS;CHEMISTRY;COMPUTER SCIENCE;HISTORY;SOCIOLOGY","55;12;4;4;4;3;3;2;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;IMMUNOLOGY;PSYCHIATRY;RADIOLOGY;SURGERY;PEDIATRICS;GENETICS;GASTROENTEROLOGY;ANATOMY;CARDIOLOGY;NUCLEAR MEDICINE;ONCOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENERAL SURGERY;INTENSIVE CARE MEDICINE;PALEONTOLOGY;ANESTHESIA;AUDIOLOGY;BIOCHEMISTRY;EPISTEMOLOGY;LAW;NEUROSCIENCE;NURSING","34;19;11;11;10;10;8;7;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","CANCER;GENE;IMMUNOHISTOCHEMISTRY;ANTIBODY;DISEASE;HEPATOCELLULAR CARCINOMA;LAPAROSCOPY;MAGNETIC RESONANCE IMAGING;VIRUS;ALTERNATIVE MEDICINE;COHORT;EPILEPSY;HEALTH CARE;HEPATITIS B;LUNG;LUNG CANCER;POPULATION;RECEPTOR;SMOKING CESSATION;STAGE (STRATIGRAPHY)","10;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","ADENOCARCINOMA;HEPATITIS B VIRUS;BREAST CANCER;DIFFUSION MRI;GENE EXPRESSION;IMMUNOSTAINING;INTERSTITIAL LUNG DISEASE;LAPAROSCOPIC SURGERY;PANCREATIC CANCER;PNEUMOPERITONEUM;ABSOLUTE THRESHOLD OF HEARING;AGONIST;AMYLASE;ANTIPSYCHOTIC;AORTIC ROOT;AORTIC SINUS;AORTIC VALVE STENOSIS;APLASTIC ANEMIA;AUDITORY BRAINSTEM RESPONSE;AUTOANTIBODY;AUTOIMMUNE PANCREATITIS;BEVACIZUMAB;BILE LEAK;BLASTEMA;CARBAMAZEPINE;CEREBELLAR VERMIS;CHEMOKINE;CHROMOGRANIN A;CHROMOSOME;CHRONIC HEPATITIS;CLINICAL ENDPOINT;CLONE (JAVA METHOD);COGNITIVE IMPAIRMENT;COLORECTAL CANCER;CONTRAINDICATION;CORNEAL EPITHELIUM;DEFECOGRAPHY;DEPRESSIVE SYMPTOMS;DYSSYNERGIA;EFFECTIVE DIFFUSION COEFFICIENT;EMBRYONIC STEM CELL;ENTEROSCOPY;EPIDERMAL GROWTH FACTOR RECEPTOR;EPIDIDYMIS;EVIDENCE-BASED MEDICINE;FUNCTIONAL INDEPENDENCE MEASURE;GENOTYPE;HAEMATOPOIESIS;HALOPERIDOL;HEPATITIS C VIRUS;ICTAL;IMMUNIZATION;IMMUNOFLUORESCENCE;IMMUNOPHENOTYPING;INFERIOR COLLICULUS;INTERNATIONAL CLASSIFICATION OF HEADACHE DISORDERS;KERATOCONUS;KI-67;KIDNEY TRANSPLANTATION;LEFT VENTRICULAR HYPERTROPHY;LENALIDOMIDE;LIFE EXPECTANCY;LIPASE;LIVER FIBROSIS;LOG-RANK TEST;LUNG DISEASE;MALT LYMPHOMA;MESENCHYME;MESONEPHRIC DUCT;METASTASIS;MICROPHTHALMIA;MICRORNA;MUCOSITIS;MULTIDETECTOR COMPUTED TOMOGRAPHY;MYELODYSPLASTIC SYNDROMES;MYOCLONIC EPILEPSY;MYOCLONIC JERK;NEUROBLASTOMA;NEUTROPENIA;OCCULT;OFFSPRING;PANCREATIC MASS;PHASES OF CLINICAL RESEARCH;PHENOTYPE;PORTAL HYPERTENSION;POSTPRANDIAL;PRECOCIOUS PUBERTY;PROGRESSIVE DISEASE;PROSTATE;PULMONARY ATRESIA;QUALITY MANAGEMENT;RARE DISEASE;REFLEX EPILEPSY;REVASCULARIZATION;SEIZURE TYPES;SENSORINEURAL HEARING LOSS;SEROLOGY;SEROTONIN;SIX SIGMA;SOFT TISSUE SARCOMA;SORAFENIB;STROMA;TETRALOGY OF FALLOT;TRIPTANS;TYPE 1 DIABETES;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;VARICES","3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;BONE MARROW FAILURE;CARDIAC SKELETON;CHEMOKINE RECEPTOR;CXCR4;CYTOGENETICS;DESIGN FOR SIX SIGMA;DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING;DMAIC;ERLOTINIB;FLUORESCENCE IN SITU HYBRIDIZATION;FLUOXETINE;GENE EXPRESSION PROFILING;GERIATRIC DEPRESSION SCALE;HAPLOINSUFFICIENCY;HBSAG;HYPERAMYLASEMIA;HYPOTHALAMIC HAMARTOMA;IN SITU HYBRIDIZATION;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;ISOAMYLASE;LIMBIC ENCEPHALITIS;MESONEPHROS;METHYLENETETRAHYDROFOLATE REDUCTASE;OPSOCLONUS;OXALIPLATIN;OXCARBAZEPINE;PANCREATIC TUMOR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;SUMATRIPTAN;TETRALOGY;TRANSIENT ELASTOGRAPHY;TRANSPLANTED KIDNEY;VACCINATION SCHEDULE;VERESS NEEDLE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;AGED, 80 AND OVER;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;BIOMARKERS, TUMOR;BREAST NEOPLASMS;CHILD;FORKHEAD TRANSCRIPTION FACTORS;INTESTINAL OBSTRUCTION;MIGRAINE DISORDERS;ADOLESCENT;HYPERTENSION, PORTAL;LIVER CIRRHOSIS;MAGNETIC RESONANCE IMAGING","39;26;23;16;15;14;11;10;8;8;7;7;7;6;6;6;5;5;5;5","EPILEPSY AND SEIZURES;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;ETIOLOGY AND MANAGEMENT OF PERITONEAL ADHESIONS;HEPATITIS B INFECTION AND TREATMENT;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;ATRIAL FIBRILLATION;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BIOMECHANICAL PROPERTIES OF THE CORNEA AND RELATED DISEASES;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CANCER OF UNKNOWN PRIMARY SITE;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;COMPREHENSIVE APPROACH TO SCHOOL HEALTH PROMOTION;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF IGG4-RELATED DISEASE","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPATITIS B;PANCREATIC DISEASE;SMOKING CESSATION;DIFFUSION-WEIGHTED IMAGING;EPILEPSY;HBV INFECTION;IMMUNOSTAINING;INTERSTITIAL LUNG DISEASE;MAGNETIC RESONANCE IMAGING;NICOTINE ADDICTION;PERFUSION IMAGING;PULMONARY DISEASE;RESPIRATORY;SEIZURES;TREATMENT;ABDOMINAL MASS;ABDOMINAL ULTRASOUND;ACUTE PANCREATITIS;AGE-RELATED HEARING LOSS;AGENESIS","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","LUNG CANCER;SMOKING CESSATION;ANABOLIC THERAPY;CELL LUNG;HEPATOCELLULAR CARCINOMA;INTERSTITIAL LUNG;LUNG DISEASE;MAGNETIC RESONANCE;MULTICENTER STUDY;PHASE II;SOUTHERN ITALY;SUCCESSFUL SMOKING;ACUTE TREATMENT;ADHESIOLYSIS CONSENSUS;ADVANCED COLORECTAL;ADVANCED SOFT;ALTERNATING HEMIPLEGIA;ANALOGUE THERAPY;ANEURYSM TREATED;ANTHRACYCLINE-BASED THERAPY;AORTIC ROOT;AORTIC VALVE;ASTHMATIC PATIENT;ATRESIA PSEUDOTRUNCUS;ATRIAL FIBRILLATION;AUTOIMMUNE PANCREATITIS;BATH-INDUCED ALTERNATING;BILE DUCT;BIOIMPEDANCE ANALYSIS;BIOLOGICAL ACTIVITY","3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPATOCELLULAR CARCINOMA;BREAST CANCER;CEAF STROKE;DW SS-EP;PORTAL HYPERTENSION;BLACK SWAN;HEARING LOSS;PRIMARY HEADACHES;SKIN PICKING;SOUTHERN ITALY;SS-EP SEQUENCES;ANTIVIRAL TREATMENT;BENIGN FLLS;BLOOD GLUCOSE;BODY WEIGHT;FIM SCORE;INFERIOR COLLICULUS;MAGNETIC RESONANCE;MALIGNANT FLLS;NON-CEAF STROKE;SIGNIFICANT ASSOCIATION;WOMEN NA;AGE RANGE;AGED TYPE;ALLERGIC DISORDERS;BRONCHIAL BIOPSIES;CARCINOMA PATIENTS;CARDIOEMBOLIC STROKE;CBACAJ MICE;CHRONIC HEPATITIS","13;9;6;6;6;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2",7,0.13,5.68,3,1,0,0,1,2,0,1,3,0,0,1.75,0,3,0,0,1.75,0,0,0,62.5,62.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,4.2,410.4,5.88,2,0.4,41,0,0,0,1,3,0,0,1,0,5,0,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Italy;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","5;3;2;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;MENTAL HEALTH;NEUROSCIENCES;ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD);AUTOIMMUNE DISEASE;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;DEPRESSION;HEART DISEASE;HEMATOLOGY;LYMPHOMA;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;RARE DISEASES","4;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES","3;2;1;1;1","NON-HODGKIN'S LYMPHOMA","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2013,72,9.94444444444444,2.66666666666667,0.458333333333333,0.361111111111111,0.569444444444444,1.35211267605634,1.22222222222222,1.08333333333333,1.28125,0.527777777777778,2,26,13,11,8,0.36,0.18,0.15,0.11,16.39,0.46969573702233,3.71951219512195,0.208333333333333,0.861111111111111,0.358,0.331,0.303,0.306,"PIERO PAVONE;GIUSEPPE MILONE;ROSARIO FOTI;SALVATORE LEOTTA;GAETANO MAGRO;ANDREA SPADARO;FRANCESCO DI RAIMONDO;GIORGIO FRANCO;LUCA CINDOLO;MARCELLO DONATI;CORRADO TAMBURINO;ANDREA TUBARO;RAFFAELE FALSAPERLA;ANTONIO BIONDI;ALESSANDRA CUPRI;ANGELITA GIGLIO;MASSIMO MARTINO;COSTANTINO LEONARDO;COSIMO DE NUNZIO;LUCA","6;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","PIERO PAVONE;MARIA CHIARA SUDANO;SIGNORELLI;GIUSEPPE MILONE;LUCA;GIOVANNI TRIPEPI;MARCELLO DONATI;ANTONIO BIONDI;ANGELITA GIGLIO;GIOVANNA BRANCATO;RAFFAELE FALSAPERLA;GAETANO MAGRO;MASSIMILIANO SORBELLO;G FROVA;LUCA;CARMELA CALANDRA;FRANCESCO DI RAIMONDO;MAURIZIO RISTAGNO;GIADA MARIA VECCHIO;ALESSANDRA ROMANO","1.06;1;1;0.84;0.67;0.59;0.57;0.57;0.57;0.57;0.56;0.5;0.5;0.5;0.5;0.5;0.41;0.4;0.38;0.37","PIERO PAVONE;GIUSEPPE MILONE;ROSARIO FOTI;SALVATORE LEOTTA;GAETANO MAGRO;ANDREA SPADARO;FRANCESCO DI RAIMONDO;MARCELLO DONATI;RAFFAELE FALSAPERLA;ANTONIO BIONDI;ALESSANDRA CUPRI;LUCA;MARIO FALSAPERLA;ALBERTO TERMINELLA;CARMELA CALANDRA;S SAITA;GIUSEPPE CARPINTERI;AGOSTINO SERRA;LUCIA SALVATORELLI;RAFFAELE CAMPISI","6;5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2","PIERO PAVONE;MARIA CHIARA SUDANO;SIGNORELLI;GIUSEPPE MILONE;LUCA;MARCELLO DONATI;ANTONIO BIONDI;RAFFAELE FALSAPERLA;GAETANO MAGRO;MASSIMILIANO SORBELLO;LUCA;CARMELA CALANDRA;FRANCESCO DI RAIMONDO;GIADA MARIA VECCHIO;GIUSEPPE SESSA;SALVATORE DILETTOSO;GIANLUCA TESTA;ALESSANDRA UCCELLO;LUCIANO COSTARELLA;VITO PAVONE","1.06;1;1;0.84;0.67;0.57;0.57;0.56;0.5;0.5;0.5;0.5;0.41;0.38;0.37;0.37;0.37;0.37;0.37;0.37","ANDREA TUBARO;COSIMO DE NUNZIO;COSTANTINO LEONARDO;GIORGIO FRANCO;LUCA CINDOLO;MARIO FALSAPERLA;SISTO PERDONÀ;ROSARIO FOTI;A SCHEJA;ALAN TYNDALL;ALBERTO SULLI;ALESSIA BENENATI;BOJANA STAMENKOVIĆ;C. LUBATTI;CARMEN MARINA MIHAI;CODRINA ANCUȚA;CRISTIANE KAYSER;ESTHELA LOYO;EWA MORGIEL;FLORIAN MEIER","154;154;154;154;154;154;128;125;107;107;107;107;107;107;107;107;107;107;107;107","MARIO FALSAPERLA;ROSARIO FOTI;ALESSIA BENENATI;HÉCTOR SOTO PARRÀ;GIANLUCA TESTA;VITO PAVONE;GIUSEPPE CARPINTERI;GIUSEPPE MILONE;BIANCAMARIA GLIOZZO;PAOLA NOTO;GAETANO MAGRO;ALESSANDRA CUPRI;GIORGIO CONTE;GIUSEPPE SESSA;LUCIANO COSTARELLA;MARIA RICCIOLI;ANDREA SPADARO;ANNALIA DI MARCO;ELENA SCHINOCCA;ELEONORA SPINA","154;125;107;96;92;92;82;80;79;79;65;61;61;61;61;61;57;57;57;57","GIUSEPPE MILONE;PIERO PAVONE;LUCA;ROSARIO FOTI;GAETANO MAGRO;MARIO FALSAPERLA;RAFFAELE FALSAPERLA;ALESSANDRA CUPRI;ANTONIO BIONDI;MARCELLO DONATI;ALBERTO TERMINELLA;ALESSANDRA UCCELLO;ANDREA SPADARO;ANNALIA DI MARCO;CARMELA CALANDRA;ELENA SCHINOCCA;ELEONORA SPINA;GIACOMO CUSUMANO;GIADA MARIA VECCHIO;GIANLUCA TESTA","5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;POLITICAL SCIENCE;ECONOMICS;MATERIALS SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;COMPUTER SCIENCE;GEOLOGY;HISTORY;PHILOSOPHY;BUSINESS;SOCIOLOGY","71;17;5;5;4;4;3;3;3;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;ANESTHESIA;PEDIATRICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;INTENSIVE CARE MEDICINE;LAW;OPTICS;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;NURSING;ANATOMY;DERMATOLOGY;EMERGENCY MEDICINE;MACROECONOMICS;MECHANICAL ENGINEERING;OBSTETRICS;PHARMACOLOGY;PHYSICAL THERAPY;UROLOGY","49;24;13;12;12;10;9;9;9;8;5;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","CHEMOTHERAPY;DISEASE;POPULATION;COHORT;RECEPTOR;CANCER;PREGNANCY;IMMUNOHISTOCHEMISTRY;INCIDENCE (GEOMETRY);RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;ALTERNATIVE MEDICINE;CLINICAL TRIAL;DEPRESSION (ECONOMICS);EPILEPSY;HERNIA;MULTIPLE MYELOMA;MULTIVARIATE ANALYSIS;OBSERVATIONAL STUDY;PROSPECTIVE COHORT STUDY;RESPIRATORY FAILURE;RETROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS","9;9;8;7;7;6;6;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CHEMOKINE;CYCLOPHOSPHAMIDE;FETUS;GRANULOCYTE COLONY-STIMULATING FACTOR;UNIVARIATE ANALYSIS;CD34;CISPLATIN;CLINICAL ENDPOINT;EJECTION FRACTION;INGUINAL HERNIA;LEFT VENTRICULAR HYPERTROPHY;PHASES OF CLINICAL RESEARCH;PLACEBO;PLEOMORPHISM (CYTOLOGY);TYPE 2 DIABETES;VALPROIC ACID;VIMENTIN;VOLCANIC ASH;VULCANIAN ERUPTION","4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CXCR4;CARBOPLATIN;DESMIN;TRASTUZUMAB;ANTHRACYCLINE;CHORIOAMNIONITIS;CONGENITAL TALIPES EQUINOVARUS;CORONAVIRUS DISEASE 2019 (COVID-19);CROSSOVER STUDY;CYSTECTOMY;DOUBLE BLIND;FETAL HEMOGLOBIN;GASTRO-;HAMILTON DEPRESSION SCALE;HAPLOTYPE;IMATINIB MESYLATE;INSULIN ASPART;LEUKAPHERESIS;MOLAR PREGNANCY;MOLECULAR MEDICINE;NEOADJUVANT THERAPY;ONCOGENE;PEMETREXED;PHILADELPHIA CHROMOSOME;PLACENTA;PONSETI METHOD;PREMATURE RUPTURE OF MEMBRANES;PROBAND;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;REUPTAKE INHIBITOR;RUPTURE OF MEMBRANES;SEROTONERGIC;SOX10;SPECKLE TRACKING ECHOCARDIOGRAPHY;STROKE VOLUME;SUGAMMADEX;SUICIDE ATTEMPT;SUMATRIPTAN;TAXANE;TRANSURETHRAL RESECTION OF THE PROSTATE;TREATMENT-RESISTANT DEPRESSION;VINCRISTINE","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;ADULT;AGED;POSTOPERATIVE COMPLICATIONS;TREATMENT OUTCOME;ITALY;BREAST NEOPLASMS;CARCINOMA, TRANSITIONAL CELL;URINARY BLADDER NEOPLASMS;CYSTECTOMY;ADOLESCENT;BETA-THALASSEMIA;CERVICAL VERTEBRAE;COHORT STUDIES;LIVER NEOPLASMS;PROSPECTIVE STUDIES","41;35;32;31;23;21;17;14;11;10;8;8;8;7;6;6;6;6;6;6","HERNIA REPAIR TECHNIQUES AND MATERIALS;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;PRENATAL EXPOSURE TO ANTIEPILEPTIC DRUGS;RHEUMATOID ARTHRITIS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ANESTHESIA AND SEDATION MANAGEMENT;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CANCER OF UNKNOWN PRIMARY SITE;CHALLENGES IN MEDICAL WASTE MANAGEMENT DURING COVID-19 PANDEMIC;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","PLERIXAFOR;DEPRESSION (ECONOMICS);HERNIA REPAIR;INCISIONAL HERNIA;LEFT VENTRICULAR FUNCTION;UNIVARIATE ANALYSIS;CARBOPLATIN;CLINICAL ENDPOINT;DESMIN;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS;HYPERAMMONEMIA;INSULIN THERAPY;INTERNATIONAL MYELOMA WORKING GROUP;LETHARGY;MEDICATION EFFECTS;MOBILIZATION;PEDIATRIC INTUBATION;PLEOMORPHISM (CYTOLOGY);PRENATAL DIAGNOSIS;PREPAREDNESS","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HERNIA REPAIR;INGUINAL HERNIA;PERIPHERAL BLOOD;RHEUMATOID ARTHRITIS;ACUTE HEALTH;ASH EXPOSURE;BIPOLAR PATIENT;BLOOD STEM;CLAVIEN SYSTEM;EFFECTS DUE;ELDERLY BIPOLAR;ETNA SICILY;HEALTH EFFECTS;HYPERAMMONEMIC ENCEPHALOPATHY;INDUCED HYPERAMMONEMIC;ITALIAN REAL;ITALIAN STUDY;LIFE COHORT;MOUNT ETNA;MULTIPLE MYELOMA;REAL LIFE;RETROSPECTIVE STUDY;SIGNIFICANT IMPROVEMENT;SPINOUS PROCESS;STEM CELLS;VALPROATE INDUCED;VOLCANIC ASH;AB EFFECTS;ABNORMAL RIB-LIKE;ACHIEVING HBASUBCSUB","3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MOUNT ETNA;VOLCANIC ASH;LEFT VENTRICULAR;MAJOR DEPRESSION;ASH EXPOSURE;ASH FALL;CHRONIC PAIN;REUPTAKE INHIBITORS;TOTAL SCORE;ED PHYSICIANS;EXPOSURE TIME;HAM-D FACTOR;HOSPITAL STAY;INGUINAL HERNIOPLASTY;VALPROIC ACID;ACUTE HEALTH;BLOOD NGAL;CAPGRAS SYNDROME;DISEASE ACTIVITY;ED VISITS;HEALTH EFFECTS;INITIAL CLINICAL;PHYSICIANS INITIAL;RISK FACTOR;SIGNIFICANT DIFFERENCE;SPONTANEOUS LABOR;TAS- SUBSCALES;CLAVIENDINDO CLASSIFICATION;CLINICAL MANAGEMENT;CUTANEOUS WARTS","8;8;7;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3",17,0.24,3,3,2,0,0,1,0,0,1,3,0,1,3,0,0,0,2,2,1,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,3.4,449,3.6,3,0.6,116,0,0,2,0,2,0,0,1,0,4,1,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","5;3;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;LUNG;ASTHMA;AUTOIMMUNE DISEASE;BRAIN DISORDERS;CANCER;CHRONIC PAIN;COMPARATIVE EFFECTIVENESS RESEARCH;EMERGING INFECTIOUS DISEASES;INFECTIOUS DISEASES;LUNG CANCER;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;PAIN RESEARCH;PATIENT SAFETY;PREVENTION","5;4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL;CANCER","2;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","4;1;1","LUNG CANCER","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2014,96,11.8958333333333,2.83333333333333,0.364583333333333,0.3125,0.4375,1.40932642487047,1.20689655172414,1.11111111111111,1.13513513513514,0.5625,0,38,21,7,12,0.4,0.22,0.07,0.12,24.46,0.647187944405295,3.39013452914798,0.395833333333333,0.885416666666667,0.392,0.294,0.406,0.338,"GAETANO MAGRO;PIERO PAVONE;A CAVALLARO;GIUSEPPE MUSUMECI;RAFFAELE FALSAPERLA;CARMELA CALANDRA;ALESSANDRO CAPPELLANI;ANNALISA QUATTROCCHI;A RUBINO;ALESSANDRA ROMANO;GIOVANNA VITALITI;STEFANO PALMUCCI;MARIA LUCA;ANTONINA LUCA;ANTONELLA AGODI;ROSALBA PARENTI;F CARDÌ;HÉCTOR SOTO PARRÀ;FAUSTO BIANCARI;MARIA DI VITA","10;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4","GAETANO MAGRO;GIUSEPPE MUSUMECI;CARMELA CALANDRA;MARIA LUCA;ANTONINA LUCA;PIERO PAVONE;RAFFAELE FALSAPERLA;ANNALISA QUATTROCCHI;A CAVALLARO;ANTONELLA AGODI;MARTINA BARCHITTA;ROSALBA PARENTI;STEFANO PALMUCCI;GIOVANNA VITALITI;MARILENA MAGLIA;RICCARDO POLOSA;PASQUALE CAPONNETTO;MARCELLO DONATI;NICOLA CIANCIO;GIUSEPPE DI MARIA","1.49;0.79;0.72;0.72;0.72;0.72;0.65;0.57;0.57;0.57;0.57;0.52;0.5;0.48;0.48;0.48;0.48;0.45;0.45;0.45","GAETANO MAGRO;PIERO PAVONE;A CAVALLARO;RAFFAELE FALSAPERLA;CARMELA CALANDRA;ALESSANDRO CAPPELLANI;A RUBINO;ALESSANDRA ROMANO;GIOVANNA VITALITI;STEFANO PALMUCCI;MARIA LUCA;ANTONINA LUCA;ROSALBA PARENTI;F CARDÌ;HÉCTOR SOTO PARRÀ;MARIA DI VITA;GIUSEPPE MILONE;ANTONIO ZANGHÌ;CARMELO MIGNOSA;VALENTINA GIACCHI","10;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3","GAETANO MAGRO;CARMELA CALANDRA;MARIA LUCA;ANTONINA LUCA;PIERO PAVONE;RAFFAELE FALSAPERLA;A CAVALLARO;ROSALBA PARENTI;STEFANO PALMUCCI;GIOVANNA VITALITI;MARILENA MAGLIA;RICCARDO POLOSA;PASQUALE CAPONNETTO;MARCELLO DONATI;NICOLA CIANCIO;LUCIA SALVATORELLI;CLAUDIA TROMBATORE;ALESSANDRA ROMANO;FRANCESCA LONGO;ANNA MARCHESE","1.49;0.72;0.72;0.72;0.72;0.65;0.57;0.52;0.5;0.48;0.48;0.48;0.48;0.45;0.45;0.42;0.42;0.4;0.4;0.4","GAETANO MAGRO;FILIPPO LOCOCO;GIACOMO CUSUMANO;PIERLUIGI GRANONE;STEFANO MARGARITORA;A CAVALLARO;PIERO PAVONE;ALFREDO CESARIO;STEFANO PALMUCCI;A RUBINO;ALESSANDRO CAPPELLANI;ANTONIO ZANGHÌ;F CARDÌ;FAUSTO BIANCARI;MARIA DI VITA;MARILENA MAGLIA;PASQUALE CAPONNETTO;RICCARDO POLOSA;ANNALISA QUATTROCCHI;ANTONELLA AGODI","169;153;153;153;153;147;126;125;116;114;114;114;114;114;114;111;111;111;104;104","GAETANO MAGRO;GIACOMO CUSUMANO;A CAVALLARO;PIERO PAVONE;A RUBINO;ANTONIO ZANGHÌ;GIUSEPPE MILONE;ALESSANDRO CAPPELLANI;F CARDÌ;MARIA DI VITA;PAOLO DI MATTIA;VENERANDO RAPISARDA;NUNZIO PLATANIA;CRISTINA RUSSO;MARILENA MAGLIA;PASQUALE CAPONNETTO;RAFFAELE FALSAPERLA;RICCARDO POLOSA;CARMINE MATTIA;FILIPPO GRECO","169;153;132;126;114;114;101;99;99;99;99;98;93;90;90;90;90;90;88;88","GAETANO MAGRO;PIERO PAVONE;A CAVALLARO;A RUBINO;GIUSEPPE MILONE;RAFFAELE FALSAPERLA;ANTONIO ZANGHÌ;ALESSANDRA ROMANO;GIOVANNA VITALITI;HÉCTOR SOTO PARRÀ;ALESSANDRO CAPPELLANI;ANTONINA LUCA;F CARDÌ;GIACOMO CUSUMANO;MARIA DI VITA;MARIA LETIZIA MUSUMECI;PAOLO DI MATTIA;VENERANDO RAPISARDA;P SCIACCA;VALENTINA GIACCHI","10;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;ECONOMICS;SOCIOLOGY;COMPUTER SCIENCE;ENGINEERING;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;POLITICAL SCIENCE;GEOLOGY;MATHEMATICS","95;22;8;7;6;6;6;4;4;4;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;PSYCHIATRY;IMMUNOLOGY;CARDIOLOGY;GENETICS;ENVIRONMENTAL HEALTH;PEDIATRICS;ENDOCRINOLOGY;BIOCHEMISTRY;PALEONTOLOGY;ONCOLOGY;PHYSICAL THERAPY;CANCER RESEARCH;GENERAL SURGERY;ANESTHESIA;DERMATOLOGY;MACROECONOMICS;NURSING;OPTICS","70;33;21;16;14;13;12;11;11;9;9;8;7;7;6;6;5;5;4;4;4;4;4","CANCER;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;DISEASE;POPULATION;MAGNETIC RESONANCE IMAGING;GENE;ADVERSE EFFECT;CONFIDENCE INTERVAL;DIFFERENTIAL DIAGNOSIS;EPIDEMIOLOGY;ANTIBODY;ARTERY;ASYMPTOMATIC;DEPRESSION (ECONOMICS);DIABETES MELLITUS;IMMUNOHISTOCHEMISTRY;PERIOPERATIVE;RANDOMIZED CONTROLLED TRIAL;ANTIBIOTICS;ANXIETY;APOPTOSIS;BODY MASS INDEX;CELL;CHOLECYSTECTOMY;CLINICAL TRIAL;CONCOMITANT;CONTEXT (ARCHAEOLOGY);CORONARY ARTERY DISEASE;ELECTRONIC CIGARETTE;GALLBLADDER;HEART FAILURE;INCIDENCE (GEOMETRY);LUNG CANCER;MULTIVARIATE ANALYSIS;MYOCARDIAL INFARCTION;OBESITY;PROSPECTIVE COHORT STUDY;REGIMEN;VIRUS","11;9;9;8;8;7;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CISPLATIN;UNIVARIATE ANALYSIS;CADHERIN;CD34;CELL CYCLE;CHOLECYSTITIS;CLINICAL ENDPOINT;CRONBACH'S ALPHA;CYSTADENOMA;EJECTION FRACTION;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;HARMONIC SCALPEL;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MUCINOUS CYSTADENOMA;MUCOSITIS;MUTATION;OVERWEIGHT;PERCUTANEOUS CORONARY INTERVENTION;PERFORATION;PSEUDOMONAS AERUGINOSA;SEROLOGY;SEROUS CYSTADENOMA;THYMECTOMY;TYPE 1 DIABETES","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ONCOGENE;PEMETREXED;VINORELBINE;ABDOMINAL OBESITY;ACINETOBACTER BAUMANNII;AKATHISIA;ANTI-NUCLEAR ANTIBODY;ANTI-THYROID AUTOANTIBODIES;ATROPHIC GASTRITIS;AUTOIMMUNE THYROIDITIS;CARBOPLATIN;CENTRAL VENOUS PRESSURE;COPY-NUMBER VARIATION;CYCLIN D1;CYSTIC ARTERY;DEOXYCYTIDINE;DIPPER;DISCRIMINANT VALIDITY;DNA METHYLATION;EXTRAMEDULLARY PLASMACYTOMA;EXTRAPYRAMIDAL SYMPTOMS;FEBRILE NEUTROPENIA;FLUPHENAZINE;GENOME INSTABILITY;GLYCATED HEMOGLOBIN;LYMPHEDEMA;MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY;MASTECTOMY;MEN1;METHYLENETETRAHYDROFOLATE REDUCTASE;MUCOPOLYSACCHARIDOSIS TYPE II;OSTEOCALCIN;PALIPERIDONE PALMITATE;PIPERACILLIN;PROSTATECTOMY;RIBAVIRIN;RICKETTSIOSIS;RNA INTERFERENCE;SMALL INTERFERING RNA;SPECKLE TRACKING ECHOCARDIOGRAPHY;SPOTTED FEVER;STRUCTURAL VARIATION;SYSTEMIC THERAPY;TAMOXIFEN;TAXANE;TOTAL THYROIDECTOMY;TRASTUZUMAB;TSC1;TSC2;TUMOR SUPPRESSOR GENE;VE-CADHERIN;VIRILIZATION","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;;ADULT;ITALY;RETROSPECTIVE STUDIES;ADOLESCENT;POSTOPERATIVE COMPLICATIONS;AGED, 80 AND OVER;TREATMENT OUTCOME;YOUNG ADULT;OBESITY;CHILD;CHILD, PRESCHOOL;INFANT;LIVER NEOPLASMS;PANCREATIC NEOPLASMS","65;51;51;32;30;29;29;25;20;17;16;15;13;13;12;11;9;9;8;8","PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GLIOMAS;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;MELANIN PIGMENTATION IN MAMMALIAN SKIN;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;NEUROFIBROMATOSIS TYPE 1 AND TYPE 2;SMOKING CESSATION AND HEALTH EFFECTS OF TOBACCO;AMOEBIASIS: PATHOGENESIS AND CLINICAL MANAGEMENT;BREATH ANALYSIS TECHNOLOGY;CALCINEURIN-NFAT SIGNALING IN TRANSCRIPTIONAL REGULATION;CHOLANGIOCARCINOMA;CHRONIC CEREBRAL HYPOPERFUSION-RELATED NEURODEGENERATIVE DISEASES;CLASSIFICATION AND TREATMENT OF VASCULAR ANOMALIES;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DEVELOPMENT OF SUPERCONDUCTING MAGNETS FOR PARTICLE ACCELERATORS AND FUSION REACTORS","3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CONCOMITANT;DEPRESSION (ECONOMICS);ELECTRONIC CIGARETTE;NON-SMALL CELL LUNG CANCER;POSTOPERATIVE COMPLICATIONS;REGIMEN;TREATMENT;UNIVARIATE ANALYSIS;CARDIAC IMAGING;CARDIAC SURGERY RISK MODELS;CARDIOVASCULAR EVALUATION;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;CONTINUOUS GLUCOSE MONITORING;CYSTADENOMA;DIABETES;DIAGNOSIS;ECHOCARDIOGRAPHY;ENDOSCOPIC ULTRASOUND;HARMONIC SCALPEL","3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CORONARY ARTERY;ARTERY BYPASS;BYPASS GRAFTING;MULTIPLE SCLEROSIS;RETROSPECTIVE STUDY;CARDIOVASCULAR RISK;CLINICAL TRIAL;CORONARY INTERVENTION;CYSTIC PANCREATIC;DIABETIC PATIENTS;HUMAN ATHEROSCLEROTIC;IMMUNOHISTOCHEMICAL STUDY;ITALIAN MULTICENTER;LONG-TERM RESULTS;MAGNETIC RESONANCE;MULTICENTER ANALYSIS;MULTICENTER STUDY;MULTICENTRE STUDY;MULTIPLE MYELOMA;PATIENTS TREATED;PERCUTANEOUS CORONARY;TYPE DIABETIC;VINORELBINE ORALE;WILMS TUMOR;ABNORMAL WHITE;ACINETOBACTER BAUMANNII;ACUTE LYMPHOBLASTIC;ADDISONS DISEASE;ADULT SUBJECTS;ADULTS STUDY","4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CONFIDENCE INTERVAL;ADDISONS DISEASE;RATIO CONFIDENCE;HAZARD RATIO;DIABETES MELLITUS;DISEASE-FREE SURVIVAL;LOCALLY ADVANCED;MONTHS VERSUS;TYPE- DIABETES;USUAL CARE;CD MDSC;CDAI SCORE;HEALTHY CONTROLS;INITIAL THYMECTOMY;PATIENTS RECEIVED;RECURRENT THYMOMA;SURVIVAL RATES;TUBEROUS SCLEROSIS;ADVANCED NSCLC;ADVERSE EVENTS;CARDIOVASCULAR RISK;CELL LUNG;FOLATE INTAKE;HYDRATION STATUS;LUNG CANCER;MYASTHENIC CRISIS;ORAL VINORELBINE;OVERWEIGHT SUBJECTS;RISK FACTORS;STATISTICALLY SIGNIFICANT","13;9;9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5",43,0.45,2.88,4,1.25,1,1,1,1,0,1.5,4,1,1,4,0,1,2,1,3,4.5,0,0,76.5,76.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,5.5,248.5,3.31,4,0.67,55.83,0,0,0,0,4,0,0,2,0,5,1,0,0,0,0,0,0,5,1,0,6,0,0,0,0,0,0,0,0,0,"United States;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3105 GENETICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","6;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;MENTAL HEALTH;PATIENT SAFETY;RARE DISEASES;AGING;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;BREAST CANCER;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;DEPRESSION;EYE DISEASE AND DISORDERS OF VISION;GENETICS;LUNG;LYMPHOMA;NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG","6;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;EYE;MENTAL HEALTH;RESPIRATORY","2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","3;1","BREAST CANCER;LEUKEMIA / LEUKAEMIA;NON-HODGKIN'S LYMPHOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2015,124,12.1048387096774,2.85483870967742,0.346774193548387,0.282258064516129,0.459677419354839,1.75247524752475,1.3030303030303,1.4,1.23913043478261,0.419354838709677,2,45,27,23,10,0.36,0.22,0.19,0.08,19.49,0.523017783660111,3.56554307116105,0.25,0.887096774193548,0.461,0.424,0.442,0.424,"FRANCESCO DI RAIMONDO;ALESSANDRA ROMANO;GIUSEPPE MUSUMECI;DANIELE TIBULLO;GAETANO MAGRO;ANNALISA CHIARENZA;HÉCTOR SOTO PARRÀ;NUNZIATINA LAURA PARRINELLO;CONCETTA CONTICELLO;VENERANDO RAPISARDA;STEFANO PALMUCCI;GIACOMO CUSUMANO;PAOLO VIGNERI;CESARINA GIALLONGO;GIUSEPPE MILONE;GIUSEPPE MICALI;PIERO PAVONE;GIUSEPPE A. PALUMBO;CARMELO MIGNOSA;S. BELLOFIORE","14;11;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;5;4;4","PIERO PAVONE;MASSIMILIANO SORBELLO;FRANCESCO DI RAIMONDO;RICCARDO POLOSA;GIUSEPPE MICALI;GAETANO MAGRO;GIUSEPPE MUSUMECI;RENATA RIZZO;ALESSANDRA ROMANO;RAFFAELE FALSAPERLA;DANIELE TIBULLO;GIACOMO CUSUMANO;ANNA ELISA VERZÌ;FRANCESCO LACARRUBBA;VENERANDO RAPISARDA;NUNZIATINA LAURA PARRINELLO;STEFANO PALMUCCI;S. BELLOFIORE;S SAITA;IVANA ZDRAVKOVIĆ","1.74;1.58;1.25;1.25;1.24;1.18;1.15;1.03;1.02;0.85;0.82;0.76;0.73;0.73;0.68;0.68;0.64;0.59;0.59;0.58","FRANCESCO DI RAIMONDO;ALESSANDRA ROMANO;GIUSEPPE MUSUMECI;DANIELE TIBULLO;GAETANO MAGRO;ANNALISA CHIARENZA;HÉCTOR SOTO PARRÀ;NUNZIATINA LAURA PARRINELLO;CONCETTA CONTICELLO;VENERANDO RAPISARDA;STEFANO PALMUCCI;GIACOMO CUSUMANO;PAOLO VIGNERI;CESARINA GIALLONGO;GIUSEPPE MILONE;GIUSEPPE MICALI;PIERO PAVONE;GIUSEPPE A. PALUMBO;CARMELO MIGNOSA;S. BELLOFIORE","14;11;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;5;4;4","PIERO PAVONE;MASSIMILIANO SORBELLO;FRANCESCO DI RAIMONDO;RICCARDO POLOSA;GIUSEPPE MICALI;GAETANO MAGRO;GIUSEPPE MUSUMECI;ALESSANDRA ROMANO;RAFFAELE FALSAPERLA;DANIELE TIBULLO;GIACOMO CUSUMANO;ANNA ELISA VERZÌ;FRANCESCO LACARRUBBA;VENERANDO RAPISARDA;NUNZIATINA LAURA PARRINELLO;STEFANO PALMUCCI;S. BELLOFIORE;S SAITA;ANNALISA CHIARENZA;CESARINA GIALLONGO","1.74;1.58;1.25;1.25;1.24;1.18;1.15;1.02;0.85;0.82;0.76;0.73;0.73;0.68;0.68;0.64;0.59;0.59;0.57;0.55","GIUSEPPE MILONE;STEFANO PALMUCCI;GIUSEPPE MUSUMECI;GAETANO MAGRO;GIANCARLO ATTINÀ;PAOLO CORRADINI;ANDREA BACIGALUPO;VENERANDO RAPISARDA;VENERA CARDILE;A RUBINO;ANIELLO PAPPALARDO;CARMELO MIGNOSA;FAUSTO BIANCARI;GIUSEPPE GATTI;GIUSEPPE SANTARPINO;MAGNUS DALÉN;PETER SVENARUD;THEODOR FISCHLEIN;ROSARIO CALTABIANO;ALBERTO BOSI","260;219;198;191;179;174;173;173;167;165;165;165;165;165;165;165;165;165;161;155","GIUSEPPE MILONE;STEFANO PALMUCCI;GAETANO MAGRO;GIANCARLO ATTINÀ;A RUBINO;CARMELO MIGNOSA;GIOVANNI CARLO ETTORRE;PIETRO MILONE;PIETRO VALERIO FOTI;VENERANDO RAPISARDA;FRANCESCO DI RAIMONDO;WANDA DESTE;MARIA GABRIELLA D’ARRIGO;RENATO FARINA;ANNA MARCHESE;RICCARDO POLOSA;ALESSANDRA ROMANO;SIMONA GULINO;ROSARIO FOTI;RAFFAELE FALSAPERLA","260;219;191;179;165;165;149;149;149;146;139;138;131;131;126;111;103;100;96;91","FRANCESCO DI RAIMONDO;ALESSANDRA ROMANO;GAETANO MAGRO;HÉCTOR SOTO PARRÀ;DANIELE TIBULLO;GIUSEPPE MILONE;PIERO PAVONE;STEFANO PALMUCCI;CONCETTA CONTICELLO;GIACOMO CUSUMANO;VENERANDO RAPISARDA;A RUBINO;CARMELO MIGNOSA;CESARINA GIALLONGO;GIUSEPPE A. PALUMBO;NUNZIATINA LAURA PARRINELLO;RAFFAELE FALSAPERLA;GIUSEPPE MICALI;ALBERTO TERMINELLA;MASSIMILIANO SORBELLO","14;8;7;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATERIALS SCIENCE;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;BUSINESS;ECONOMICS;PHILOSOPHY;SOCIOLOGY;ART;GEOGRAPHY;GEOLOGY;HISTORY;POLITICAL SCIENCE","115;43;16;10;8;6;4;4;4;3;3;3;3;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GENETICS;ONCOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;BIOCHEMISTRY;RADIOLOGY;CANCER RESEARCH;PEDIATRICS;CARDIOLOGY;ENVIRONMENTAL HEALTH;DERMATOLOGY;ANESTHESIA;CELL BIOLOGY;OPTICS;PSYCHIATRY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE","85;45;32;22;22;18;18;17;16;14;13;11;11;9;8;8;7;7;6;6;6","CHEMOTHERAPY;CANCER;GENE;POPULATION;IMMUNOHISTOCHEMISTRY;LUNG;MULTIPLE MYELOMA;STEM CELL;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;DISEASE;MAGNETIC RESONANCE IMAGING;RECEPTOR;INCIDENCE (GEOMETRY);PREGNANCY;THALASSEMIA;TRANSPLANTATION;ADVERSE EFFECT;BLOOD PRESSURE;BONE MARROW;CELL;IN VITRO;LESION;MESOTHELIOMA;PATHOLOGICAL;RANDOMIZED CONTROLLED TRIAL;STENOSIS","19;18;13;10;9;8;8;8;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4","NEUTROPENIA;CD34;AORTIC VALVE REPLACEMENT;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;BEVACIZUMAB;CELL CYCLE;DOWNREGULATION AND UPREGULATION;ETANERCEPT;IMATINIB;LENALIDOMIDE;RITUXIMAB;SALVAGE THERAPY;SUPPRESSOR;T CELL;AGE OF ONSET;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BETA THALASSEMIA;BORTEZOMIB;BREAST CANCER;CHELATION THERAPY;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;COLORECTAL CANCER;CYTOTOXICITY;DEFERIPRONE;GENE EXPRESSION;GESTATION;GRANULOCYTE COLONY-STIMULATING FACTOR;HAEMATOPOIESIS;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEME;HYPOXIA (ENVIRONMENTAL);LUNG FUNCTION;MANTLE CELL LYMPHOMA;PLACEBO;PNEUMONECTOMY;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PROSTATE CANCER;RESPIRATORY DISEASE;TYROSINE KINASE;UNFOLDED PROTEIN RESPONSE;UNIVARIATE ANALYSIS;VIABILITY ASSAY;WESTERN BLOT","7;5;4;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","IMATINIB MESYLATE;MYELOID-DERIVED SUPPRESSOR CELL;ABSOLUTE NEUTROPHIL COUNT;ANTHRACYCLINE;CD33;CETUXIMAB;CYCLIN D1;DIFFUSING CAPACITY;HEME OXYGENASE;IGHV@;IRINOTECAN;METASTATIC BREAST CANCER;OXALIPLATIN;PEMETREXED;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TAXANE;ABL;ACINETOBACTER BAUMANNII;AFLIBERCEPT;AGGRESSIVE LYMPHOMA;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIGEN-PRESENTING CELL;AORTIC VALVULOPLASTY;AQUAPORIN 1;AUTOIMMUNE ENCEPHALITIS;BASIC FIBROBLAST GROWTH FACTOR;BENDAMUSTINE;BRENTUXIMAB VEDOTIN;BRONCHOPLEURAL FISTULA;BRONCHUS;BUSULFAN;CD99;COMET ASSAY;CXCR4;CYTOREDUCTIVE SURGERY;DABIGATRAN;DASATINIB;DEBULKING;DESTINATION THERAPY;DILATION AND CURETTAGE;DIOSMIN;DISINTEGRIN;DNA METHYLATION;DOPAMINE RECEPTOR D3;ERDHEIM–CHESTER DISEASE;EXTRAMEDULLARY HEMATOPOIESIS;FAMILY PLANNING;FLUDARABINE;FRACTIONAL ANISOTROPY;GANGLIONEUROMA;GENE MUTATION;GESTATIONAL HYPERTENSION;GLUTATHIONE PEROXIDASE;GRIESS TEST;HEMATOPOIETIC CELL;HES1;HPV INFECTION;HSP90;INEFFECTIVE ERYTHROPOIESIS;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;KARYOTYPE;KLEBSIELLA PNEUMONIAE;LEUKAPHERESIS;MALE INFERTILITY;MASKED HYPERTENSION;MICROARRAY ANALYSIS TECHNIQUES;MOLECULAR MEDICINE;NESTED POLYMERASE CHAIN REACTION;NEUROACTIVE STEROID;PHILADELPHIA CHROMOSOME;PLACEBO GROUP;PLEURAL DISEASE;PLEURECTOMY;PORTOSYSTEMIC SHUNT;PRENATAL DIAGNOSIS;PROSTATECTOMY;SANGER SEQUENCING;SEMEN ANALYSIS;SMALL INTERFERING RNA;SMOKELESS TOBACCO;SOBP;SOLITARY FIBROUS TUMOR;TOBACCO HARM REDUCTION;TRANSIENT ELASTOGRAPHY;USTEKINUMAB;VERESS NEEDLE;VINCRISTINE;VINORELBINE;WHITE COAT HYPERTENSION","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;RETROSPECTIVE STUDIES;IRON OVERLOAD;YOUNG ADULT;ADOLESCENT;THALIDOMIDE;TREATMENT OUTCOME;BETA-THALASSEMIA;BRAIN NEOPLASMS;DIABETES MELLITUS, TYPE 2;GLIOBLASTOMA;INFLAMMATION;LIVER;PSORIASIS","60;59;41;41;27;27;23;18;12;12;10;10;10;9;9;9;9;9;9;9","MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL SKIN INFECTIONS;MANAGEMENT OF VALVULAR HEART DISEASE;RECIPROCAL DEVELOPMENT OF TH17 AND TREG CELLS;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANORECTAL SURGICAL PROCEDURES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHITIN METABOLISM IN INSECTS AND MAMMALS;CLASSIFICATION AND TREATMENT OF HISTIOCYTIC DISORDERS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EFFICACY AND RESISTANCE IN CML TREATMENT;EPILEPSY AND SEIZURES;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEMATOPOIETIC STEM CELL BIOLOGY;LYMPHOID NEOPLASMS;MACROPHAGE ACTIVATION AND POLARIZATION;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE","8;6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ASBESTOS EXPOSURE;CLINICAL ENDPOINT;MALIGNANT PLEURAL MESOTHELIOMA;PROSTHETIC VALVES EVALUATION;SURGICAL AORTIC-VALVE REPLACEMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;IMATINIB MESYLATE;IRON OVERLOAD;MYELOID-DERIVED SUPPRESSOR CELL;MYELOID-DERIVED SUPPRESSOR CELLS;PSORIASIS;SALVAGE THERAPY;ABSOLUTE NEUTROPHIL COUNT;AORTIC ROOT REPLACEMENT;AUTOLOGOUS STEM-CELL TRANSPLANTATION;BETA THALASSEMIA;BREAST CANCER;CARDIOTHORACIC SURGERY;CARDIOVASCULAR EVALUATION;CHELATION THERAPY","4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","RETROSPECTIVE STUDY;MULTIPLE MYELOMA;AORTIC VALVE;CONTROLLED TRIAL;DERIVED SUPPRESSOR;ITALIAN MULTICENTER;MULTICENTER RETROSPECTIVE;MYELOID DERIVED;SUPPRESSOR CELLS;VALVE REPLACEMENT;ACUTE MYELOID;BLOOD STEM;BREAST CANCER;CANCER ELIGIBLE;CANCER MBC;CHRONIC LYMPHOCYTIC;DEL GINOCCHIO;GLIOBLASTOMA MULTIFORME;GRANULOCYTE-LIKE MYELOID;HUMAN GLIOBLASTOMA;IMMUNOHISTOCHEMICAL STUDY;IRON CONCENTRATION;LIVER IRON;LYMPHOCYTE RATIO;LYMPHOCYTIC LEUKEMIA;MALIGNANT PLEURAL;MESENCHYMAL STEM;METASTATIC BREAST;MINIMALLY INVASIVE;MULTICENTER REGISTRY","7;5;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FEG DW;MG FEG;MGG DW;IRON OVERLOAD;MEDIAN MG;MRI LIC;MGG NA;MYOPIC CNV;LIC VALUES;SERUM FERRITIN;THALASSEMIA MAJOR;CLINICAL TRIALS;CURVE ANALYSIS;HPV INFECTION;OPERATING CHARACTERISTIC;RECEIVER OPERATING;SIGNIFICANT DIFFERENCE;SPEAKERS BUREAU;STABLE DISEASE;ADVISORY COMMITTEES;CELL DISEASE;DEAD PATIENTS;DFP DOSE;DISEASE PATIENTS;ECOG PS;ENTITYS BOARD;FERRITIN LEVELS;FOLATE DEFICIENCY;HR CI-;MEDIAN PFS","18;18;18;12;10;9;8;8;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5",38,0.31,5.88,4.75,2,1,13,1,1.5,0,1.5,5.75,3,0,4.25,2.5,1,2.5,5,3,1.75,0,0,72.75,72.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,4.7,472.4,5.35,7,0.7,93.2,1,1,3,0,2,0,0,3,0,9,1,0,0,0,0,0,0,8,2,0,9,0,0,1,0,0,0,0,0,0,"United States;Japan","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","10;4;4;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;BREAST CANCER;CHILDHOOD LEUKEMIA;PATIENT SAFETY;PEDIATRIC;PEDIATRIC CANCER;AUTOIMMUNE DISEASE;CROHN'S DISEASE;CYSTIC FIBROSIS;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;EYE DISEASE AND DISORDERS OF VISION;INFLAMMATORY BOWEL DISEASE;LUNG;ORPHAN DRUG;PEDIATRIC RESEARCH INITIATIVE","10;7;5;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CONGENITAL;EYE;ORAL AND GASTROINTESTINAL","4;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS","10;2;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER","3;2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","5",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2016,152,13.9868421052632,2.5328947368421,0.368421052631579,0.328947368421053,0.401315789473684,1.73423423423423,1.47368421052632,1.66666666666667,1.48780487804878,0.493421052631579,2,75,35,8,16,0.49,0.23,0.05,0.11,24.8,0.763557055928286,3.5792349726776,0.342105263157895,0.907894736842105,0.437,0.423,0.495,0.404,"FRANCESCO DI RAIMONDO;RAFFAELE FALSAPERLA;PIERO PAVONE;ALESSANDRA ROMANO;ANNALISA CHIARENZA;CESARINA GIALLONGO;DANIELE TIBULLO;GIUSEPPE GROSSO;GIOVANNA VITALITI;RICCARDO LUBRANO;NUNZIATINA LAURA PARRINELLO;PIERA LA CAVA;NASSIM MATIN;CONCETTA CONTICELLO;LUCA LO NIGRO;L. RAFFAELE;CATERINA LEDDA;ANDREA DI CATALDO;ANDREA MUSUMECI;ANNA MARIA GUELI","21;12;11;10;8;8;8;7;7;7;7;7;6;6;6;6;5;5;5;5","PIERO PAVONE;RAFFAELE FALSAPERLA;FRANCESCO DI RAIMONDO;GIUSEPPE GROSSO;NOEMI OGNIBENE;ALESSIA PALLADINO;FABIO GALVANO;ALESSANDRA ROMANO;GIOVANNA VITALITI;RICCARDO LUBRANO;L. RAFFAELE;ANNA MARIA GUELI;G. ASERO;NASSIM MATIN;ANDREA D. PRATICÒ;MARTINO RUGGIERI;S. SPAMPINATO;CESARINA GIALLONGO;DANIELE TIBULLO;GIOVANNI MANNINO","1.7;1.66;1.55;1.44;1.32;1;0.9;0.83;0.82;0.82;0.81;0.78;0.78;0.76;0.74;0.69;0.68;0.58;0.58;0.58","FRANCESCO DI RAIMONDO;RAFFAELE FALSAPERLA;PIERO PAVONE;ALESSANDRA ROMANO;ANNALISA CHIARENZA;CESARINA GIALLONGO;DANIELE TIBULLO;GIUSEPPE GROSSO;GIOVANNA VITALITI;NUNZIATINA LAURA PARRINELLO;PIERA LA CAVA;CONCETTA CONTICELLO;LUCA LO NIGRO;L. RAFFAELE;ANDREA DI CATALDO;ANDREA MUSUMECI;ROSARIO CALTABIANO;GIOVANNI MANNINO;S. SPAMPINATO;GAETANO MAGRO","21;12;11;10;8;8;8;7;7;7;7;6;6;6;5;5;5;4;4;4","PIERO PAVONE;RAFFAELE FALSAPERLA;FRANCESCO DI RAIMONDO;GIUSEPPE GROSSO;NOEMI OGNIBENE;ALESSIA PALLADINO;ALESSANDRA ROMANO;GIOVANNA VITALITI;L. RAFFAELE;S. SPAMPINATO;CESARINA GIALLONGO;DANIELE TIBULLO;GIOVANNI MANNINO;MARCELLO DONATI;ANDREA DI CATALDO;ENRICO HEFFLER;CARLO GRECO;GIUSEPPE MICALI;ANTONIO PESCE;STEFANO PULEO","1.7;1.66;1.55;1.44;1.32;1;0.83;0.82;0.81;0.68;0.58;0.58;0.58;0.58;0.55;0.55;0.53;0.53;0.5;0.5","FRANCESCA PATRIARCA;ANGELO MICHELE CARELLA;ARNON NAGLER;DOMENICO RUSSO;GIUSEPPE MILONE;ANDREAS VÖLP;ANTONIO M. RISITANO;CARLOS SOLANO;CARMINE SELLERI;CHRISTELLE FERRÁ;CHRISTINE WOLSCHKE;DOMENICO PASTORE;ELISABETTA TERRUZZI;FABIO BENEDETTI;FRANCESCA BONIFAZI;FRANCIS AYUK;FRANCO NARNI;GIUSEPPE BANDINI;GIUSEPPE MESSINA;JAIME PÉREZ DE OTEYZA","607;521;521;482;479;478;478;478;478;478;478;478;478;478;478;478;478;478;478;478","GIUSEPPE MILONE;GIUSEPPE GROSSO;RICCARDO POLOSA;LUCA LO NIGRO;MASSIMO CARUSO;CONCETTA CONTICELLO;FRANCESCO DI RAIMONDO;DAVIDE CAMPAGNA;MARIA DOMENICA AMARADIO;PASQUALE CAPONNETTO;LUCA PLACIDI;RAFFAELE FALSAPERLA;PIETRO VALERIO FOTI;PIERO PAVONE;GAETANO MAGRO;GIOVANNI SORGE;ANDREA MUSUMECI;ALESSANDRA ROMANO;ENRICO HEFFLER;GIOVANNI CARLO ETTORRE","479;433;413;293;270;186;185;156;156;156;155;141;122;121;113;111;105;104;98;94","FRANCESCO DI RAIMONDO;RAFFAELE FALSAPERLA;PIERO PAVONE;ALESSANDRA ROMANO;LUCA LO NIGRO;GIOVANNA VITALITI;GIUSEPPE GROSSO;ANDREA MUSUMECI;L. RAFFAELE;ENRICO HEFFLER;GIOVANNI MANNINO;PIETRO VALERIO FOTI;RICCARDO POLOSA;GAETANO MAGRO;HÉCTOR SOTO PARRÀ;MARCELLO DONATI;CONCETTA CONTICELLO;FRANCESCO PATTI;GIOVANNI CARLO ETTORRE;MARIO FALSAPERLA","19;11;10;9;6;6;6;5;5;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;SOCIOLOGY;MATERIALS SCIENCE;ECONOMICS;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;PHILOSOPHY;GEOGRAPHY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY;POLITICAL SCIENCE","139;38;21;14;11;11;10;7;7;7;6;3;2;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;ONCOLOGY;PSYCHIATRY;GENETICS;IMMUNOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;RADIOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;PHYSICAL THERAPY;OPTICS;ANESTHESIA;CARDIOLOGY;DEMOGRAPHY;DERMATOLOGY;NUCLEAR MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;NURSING;QUANTUM MECHANICS","91;38;32;23;23;22;21;21;18;18;17;13;13;12;9;9;9;9;9;8;8;8;8","DISEASE;POPULATION;CANCER;GENE;CHEMOTHERAPY;PROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;CLINICAL TRIAL;COHORT;MAGNETIC RESONANCE IMAGING;ADVERSE EFFECT;BONE MARROW;LEUKEMIA;MULTIPLE MYELOMA;OBSERVATIONAL STUDY;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;ASTHMA;IMMUNE SYSTEM;INCIDENCE (GEOMETRY)","17;17;16;14;13;12;10;8;8;8;7;7;7;7;7;7;7;6;6;6","HAZARD RATIO;BREAST CANCER;CHRONIC LYMPHOCYTIC LEUKEMIA;MUTATION;PROGRESSION-FREE SURVIVAL;BORTEZOMIB;CLINICAL ENDPOINT;COLORECTAL CANCER;DIFFUSION MRI;EXON;GRAFT-VERSUS-HOST DISEASE;HEART RATE;HOSPITAL ANXIETY AND DEPRESSION SCALE;IMMUNOTHERAPY;INCLUSION AND EXCLUSION CRITERIA;LENALIDOMIDE;MONOCLONAL ANTIBODY;OVERWEIGHT;PHASES OF CLINICAL RESEARCH;PROTEIN KINASE B;SPIROMETRY","5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","IGHV@;MONOCLONAL;DASATINIB;FLUDARABINE;FRAMESHIFT MUTATION;IMATINIB MESYLATE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;MISSENSE MUTATION;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NIVOLUMAB;ABSOLUTE NEUTROPHIL COUNT;ACUTE LYMPHOCYTIC LEUKEMIA;ADIPOKINE;ADIPONECTIN;AFLIBERCEPT;ALLERGIC RESPONSE;ARGINASE;ASCUS (BRYOZOA);ATAXIA-TELANGIECTASIA;B-CELL RECEPTOR;BRONCHIAL HYPERRESPONSIVENESS;BRONCHODILATOR AGENTS;CAREGIVER BURDEN;CD23;CERVICAL INTRAEPITHELIAL NEOPLASIA;CHILD ABUSE;CHILDHOOD OBESITY;CHROMOSOMAL REGION;COLON ADENOCARCINOMA;COMPARATIVE GENOMIC HYBRIDIZATION;COOPERATIVENESS;COPY-NUMBER VARIATION;CROHN DISEASE;CXCR4;CYCLIN D1;DIFFUSING CAPACITY;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA METHYLATION;DNA MICROARRAY;DORZOLAMIDE;ERLOTINIB;ESTROGEN RECEPTOR;EXHALED NITRIC OXIDE;FANCONI ANEMIA;FETAL GROWTH;GANGLIONEUROMA;GENOTYPING;GERD;GERMLINE MUTATION;GLUCOCEREBROSIDE;HALLUX RIGIDUS;HAPLOINSUFFICIENCY;HARM AVOIDANCE;HEME OXYGENASE;HISTONE DEACETYLASE;HPV INFECTION;IN UTERO;IONIZATION CHAMBER;IPILIMUMAB;KARYOTYPE;MAMMOGRAPHY;METASTATIC ADENOCARCINOMA;MICRODELETION SYNDROME;MINI–MENTAL STATE EXAMINATION;MMP9;MYELOID-DERIVED SUPPRESSOR CELL;NEOADJUVANT THERAPY;NEONATAL RESPIRATORY DISTRESS SYNDROME;NESTED POLYMERASE CHAIN REACTION;NILOTINIB;NOVELTY SEEKING;OFATUMUMAB;OMALIZUMAB;OXALIPLATIN;PITTSBURGH SLEEP QUALITY INDEX;PLASMA CELL NEOPLASM;POINT MUTATION;POSTURAL INSTABILITY;PROBAND;PROSTATECTOMY;PTEN;RESPIRATORY EXCHANGE RATIO;RESPIRATORY RATE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RIBAVIRIN;ROTAVIRUS VACCINE;RUXOLITINIB;SEXUAL ABUSE;SUBSTRATE REDUCTION THERAPY;SYSTEMIC THERAPY;TAMOXIFEN;TEMPERAMENT AND CHARACTER INVENTORY;THIOTEPA;TRANSIENT ELASTOGRAPHY;UNTRANSLATED REGION;VASOACTIVE INTESTINAL PEPTIDE;VIRAL ENCEPHALITIS;VO2 MAX;ZIPRASIDONE","3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ADOLESCENT;ITALY;TREATMENT OUTCOME;YOUNG ADULT;CHILD;PROSPECTIVE STUDIES;AGED, 80 AND OVER;CHILD, PRESCHOOL;CROSS-SECTIONAL STUDIES;RETROSPECTIVE STUDIES;INFANT;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;LUNG DISEASES, INTERSTITIAL","80;71;63;62;42;37;32;24;23;19;19;16;15;13;11;11;11;10;10;9","DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;MACROPHAGE ACTIVATION AND POLARIZATION;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;CANCER IMMUNOTHERAPY;DIAGNOSIS AND MANAGEMENT OF CHRONIC COUGH;EFFICACY AND RESISTANCE IN CML TREATMENT;GASTROINTESTINAL VIRAL INFECTIONS AND VACCINES DEVELOPMENT;MALE CIRCUMCISION FOR HIV PREVENTION AND PENILE HEALTH;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANISMS OF DRUG-INDUCED HEPATOTOXICITY;OCULAR CANCER RESEARCH AND TREATMENT;PREVALENCE AND MANAGEMENT OF KIDNEY STONES","6;6;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","ETIOLOGY;REGIMEN;TREATMENT;CARDIAC IMAGING;DEPRESSION (ECONOMICS);MYELOID-DERIVED SUPPRESSOR CELLS;PROGRESSION-FREE SURVIVAL;ASBESTOS EXPOSURE;AUTOLOGOUS TRANSPLANTATION;CLINICAL ENDPOINT;CROSS-SECTIONAL STUDY;DIAGNOSTIC IMAGING;DIFFUSION-WEIGHTED IMAGING;IGHV@;INTERQUARTILE RANGE;MEDITERRANEAN DIET;PARENCHYMA;PERFUSION IMAGING;SMOKING CESSATION;B CELL ABNORMALITIES","5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2","MULTIPLE MYELOMA;MULTIPLE SCLEROSIS;ACUTE LYMPHOBLASTIC;CHRONIC LYMPHOCYTIC;LYMPHOBLASTIC LEUKEMIA;LYMPHOCYTIC LEUKEMIA;AORTIC VALVE;CHILDHOOD ACUTE;CLASSIC HODGKIN;ELECTRONIC CIGARETTES;HODGKIN LYMPHOMA;MYELOID-MEDIATED IMMUNOSUPPRESSION;NEWLY DIAGNOSED;PLEURAL PLAQUES;RISK FACTORS;ACCESS PROGRAMME;CARDIAC REHABILITATION;CELL TRANSPLANTATION;CESSATION TRIAL;CHRONIC MYELOID;COMBINED INTRARENAL;CROSS-SECTIONAL STUDY;DENDRITIC CELLS;DIAGNOSED MULTIPLE;DOSE INCREMENT;ENDOSCOPIC COMBINED;EUROPEAN COUNTRIES;EXPANDED ACCESS;HIGH-DENSITY NEUTROPHILS;IMMUNOSUPPRESSION MARKER","7;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NOTCH MUTATIONS;CONSULTANCY HONORARIA;BLOOD PRESSURE;HR CI;ADVERSE EVENTS;SPEAKERS BUREAU;UTR NOTCH-MUT;CODING NOTCH-MUT;CATANIA ITALY;GAUCHER DISEASE;DISEASE TYPE;ENZYME REPLACEMENT;MULTIPLE MYELOMA;SUCROSOMIAL IRON;ADVISORY COMMITTEES;BONE MARROW;ENTITYS BOARD;NOTCH MUTATION;OVERWEIGHT SUBJECTS;OXIDATIVE STRESS;POLYPHENOL INTAKE;RELATIVE LYSIS;REPLACEMENT THERAPY;SIGNIFICANT DIFFERENCE;SMOKING PHENOTYPE;UTR NOTCH;CATANIA CATANIA;CD LEVELS;CLINICAL PRACTICE;CLINICAL TRIAL","24;14;12;12;10;10;10;9;8;8;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5",54,0.36,6.68,6.75,4,1,1,7.25,5,0,1.75,7,0,1,6,1,1,2.5,3,5,3,0,0,106.75,106.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,2.75,763.5,4.35,3,0.33,57.67,0,0,3,0,2,0,0,4,0,4,4,0,0,0,0,0,0,8,0,1,8,1,0,0,0,0,0,0,0,0,"Italy;Japan","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","9;6;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;CANCER;PATIENT SAFETY;BIOMEDICAL IMAGING;HEMATOLOGY;LUNG CANCER;ORPHAN DRUG;PREVENTION;RARE DISEASES;TRANSPLANTATION;ARTHRITIS;AUTOIMMUNE DISEASE;BIOENGINEERING;CARDIOVASCULAR;KIDNEY DISEASE;ORGAN TRANSPLANTATION;PEDIATRIC;PNEUMONIA","8;5;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;RENAL AND UROGENITAL","3;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","4;1;1;1","LUNG CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NON-HODGKIN'S LYMPHOMA","4;1;1;1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2017,158,13.1139240506329,2.27848101265823,0.310126582278481,0.272151898734177,0.367088607594937,1.75980392156863,1.32432432432432,1.38709677419355,1.41463414634146,0.563291139240506,4,59,34,20,26,0.37,0.22,0.13,0.16,20.78,0.704952057983484,3.79955456570156,0.265822784810127,0.943037974683544,0.49,0.518,0.473,0.494,"HÉCTOR SOTO PARRÀ;RAFFAELE FALSAPERLA;PIERO PAVONE;DOMENICO GALETTA;GIOVANNA VITALITI;GIUSEPPE MILONE;ANDREA D. PRATICÒ;FRANCESCO GROSSI;FILIPPO DE MARINIS;PAOLO VIGNERI;RICCARDO LUBRANO;ROSARIO CALTABIANO;MARTINO RUGGIERI;SALVATORE LEOTTA;GIUSEPPE GROSSO;ROSARIO FOTI;FRANCESCO COGNETTI;MARCO MARIA AIELLO;LUCIA SALVATORELLI;RITA CHIARI","19;15;12;10;9;9;8;8;7;7;7;7;7;6;6;6;6;6;5;5","MASSIMILIANO SORBELLO;RAFFAELE FALSAPERLA;PIERO PAVONE;HÉCTOR SOTO PARRÀ;GIUSEPPE MILONE;SALVATORE MARCHESE;ROSARIO CALTABIANO;ANDREA D. PRATICÒ;GIOVANNA VITALITI;MARTINO RUGGIERI;GIUSEPPE GROSSO;MARCELLO MIGLIORE;RICCARDO LUBRANO;MARCO MARIA AIELLO;JUSTYNA GODOS;ANTONIO MISTRETTA;STEFANO MARVENTANO;FABIO GALVANO;GIUSEPPE ANGELICO;PAOLO VIGNERI","2.18;1.92;1.69;1.48;1.48;1.33;1.22;1.21;1.07;1.07;1.06;1;0.88;0.78;0.7;0.7;0.7;0.7;0.68;0.62","HÉCTOR SOTO PARRÀ;RAFFAELE FALSAPERLA;PIERO PAVONE;GIOVANNA VITALITI;GIUSEPPE MILONE;ANDREA D. PRATICÒ;PAOLO VIGNERI;RICCARDO LUBRANO;ROSARIO CALTABIANO;MARTINO RUGGIERI;SALVATORE LEOTTA;GIUSEPPE GROSSO;ROSARIO FOTI;MARCO MARIA AIELLO;LUCIA SALVATORELLI;MASSIMILIANO SORBELLO;ALESSANDRA CUPRI;GIOVANNA RUSSO;GIUSEPPE ANGELICO;JUSTYNA GODOS","19;15;12;9;9;8;7;7;7;7;6;6;6;6;5;5;5;5;4;4","MASSIMILIANO SORBELLO;RAFFAELE FALSAPERLA;PIERO PAVONE;HÉCTOR SOTO PARRÀ;GIUSEPPE MILONE;SALVATORE MARCHESE;ROSARIO CALTABIANO;ANDREA D. PRATICÒ;GIOVANNA VITALITI;MARTINO RUGGIERI;GIUSEPPE GROSSO;RICCARDO LUBRANO;MARCO MARIA AIELLO;JUSTYNA GODOS;FABIO GALVANO;GIUSEPPE ANGELICO;PAOLO VIGNERI;STEFANO PALMUCCI;NUNZIO RESTUCCIA;LUCIA SALVATORELLI","2.18;1.92;1.69;1.48;1.48;1.33;1.22;1.21;1.07;1.07;1.06;0.88;0.78;0.7;0.7;0.68;0.62;0.56;0.56;0.55","MASSIMO MIDIRI;A MADEDDU;ADRIANO GIACOMIN;ALAIN MONNEREAU;ALESSANDRO BARCHIELLI;ALICE NENNECKE;ANDREA TAVILLA;ANNA LUISA CAIAZZO;ANNALISA TRAMA;ANNE‐SOPHIE WORONOFF;ANNE‐VALÉRIE GUIZARD;ANNE–MARIE BOUVIER;ANTONELLA SUTERA SARDO;ANTONINO ZIINO COLANINO;ARNOLD KNIJN;ARTURO IANNELLI;BERND HOLLECZEK;BRIGITTE TRÉTARRE;BÉNÉDICTE LAPÔTRE-LEDOUX;C. SCHVARTZ","582;346;346;346;346;346;346;346;346;346;346;346;346;346;346;346;346;346;346;346","ANNE‐VALÉRIE GUIZARD;FRANCESCA BELLA;GIUSEPPE GROSSO;GIUSEPPE MILONE;JUSTYNA GODOS;GIAMBATTISTA PRIVITERA;RAFFAELE FALSAPERLA;GIUSEPPE MICALI;LUCIA SALVATORELLI;PIERO PAVONE;GIOVANNA VITALITI;GIUSEPPE A. PALUMBO;GIOVANNA RUSSO;G RAVIZZOLA;G. MIRAGLIOTTA;PAOLO VIGNERI;GIUSEPPE ANGELICO;ANDREA D. PRATICÒ;MARTINO RUGGIERI;MASSIMILIANO SORBELLO","346;346;345;318;301;291;203;193;170;168;156;156;154;130;130;114;101;95;95;89","HÉCTOR SOTO PARRÀ;RAFFAELE FALSAPERLA;PIERO PAVONE;GIUSEPPE MILONE;GIOVANNA VITALITI;GIUSEPPE GROSSO;ROSARIO FOTI;MARCO MARIA AIELLO;GIOVANNA RUSSO;LUCIA SALVATORELLI;MASSIMILIANO SORBELLO;SALVATORE LEOTTA;ALESSANDRA CUPRI;MICHELE VECCHIO;NUNZIO RESTUCCIA;PAOLO VIGNERI;JUSTYNA GODOS;ANDREA SPADARO;CÁTIA ROMANO;FABRIZIO PUGLISI","19;14;11;9;7;6;6;5;5;5;5;5;4;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;SOCIOLOGY;MATHEMATICS;PHILOSOPHY;ENGINEERING;POLITICAL SCIENCE;ECONOMICS;PSYCHOLOGY;HISTORY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY","153;56;19;17;11;8;7;7;6;6;5;5;4;4;2;2","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PEDIATRICS;GASTROENTEROLOGY;PALEONTOLOGY;RADIOLOGY;BIOCHEMISTRY;PSYCHIATRY;INTENSIVE CARE MEDICINE;CARDIOLOGY;OPTICS;ANESTHESIA;DERMATOLOGY;ANATOMY;CANCER RESEARCH;DEMOGRAPHY;PHYSICAL THERAPY","117;47;31;27;24;23;19;19;17;16;14;13;12;11;10;10;9;8;7;7;7;7","CANCER;POPULATION;DISEASE;ADVERSE EFFECT;CHEMOTHERAPY;GENE;LUNG CANCER;COHORT;STAGE (STRATIGRAPHY);TRANSPLANTATION;INCIDENCE (GEOMETRY);LYMPHOMA;OBSERVATIONAL STUDY;STEM CELL;CLINICAL TRIAL;BONE MARROW;EXPANDED ACCESS;MEDITERRANEAN DIET;MULTIPLE MYELOMA;RANDOMIZED CONTROLLED TRIAL","26;22;21;15;15;15;15;11;9;9;8;8;8;8;7;6;6;6;6;6","IMMUNOTHERAPY;HEMATOPOIETIC STEM CELL TRANSPLANTATION;CLINICAL ENDPOINT;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;PROGRESSIVE DISEASE;HAEMATOPOIESIS;ADALIMUMAB;BREAST CANCER;GENOTYPE;PSORIATIC ARTHRITIS;RITUXIMAB;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR RECEPTOR;IMATINIB;INFLIXIMAB;MUTATION;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;PLACEBO;TOLERABILITY","10;8;7;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ABATACEPT;ERLOTINIB;HEMATOPOIETIC CELL;SINGLE-NUCLEOTIDE POLYMORPHISM;ABL;ANAPLASTIC LYMPHOMA KINASE;BASDAI;CRIZOTINIB;IMATINIB MESYLATE;POSTURAL INSTABILITY;ADIPOKINE;ALLELE FREQUENCY;ALPORT SYNDROME;AMPLICON;ANDROGEN RECEPTOR;ANTEPARTUM HAEMORRHAGE;ANTHRACYCLINE;ANTI-NMDA RECEPTOR ENCEPHALITIS;ARGATROBAN;AUTOIMMUNE ENCEPHALITIS;BIORESORBABLE SCAFFOLD;CARBOPLATIN;CAREGIVER BURDEN;CELL CYCLE CHECKPOINT;CELL CYCLE PROGRESSION;CETUXIMAB;CHROMATIN REMODELING;COLONOSCOPY;CONGENITAL NEUTROPENIA;CXCR4;CYSTIC ARTERY;DEBULKING;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ELTROMBOPAG;ENTHESITIS;ENTROPY RATE;FANCONI ANEMIA;FLAVONOLS;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;GEFITINIB;GENOTYPING;GERMLINE MUTATION;GLOMERULOSCLEROSIS;GOLIMUMAB;HAPLOTYPE;HEME OXYGENASE;HLA-A;IMMUNE CHECKPOINT;INEFFECTIVE ERYTHROPOIESIS;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;IRON STATUS;ISOPROSTANE;KAEMPFEROL;LDL RECEPTOR;LEUKAPHERESIS;MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY;MAGNETIC RESONANCE ELASTOGRAPHY;MECHANICAL INDEX;MERLIN (PROTEIN);METASTATIC BREAST CANCER;MICROSATELLITE;MITOCHONDRIAL DISEASE;MULTICENTER TRIAL;MULTINODULAR GOITRE;NUCLEATED RED BLOOD CELL;NUCLEOTIDE EXCISION REPAIR;OMALIZUMAB;OXALIPLATIN;PEMETREXED;PHILADELPHIA CHROMOSOME;PLACENTAL ABRUPTION;PLEURAL DISEASE;POMALIDOMIDE;POSACONAZOLE;PRASUGREL;PROTEIN KINASE DOMAIN;REGORAFENIB;RELATIVE SURVIVAL;RIBAVIRIN;RIBOSOME;RNA SPLICING;ROS1;RUXOLITINIB;SECUKINUMAB;SH-SY5Y;SPECIES COMPLEX;SYSTEMIC THERAPY;TAXANE;THROMBOPOIETIN;TICAGRELOR;TICLOPIDINE;TOTAL MESORECTAL EXCISION;TRIPLE-NEGATIVE BREAST CANCER;URETEROPELVIC JUNCTION;USTEKINUMAB;VARICOCELE;VEDOLIZUMAB","10;6;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;ITALY;ADOLESCENT;CHILD;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;MULTIPLE MYELOMA;YOUNG ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;CHILD, PRESCHOOL;CARCINOMA, NON-SMALL-CELL LUNG;HEMATOPOIETIC STEM CELL TRANSPLANTATION;LUNG NEOPLASMS","82;76;54;49;35;27;26;19;17;16;13;11;11;11;11;10;10;9;9;9","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;RHEUMATOID ARTHRITIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;ASTHMA;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;LYMPHOID NEOPLASMS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;ROLE OF MEDITERRANEAN DIET IN HEALTH OUTCOMES;ANTIOXIDANTS AND FREE RADICALS IN HEALTH AND DISEASE;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;EFFECTS OF KETOGENIC DIET ON HEALTH;EPILEPSY AND SEIZURES;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;GENETIC AND MOLECULAR STUDIES OF CONNECTIVE TISSUE DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEMATOPOIETIC STEM CELL BIOLOGY;MANAGEMENT OF VALVULAR HEART DISEASE","9;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;TREATMENT;EXPANDED ACCESS;MEDITERRANEAN DIET;DISCONTINUATION;REFRACTORY (PLANETARY SCIENCE);DIET QUALITY;DIETARY PATTERNS;NON-SMALL CELL LUNG CANCER;ABATACEPT;BREAST CANCER;DISEASE-MODIFYING ANTIRHEUMATIC DRUGS;EGFR MUTATIONS;ETIOLOGY;INTERNATIONAL MYELOMA WORKING GROUP;STROKE (ENGINE);TOLERABILITY;ABL;AIRWAY MANAGEMENT;BASFI","8;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;2;2;2","LUNG CANCER;CELL LUNG;NON-SMALL CELL;EXPANDED ACCESS;ITALIAN NIVOLUMAB;NIVOLUMAB EXPANDED;OBSERVATIONAL STUDY;ACCESS PROGRAMME;ALLOGENEIC HEMATOPOIETIC;CANCER PATIENTS;RHEUMATOID ARTHRITIS;STEM CELL;ACCESS PROGRAM;ADVANCED NSCLC;CELL TRANSPLANTATION;HEALTHY EATING;HEMATOPOIETIC TRANSPLANTATION;INVASIVE TREATMENT;ITALIAN SOCIETY;MEAL STUDY;MEDITERRANEAN DIET;MEDITERRANEAN HEALTHY;MINIMALLY INVASIVE;MULTIPLE MYELOMA;NON-SQUAMOUS NON-SMALL;PATIENTS TREATED;REAL-WORLD RESULTS;STUDY COHORT;ACUTE LEUKEMIA;ADIPOSE-DERIVED MESENCHYMAL","11;9;9;7;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","ADVERSE EVENTS;MEDIAN FOLLOW-UP;MEDITERRANEAN DIET;CLINICAL PRACTICE;LUNG CANCER;ADVISORY ROLE;BRISTOL-MYERS SQUIBB;SURVIVAL OS;CATANIA ITALY;PATIENTS PTS;PRIMARY MALIGNANCIES;PROGRESSION-FREE SURVIVAL;RESPONSE RATE;DISCONTINUED TREATMENT;RARE CANCERS;RESPONSE RATES;SAFETY PROFILE;SYSTEMIC TREATMENT;WOOLY HAIR;ADMINISTERED INTRAVENOUSLY;ALTERNATIVE DONOR;AOV STENOSIS;CD PATIENTS;CELL CARCINOMA;CELL LUNG;CHELATION REGIMENS;CHRONIC MYELOID;CHRONIC RESPIRATORY;CLINICAL TRIAL;COMMON TERMINOLOGY","19;15;11;10;10;9;9;9;8;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6",58,0.37,5.14,6.75,2,3.25,1,4.5,1,0,2.25,7,1,0,6,0,2,2,3,6,2,0,0,58.75,51,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,4.85,356.85,7.03,6,0.46,51.69,1,3,1,0,3,0,0,5,0,10,3,0,0,0,0,0,0,13,0,0,13,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan","7;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4203 HEALTH SERVICES AND SYSTEMS;3207 MEDICAL MICROBIOLOGY","12;8;3;3;2;2;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;AGING;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEALTH SERVICES;HEART DISEASE;HEMATOLOGY;LUNG;ORPHAN DRUG;PEDIATRIC;RARE DISEASES;ARTHRITIS;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;CHILDHOOD LEUKEMIA;CYSTIC FIBROSIS;INFECTIOUS DISEASES","13;9;4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;BLOOD;CONGENITAL;INFLAMMATORY AND IMMUNE SYSTEM","2;2;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","7;3;1;1","LUNG CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NOT SITE-SPECIFIC CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2018,204,14.8823529411765,2.81862745098039,0.377450980392157,0.318627450980392,0.446078431372549,1.91029900332226,1.54,1.80555555555556,1.51666666666667,0.519607843137255,3,80,34,38,28,0.39,0.17,0.19,0.14,22.92,0.751323508047447,3.86338797814208,0.362745098039216,0.946078431372549,0.532,0.443,0.432,0.431,"MASSIMILIANO SORBELLO;RAFFAELE FALSAPERLA;PIERO PAVONE;MARCO BARBANTI;CORRADO TAMBURINO;MARTINO RUGGIERI;CARLO VANCHERI;STEFANO PALMUCCI;GIUSEPPE SESSA;VITO PAVONE;GIACOMO CUSUMANO;DAVIDE CAPODANNO;SEBASTIANO EMANUELE TORRISI;G ZANGHÍ;CLAUDIA CRIMI;GIANLUCA TESTA;ADA VANCHERI;NUNZIO CRIMI;ALBERTO TERMINELLA;ANDREA D. PRATICÒ","16;13;13;10;10;10;9;9;9;9;8;8;7;7;7;7;7;6;6;6","MASSIMILIANO SORBELLO;GIUSEPPE GROSSO;RAFFAELE FALSAPERLA;PIERO PAVONE;MARTINO RUGGIERI;VITO PAVONE;GIUSEPPE SESSA;CORRADO TAMBURINO;G ZANGHÍ;GIANLUCA TESTA;MARCO BARBANTI;SILVIA MARINO PIERO PAVONE;CLAUDIA CRIMI;STEFANO PALMUCCI;CARLO VANCHERI;DAVIDE CAPODANNO;ANDREA D. PRATICÒ;NUNZIO CRIMI;GIACOMO CUSUMANO;ADA VANCHERI","4.21;2.83;1.91;1.84;1.49;1.46;1.41;1.15;1.14;1.09;1.03;1;0.95;0.91;0.87;0.86;0.85;0.78;0.77;0.76","MASSIMILIANO SORBELLO;RAFFAELE FALSAPERLA;PIERO PAVONE;MARCO BARBANTI;CORRADO TAMBURINO;MARTINO RUGGIERI;CARLO VANCHERI;STEFANO PALMUCCI;GIUSEPPE SESSA;VITO PAVONE;GIACOMO CUSUMANO;DAVIDE CAPODANNO;SEBASTIANO EMANUELE TORRISI;G ZANGHÍ;CLAUDIA CRIMI;GIANLUCA TESTA;ADA VANCHERI;NUNZIO CRIMI;ALBERTO TERMINELLA;ANDREA D. PRATICÒ","16;13;13;10;10;10;9;9;9;9;8;8;7;7;7;7;7;6;6;6","MASSIMILIANO SORBELLO;GIUSEPPE GROSSO;RAFFAELE FALSAPERLA;PIERO PAVONE;MARTINO RUGGIERI;VITO PAVONE;GIUSEPPE SESSA;CORRADO TAMBURINO;G ZANGHÍ;GIANLUCA TESTA;MARCO BARBANTI;SILVIA MARINO PIERO PAVONE;CLAUDIA CRIMI;STEFANO PALMUCCI;CARLO VANCHERI;DAVIDE CAPODANNO;ANDREA D. PRATICÒ;NUNZIO CRIMI;GIACOMO CUSUMANO;ADA VANCHERI","4.21;2.83;1.91;1.84;1.49;1.46;1.41;1.15;1.14;1.09;1.03;1;0.95;0.91;0.87;0.86;0.85;0.78;0.77;0.76","FERNÁNDO ALFONSO;TOM JOHNSON;GAETANO BERTINO;A. AVERNA;A. DAVÌ;A. DIGIACOMO;ANTONIO CRAXÌ;CALOGERO CAMMÀ;CARMELO IACOBELLO;F. CARTABELLOTTA;GIOVANNI MAZZOLA;GIOVANNI RAIMONDO;IRENE CACCIOLA;MARCO DISTEFANO;MAURIZIO RUSSELLO;SALVATORE PETTA;TULLIO PRESTILEO;V. CALVARUSO;V. DI MARCO;ANNA LICATA","1049;1049;658;652;652;652;652;652;652;652;652;652;652;652;652;652;652;652;652;646","MARCO DISTEFANO;DAVIDE CAPODANNO;PIERA CAPRANZANO;F LATTERI;F LOMONACO;F. MAFFEO;FEDERICA PULVIRENTI;FRANCESCO DI LORENZO;G. SCIFO;GAETANO SCIFO;ANTONIO MAGNANO;RAFFAELE FALSAPERLA;CARLO VANCHERI;RITA BELLA;MARCO BARBANTI;CLAUDIA CRIMI;GIUSEPPE GROSSO;NUNZIO CRIMI;RAFFAELE CAMPISI;PIERO PAVONE","646;626;547;323;323;323;323;323;323;323;276;224;169;169;152;150;149;147;147;141","MASSIMILIANO SORBELLO;RAFFAELE FALSAPERLA;PIERO PAVONE;VITO PAVONE;GIUSEPPE SESSA;CARLO VANCHERI;STEFANO PALMUCCI;MARCO BARBANTI;CLAUDIA CRIMI;DAVIDE CAPODANNO;GIANLUCA TESTA;ADA VANCHERI;GIACOMO CUSUMANO;G ZANGHÍ;SEBASTIANO EMANUELE TORRISI;ALBERTO TERMINELLA;ANTONIO MAGNANO;GIUSEPPE GROSSO;MAURO PAVONE;HÉCTOR SOTO PARRÀ","16;13;10;9;9;9;9;9;7;7;7;7;7;7;7;6;6;6;6;5","MEDICINE;BIOLOGY;MATHEMATICS;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;PSYCHOLOGY;PHILOSOPHY;BUSINESS;ECONOMICS;SOCIOLOGY;ART;GEOGRAPHY;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;HISTORY;POLITICAL SCIENCE","191;43;15;14;12;10;8;8;5;4;4;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;PEDIATRICS;PATHOLOGY;RADIOLOGY;CARDIOLOGY;GENETICS;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;ANESTHESIA;ONCOLOGY;PHYSICAL THERAPY;BIOCHEMISTRY;CANCER RESEARCH;GENERAL SURGERY;PALEONTOLOGY;MICROBIOLOGY;OPTICS","126;56;28;27;27;25;23;21;21;20;19;18;17;17;17;13;10;10;9;7;7","DISEASE;GENE;COHORT;CANCER;LUNG;POPULATION;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;CHEMOTHERAPY;MAGNETIC RESONANCE IMAGING;THYROID;ADVERSE EFFECT;ALTERNATIVE MEDICINE;BONE MARROW;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;AIRWAY;ANTIBODY;AORTIC VALVE;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;INCIDENCE (GEOMETRY);LUNG CANCER","24;19;15;14;12;12;10;9;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6","IMMUNOTHERAPY;LUNG FUNCTION;PERCUTANEOUS CORONARY INTERVENTION;CONVENTIONAL PCI;IDIOPATHIC PULMONARY FIBROSIS;INFLAMMATORY BOWEL DISEASE;UNIVARIATE ANALYSIS;ACUTE CORONARY SYNDROME;ADALIMUMAB;CROHN'S DISEASE;GENE EXPRESSION;MYELOFIBROSIS;PHENOTYPE;AIRWAY MANAGEMENT;CD34;CLOPIDOGREL;CORONARY ANGIOGRAPHY;DOWNREGULATION AND UPREGULATION;EJECTION FRACTION;GENE DUPLICATION;HAZARD RATIO;INFLIXIMAB;MICRORNA;NEUTROPENIA;PLATELET AGGREGATION INHIBITOR;RESTENOSIS;RITUXIMAB;THYROIDECTOMY;ULCERATIVE COLITIS;VORICONAZOLE","6;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","DIFFUSING CAPACITY;NIVOLUMAB;MICROARRAY;POSACONAZOLE;RUXOLITINIB;COMPARATIVE GENOMIC HYBRIDIZATION;GIANT CELL ARTERITIS;MICROARRAY ANALYSIS TECHNIQUES;MICROVESICLES;P2Y12;POUCHITIS;RNA INTERFERENCE;SOLITARY FIBROUS TUMOR;VEDOLIZUMAB;ABATACEPT;ABSOLUTE NEUTROPHIL COUNT;ACUTE AORTIC SYNDROME;ALPHA-GALACTOSIDASE;AMYLOID FIBRIL;ANAPLASTIC THYROID CANCER;ANTI-NUCLEAR ANTIBODY;ANTIPLATELET DRUG;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;ARTERY DISSECTION;BARDET–BIEDL SYNDROME;BASOPHIL;BENDAMUSTINE;BICUSPID VALVE;BRADYCARDIA;BROTH MICRODILUTION;CALPROTECTIN;CARDIAC SKELETON;CHEMOIMMUNOTHERAPY;CIRCULAR RNA;CONTRAST-INDUCED NEPHROPATHY;COPY-NUMBER VARIATION;CYCLIC NEUTROPENIA;CYSTIC ARTERY;DDR1;DEBULKING;DESMIN;DNA METHYLATION;DRUG-ELUTING STENT;DUAL-ENERGY X-RAY ABSORPTIOMETRY;DUP;DYSKINESIA;EPITHELIAL–MESENCHYMAL TRANSITION;EXHALED NITRIC OXIDE;FLAVONOLS;FRACTIONAL ANISOTROPY;FRACTIONAL FLOW RESERVE;GENE MUTATION;GENOTYPE-PHENOTYPE DISTINCTION;GENOTYPING;GOLIMUMAB;HEMATOPOIETIC STEM CELL;HEME OXYGENASE;HEPACIVIRUS;HERPESVIRIDAE;HISTONE DEACETYLASE;IBRUTINIB;IGHV@;INDUCED PLURIPOTENT STEM CELL;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRACRANIAL ARTERIOVENOUS MALFORMATIONS;LEGIONNAIRES' DISEASE;LONG NON-CODING RNA;MUTATION TESTING;MYELOPROLIFERATIVE NEOPLASM;NATIONAL DEATH INDEX;NEOINTIMA;NERVE SHEATH NEOPLASM;NINTEDANIB;NON-CODING RNA;NON-SMALL CELL LUNG CANCER (NSCLC);NUCLEAR PROTEIN;PAPILLARY CARCINOMA;PEDIATRIC STROKE;PERFLUOROOCTANE;PHILADELPHIA CHROMOSOME;POINT MUTATION;PRASUGREL;PROBAND;PROSTATE BIOPSY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETICULOCYTE;SCEDOSPORIUM APIOSPERMUM;SILENT PERIOD;SPECKLE TRACKING ECHOCARDIOGRAPHY;SYMPORTER;TAKAYASU ARTERITIS;TARGET LESION;TERIFLUNOMIDE;TICAGRELOR;TOTAL THYROIDECTOMY;TRANSCRIPTOME;TWIN PREGNANCY;USTEKINUMAB;VENETOCLAX;VINORELBINE","4;4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;ADOLESCENT;CHILD;AGED, 80 AND OVER;CORONARY ARTERY DISEASE;TREATMENT OUTCOME;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;CHILD, PRESCHOOL;YOUNG ADULT;BIOMARKERS, TUMOR;PERCUTANEOUS CORONARY INTERVENTION;LUNG NEOPLASMS","114;88;69;63;39;33;32;30;21;18;17;16;14;13;13;12;12;11;11;10","MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MANAGEMENT OF VALVULAR HEART DISEASE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;LYMPHOID NEOPLASMS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ASTHMA;CANCER IMMUNOTHERAPY;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS","12;11;7;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","TRANSCATHETER AORTIC-VALVE REPLACEMENT;PROSTHETIC VALVES EVALUATION;DIFFICULT AIRWAY SOCIETY;IDIOPATHIC PULMONARY FIBROSIS;SURGICAL AORTIC-VALVE REPLACEMENT;UNIVARIATE ANALYSIS;AIRWAY MANAGEMENT;CARDIAC IMAGING;DISCONTINUATION;DLCO;KURTOSIS;MEDITERRANEAN DIET;TREATMENT;BIOMARKERS FOR IMMUNOTHERAPY;CARDIOVASCULAR RISK ASSESSMENT;DIFFERENTIATED THYROID CANCER;DRUG-ELUTING STENTS;EPILEPSY;GUIDELINE;HEPATITIS C","10;8;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3","AORTIC VALVE;VALVE IMPLANTATION;TRANSCATHETER AORTIC;IDIOPATHIC PULMONARY;PULMONARY FIBROSIS;CORONARY ARTERY;HRCT INDEXES;MULTICENTER STUDY;MULTIPLE SCLEROSIS;PATIENTS TREATED;PATIENTS UNDERGOING;AIRWAY MANAGEMENT;ANTIPLATELET THERAPY;ARTERY DISEASE;CASE-CONTROL STUDY;CONSENSUS DOCUMENT;ENDOBRONCHIAL VALVES;GISEA REGISTRY;INFLAMMATORY BOWEL;LUNG CANCER;QUANTITATIVE HRCT;STEM CELL;ACTION PLAN;AIRWAY CONGRESS;ANTIMICROBIAL RESISTANCE;ARTHRITIS RESULTS;BICUSPID AORTIC;BONE METASTASES;BOWEL DISEASE;CANCER PATIENTS","9;7;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;HONORARIA MEMBERSHIP;ADVISORY BOARD;PATIENTS TREATED;BOARD SPEAKERS;RA PATIENTS;RESEARCH FUNDING;AORTIC VALVE;MS PATIENTS;RUX START;VERSUS MONTHS;COMMITTEES RESEARCH;FUNDING SPEAKERS;BONE MARROW;DEPRESSIVE SYMPTOMS;MULTIVARIATE ANALYSIS;OVERT PMF;VALVE TREATMENT;CLINICAL OUTCOMES;CLINICAL PRACTICE;MULTIPLE SCLEROSIS;RECEIVED LENALIDOMIDE;SURVIVAL OS;BE-VALVES COMPARED;BILE DUCT;BUREAU JANSSEN;CENTRAL VENOUS;CLINICAL BENEFIT","39;39;38;26;15;14;12;12;11;10;10;10;10;9;9;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6",72,0.35,6.53,5.5,2.75,1,1,2,1.75,0,1,6.25,0,1,6,2,1.5,1,4.5,5.75,4,0,0,69,69,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,3.08,784.75,4.26,3,0.25,42.67,0,0,0,0,3,0,2,7,0,7,5,0,0,0,0,0,0,10,2,0,12,0,0,0,0,0,0,0,0,0,"Italy;Germany;United States","9;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;3203 DENTISTRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4204 MIDWIFERY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","12;4;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CARDIOVASCULAR;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEART DISEASE;AUTOIMMUNE DISEASE;DIGESTIVE DISEASES;GENETICS;INFECTIOUS DISEASES;LUNG;PATIENT SAFETY;RARE DISEASES;AGING;ARTHRITIS;BIOMEDICAL IMAGING;CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;DENTAL/ORAL AND CRANIOFACIAL DISEASE;EMERGENCY CARE;EMERGING INFECTIOUS DISEASES","10;5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;ORAL AND GASTROINTESTINAL;RESPIRATORY;CANCER;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH","3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES","6;1;1;1;1","LEUKEMIA / LEUKAEMIA;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","2;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"PUBLIC LIBRARY OF SCIENCE","6","52 PSYCHOLOGY;32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING;5202 BIOLOGICAL PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","5;3;2;1;1;1;1;1","AUTOIMMUNE DISEASE;BRAIN DISORDERS;CLINICAL RESEARCH;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;HEADACHES;PAIN RESEARCH","2;2;2;2;2;2;1;1","NEUROLOGICAL","2","7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1","CLINICAL","3","CLINICAL MEDICINE AND SCIENCE","5",NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2019,256,15.25390625,3.1640625,0.35546875,0.3125,0.44921875,2.34492753623188,1.421875,1.6,1.51315789473684,0.62890625,1,107,37,25,43,0.42,0.14,0.1,0.17,20.76,0.853637732533622,4.2008797653959,0.3203125,0.96875,0.528,0.455,0.486,0.476,"FRANCESCO DI RAIMONDO;CONCETTA CONTICELLO;ALESSANDRA ROMANO;DAVIDE CAPODANNO;FABIO STAGNO;CORRADO TAMBURINO;UROŠ MARKOVIC;RAFFAELE FALSAPERLA;VALERIO LEOTTA;MARIA GRAZIA SCUDERI;ENRICA ANTONIA MARTINO;VITTORIO DEL FABRO;ROBERTO CHIMENZ;STEFANIA STELLA;MARCO BARBANTI;ALESSANDRA IURLO;STEFANO PALMUCCI;PASQUA BETTA;HÉCTOR SOTO PARRÀ;NUNZIATINA LAURA PARRINELLO","28;17;17;17;16;14;13;13;12;12;11;11;11;11;10;10;10;10;10;10","DAVIDE CAPODANNO;MASSIMILIANO SORBELLO;FRANCESCO DI RAIMONDO;PIERO PAVONE;RAFFAELE FALSAPERLA;CORRADO TAMBURINO;CONCETTA CONTICELLO;VITO PAVONE;ALESSANDRA ROMANO;GIANLUCA TESTA;STEFANO PALMUCCI;ENRICA ANTONIA MARTINO;UROŠ MARKOVIC;VALERIA CALAFIORE;VALERIO LEOTTA;GIUSEPPE SESSA;MARIA GRAZIA SCUDERI;ROBERTO CHIMENZ;VITTORIO DEL FABRO;GIOVANNI CORSELLO","2.42;2.33;2.32;1.91;1.7;1.49;1.45;1.45;1.44;1.13;1.09;1.06;1.03;0.98;0.98;0.97;0.95;0.94;0.92;0.92","FRANCESCO DI RAIMONDO;CONCETTA CONTICELLO;ALESSANDRA ROMANO;DAVIDE CAPODANNO;FABIO STAGNO;CORRADO TAMBURINO;UROŠ MARKOVIC;RAFFAELE FALSAPERLA;VALERIO LEOTTA;MARIA GRAZIA SCUDERI;ENRICA ANTONIA MARTINO;VITTORIO DEL FABRO;STEFANIA STELLA;MARCO BARBANTI;STEFANO PALMUCCI;PASQUA BETTA;HÉCTOR SOTO PARRÀ;NUNZIATINA LAURA PARRINELLO;SILVIA RITA VITALE;VINCENZO DI BENEDETTO","28;17;17;17;16;14;13;13;12;12;11;11;11;10;10;10;10;10;10;10","DAVIDE CAPODANNO;MASSIMILIANO SORBELLO;FRANCESCO DI RAIMONDO;PIERO PAVONE;RAFFAELE FALSAPERLA;CORRADO TAMBURINO;CONCETTA CONTICELLO;VITO PAVONE;ALESSANDRA ROMANO;GIANLUCA TESTA;STEFANO PALMUCCI;ENRICA ANTONIA MARTINO;UROŠ MARKOVIC;VALERIA CALAFIORE;VALERIO LEOTTA;GIUSEPPE SESSA;MARIA GRAZIA SCUDERI;VITTORIO DEL FABRO;FABIO STAGNO;PASQUA BETTA","2.42;2.33;2.32;1.91;1.7;1.49;1.45;1.45;1.44;1.13;1.09;1.06;1.03;0.98;0.98;0.97;0.95;0.92;0.91;0.88","DAVIDE CAPODANNO;CORRADO TAMBURINO;ROBERT A. BYRNE;MARCO BARBANTI;ROXANA MEHRAN;FRANCESCO PRATI;WILLIAM WIJNS;DOMINICK J. ANGIOLILLO;AKIHIDE KONISHI;ANDREW FARB;C. MICHAEL GIBSON;DARREN MYLOTTE;DONALD E. CUTLIP;ERNEST SPITZER;HYO‐SOO KIM;JOHN C. LASCHINGER;JOHN GREGSON;JOHN W. EIKELBOOM;MARCO VALGIMIGLI;MARIE-CLAUDE MORICE","1251;757;686;660;632;574;463;409;408;408;408;408;408;408;408;408;408;408;408;408","DAVIDE CAPODANNO;MARCO BARBANTI;CORRADO TAMBURINO;HÉCTOR SOTO PARRÀ;ALESSIO LA MANNA;GIANNI RUSCICA;FABIO STAGNO;RAFFAELE FALSAPERLA;STEFANIA STELLA;FRANCESCO DI RAIMONDO;CARLO VANCHERI;PAOLO VIGNERI;ROSSELLA CACCIOLA;VITO PAVONE;STEFANO PALMUCCI;GIANLUCA TESTA;SILVIA RITA VITALE;GIULIANO COSTA;GIUSEPPE SESSA;ELENA TIRRÒ","1236;574;573;382;323;296;242;210;192;185;167;155;145;137;134;130;118;116;116;108","FRANCESCO DI RAIMONDO;DAVIDE CAPODANNO;FABIO STAGNO;RAFFAELE FALSAPERLA;CONCETTA CONTICELLO;MARIA GRAZIA SCUDERI;CORRADO TAMBURINO;UROŠ MARKOVIC;STEFANIA STELLA;VALERIO LEOTTA;HÉCTOR SOTO PARRÀ;VINCENZO DI BENEDETTO;PASQUA BETTA;MARCO BARBANTI;VITTORIO DEL FABRO;MASSIMILIANO SORBELLO;SILVIA RITA VITALE;VITO PAVONE;STEFANO PALMUCCI;NUNZIATINA LAURA PARRINELLO","21;16;15;13;12;12;11;11;10;10;10;10;10;9;9;9;9;9;9;9","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY;CHEMISTRY;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY;MATHEMATICS;GEOLOGY;ART;BUSINESS;GEOGRAPHY","242;62;23;18;11;11;10;9;8;6;6;5;4;3;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;GENETICS;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PEDIATRICS;RADIOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;ANESTHESIA;PSYCHIATRY;DERMATOLOGY;OPTICS;NURSING;PALEONTOLOGY;LAW","174;92;42;38;36;33;33;29;24;24;23;21;17;14;14;13;13;12;12;11","CANCER;COHORT;DISEASE;POPULATION;GENE;MULTIPLE MYELOMA;ADVERSE EFFECT;CHEMOTHERAPY;MYELOID LEUKEMIA;LUNG;RANDOMIZED CONTROLLED TRIAL;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);CLINICAL TRIAL;PROSPECTIVE COHORT STUDY;STENOSIS;TRANSPLANTATION;ANTIBODY;AORTIC VALVE;OBSERVATIONAL STUDY;PERCUTANEOUS;PREGNANCY;REGIMEN","27;25;25;24;21;19;18;15;15;14;14;13;13;13;12;11;11;10;10;8;8;8;8;8;8","CLINICAL ENDPOINT;IMATINIB;LENALIDOMIDE;PERCUTANEOUS CORONARY INTERVENTION;AORTIC VALVE STENOSIS;HAZARD RATIO;CHROMOSOMAL TRANSLOCATION;EJECTION FRACTION;INTERSTITIAL LUNG DISEASE;BORTEZOMIB;BREAST CANCER;CHROMOSOME;IDIOPATHIC PULMONARY FIBROSIS;IMMUNOTHERAPY;MYELOFIBROSIS;PSORIATIC ARTHRITIS;TOLERABILITY;TYROSINE KINASE;ADALIMUMAB;BREAKPOINT CLUSTER REGION;INFLIXIMAB;LUNG FUNCTION;NEUTROPENIA;VALVE REPLACEMENT","11;11;9;9;8;7;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4","POMALIDOMIDE;DASATINIB;IMATINIB MESYLATE;NILOTINIB;PHILADELPHIA CHROMOSOME;CARFILZOMIB;DARATUMUMAB;DIFFUSING CAPACITY;FUSION TRANSCRIPT;NIVOLUMAB;KARYOTYPE;MACE;MONOCLONAL;RUXOLITINIB;ABL;BIORESORBABLE SCAFFOLD;COMPARATIVE GENOMIC HYBRIDIZATION;FRACTIONAL FLOW RESERVE;FUNCTIONAL MITRAL REGURGITATION;KLEBSIELLA PNEUMONIAE;PIRFENIDONE;SANGER SEQUENCING","6;5;5;5;5;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;POSTOPERATIVE COMPLICATIONS;TREATMENT OUTCOME;AGED, 80 AND OVER;AORTIC VALVE STENOSIS;LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;AORTIC VALVE;TRANSCATHETER AORTIC VALVE REPLACEMENT;RETROSPECTIVE STUDIES;FUSION PROTEINS, BCR-ABL;CORONARY ARTERY DISEASE;PROSPECTIVE STUDIES;RISK FACTORS","128;125;86;82;58;57;42;39;36;36;29;28;28;27;27;23;21;20;18;17","MANAGEMENT OF VALVULAR HEART DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;TREATMENT AND OUTCOMES OF HAND INJURIES;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CANCER IMMUNOTHERAPY;LYMPHOID NEOPLASMS;PEDIATRIC URINARY TRACT INFECTIONS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;HIP ARTHROPLASTY TECHNIQUES AND MATERIALS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND TREATMENT OF LUNG CANCER","18;16;15;9;9;8;8;5;4;4;4;4;3;3;2;2;2;2;2;2","PROSTHETIC VALVES EVALUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CLINICAL ENDPOINT;INTERNATIONAL MYELOMA WORKING GROUP;REGIMEN;SURGICAL AORTIC-VALVE REPLACEMENT;CARDIOVASCULAR RISK ASSESSMENT;DISCONTINUATION;CARDIAC IMAGING;TREATMENT;CORONARY STENTS;IDIOPATHIC PULMONARY FIBROSIS;POMALIDOMIDE;STROKE (ENGINE);TOLERABILITY;DISTAL RADIUS FRACTURES;DRUG-ELUTING STENTS;FRACTURE CLASSIFICATION;HEMATOLOGY;IMATINIB MESYLATE","15;15;11;9;9;9;8;8;7;7;6;6;6;6;6;5;5;5;5;5","AORTIC VALVE;MULTIPLE MYELOMA;PATIENTS TREATED;TRANSCATHETER AORTIC;MYELOMA PATIENTS;OBSERVATIONAL STUDY;VALVE IMPLANTATION;CHRONIC MYELOID;ITALIAN SOCIETY;MYELOID LEUKEMIA;REAL LIFE;STEM CELL;TRANSFEMORAL TRANSCATHETER;CML PATIENT;CML PATIENTS;CONSENSUS DOCUMENT;CONTROLLED TRIAL;INTERSTITIAL LUNG;KINASE INHIBITORS;LEFT MAIN;PATIENT EXPRESSING;PATIENTS UNDERGOING;PSORIATIC ARTHRITIS;RETROSPECTIVE STUDY;TYROSINE KINASE;ADULT PATIENTS;ARTERY DISEASE;CELL TRANSPLANTATION;CORONARY ARTERY;IDIOPATHIC PULMONARY","11;10;9;8;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;CONSULTANCY HONORARIA;RESEARCH FUNDING;HONORARIA MEMBERSHIP;PATIENTS TREATED;HONORARIA INCYTE;INCYTE HONORARIA;NOVARTIS HONORARIA;PFIZER HONORARIA;ADVERSE EVENTS;SCIENTIFIC ADVICE;HONORARIA NOVARTIS;HONORARIA PFIZER;DEPENDANT HONORARIA;FINANCIAL DEPENDANT;SPOUSE FINANCIAL;MG OAD;HONORARIA RESEARCH;BMS HONORARIA;COMMITTEES SPEAKERS;MULTIPLE MYELOMA;CLINICAL TRIALS;MEDIAN OS;MITRAL VALVE;MEDIAN AGE;RISK FACTORS;SIGNIFICANT DIFFERENCES;SURVIVAL OS","70;70;50;46;38;37;36;27;26;26;25;23;23;21;21;20;20;20;19;16;15;15;15;14;14;14;13;13;13;13",91,0.36,8.53,10.5,1.25,1,0,1,0,0,1,11,1,1,10,0,2,2,6,10,5,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,3,232.33,2.78,6,0.67,93,0,1,0,1,5,0,1,1,0,8,1,0,0,0,0,0,0,9,0,0,9,0,0,0,0,0,0,0,0,0,"United States","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","9;5;4;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;ARTHRITIS;BRAIN DISORDERS;LUNG;LUNG CANCER;NEURODEGENERATIVE;NEUROSCIENCES;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BREAST CANCER;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEMATOLOGY;LYMPHOMA;PEDIATRIC;PREVENTION;PSORIASIS","9;8;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;SKIN","3;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","8;1;1","LUNG CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","4;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"FRONTIERS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","2;1","CANCER;GENETICS;HEMATOLOGY","1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1;1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","1","MYELOMA","1",NA,NA
"AOUSSN_VITTORIOEMANUELE",2020,278,16.3561151079137,2.7158273381295,0.31294964028777,0.298561151079137,0.384892086330935,2.04054054054054,1.359375,1.56603773584906,1.46575342465753,0.697841726618705,1,104,56,39,23,0.37,0.2,0.14,0.08,20.25,0.803545765401967,5.31729667812143,0.320143884892086,0.964028776978417,0.501,0.449,0.446,0.45,"CARLO VANCHERI;DAVIDE CAPODANNO;CORRADO TAMBURINO;FRANCESCO DI RAIMONDO;MARCO BARBANTI;PIERO PAVONE;ALESSANDRA ROMANO;STEFANO PALMUCCI;GIANLUCA SAMBATARO;ANTONIO BASILE;RAFFAELE FALSAPERLA;NUNZIO CRIMI;CLAUDIA CRIMI;HÉCTOR SOTO PARRÀ;DANIELE TIBULLO;VITO PAVONE;GIANLUCA TESTA;FABIO STAGNO;GIOVANNI CORSELLO;RAFFAELE CAMPISI","18;18;16;15;12;12;11;11;11;11;11;10;9;9;9;9;8;8;7;7","DAVIDE CAPODANNO;EVA INTAGLIATA;CLAUDIA CRIMI;CARLO VANCHERI;PIERO PAVONE;CORRADO TAMBURINO;VITO PAVONE;RAFFAELE FALSAPERLA;NUNZIO CRIMI;ANTONIO BASILE;GIANLUCA TESTA;STEFANO PALMUCCI;RAFFAELE CAMPISI;ANTONELLA AGODI;MARTINA BARCHITTA;ALESSANDRA ROMANO;FRANCESCO DI RAIMONDO;SARA MANTI;ANDREA MAUGERI;GIOVANNI CORSELLO","2.7;1.87;1.58;1.51;1.5;1.5;1.33;1.24;1.15;1.13;1.13;1.08;1.03;1.02;1.02;0.97;0.96;0.94;0.93;0.88","CARLO VANCHERI;DAVIDE CAPODANNO;CORRADO TAMBURINO;FRANCESCO DI RAIMONDO;MARCO BARBANTI;PIERO PAVONE;ALESSANDRA ROMANO;STEFANO PALMUCCI;GIANLUCA SAMBATARO;ANTONIO BASILE;RAFFAELE FALSAPERLA;NUNZIO CRIMI;CLAUDIA CRIMI;HÉCTOR SOTO PARRÀ;VITO PAVONE;GIANLUCA TESTA;FABIO STAGNO;RAFFAELE CAMPISI;GIUSEPPE A. PALUMBO;NUNZIATINA LAURA PARRINELLO","18;18;16;15;12;12;11;11;11;11;11;10;9;9;9;8;8;7;7;7","DAVIDE CAPODANNO;EVA INTAGLIATA;CLAUDIA CRIMI;CARLO VANCHERI;PIERO PAVONE;CORRADO TAMBURINO;VITO PAVONE;RAFFAELE FALSAPERLA;NUNZIO CRIMI;ANTONIO BASILE;GIANLUCA TESTA;STEFANO PALMUCCI;RAFFAELE CAMPISI;ANTONELLA AGODI;ALESSANDRA ROMANO;FRANCESCO DI RAIMONDO;SARA MANTI;ROSARIO VECCHIO;GIANLUCA SAMBATARO;ANDREA VESCIO","2.7;1.87;1.58;1.51;1.5;1.5;1.33;1.24;1.15;1.13;1.13;1.08;1.03;1.02;0.97;0.96;0.94;0.87;0.85;0.85","DAVIDE CAPODANNO;ROXANA MEHRAN;CHIARA FRACCARO;ANDREAS BAUMBACH;HÉCTOR SOTO PARRÀ;ALAIDE CHIEFFO;JAVIER ESCANED;VIJAY KUNADIAN;ALEXANDRA J. LANSKY;ANGELA H.E.M. MAAS;COLIN BERRY;DIRK J. DUNCKER;EVA PRESCOTT;EVELYN REGAR;GILL LOUISE BUCHANAN;J. DAWN ABBOTT;LINA BADIMÓN;NICOLE KARAM;PAOLO G. CAMICI;RASHA AL-LAMEÉ","1029;673;599;592;565;564;562;558;505;505;505;505;505;505;505;505;505;505;505;505","DAVIDE CAPODANNO;HÉCTOR SOTO PARRÀ;CARLO VANCHERI;CLAUDIA CRIMI;GIANLUCA SAMBATARO;ANTONELLA AGODI;FRANCESCO DI RAIMONDO;CONCETTA PALERMO;STEFANO PALMUCCI;NUNZIO CRIMI;ALESSANDRA ROMANO;ANTONIO BASILE;CORRADO TAMBURINO;ANTONINO LO GIUDICE;MARINELLA ASTUTO;ALESSANDRO BARBATO;NUNZIATINA LAURA PARRINELLO;RAFFAELE CAMPISI;FABRIZIO PUGLISI;ANTONIO POPOLO RUBBIO","1029;565;364;232;222;215;206;199;190;179;174;169;167;165;149;146;132;127;123;122","DAVIDE CAPODANNO;CARLO VANCHERI;CORRADO TAMBURINO;FRANCESCO DI RAIMONDO;MARCO BARBANTI;RAFFAELE FALSAPERLA;ANTONIO BASILE;GIANLUCA SAMBATARO;STEFANO PALMUCCI;NUNZIO CRIMI;CLAUDIA CRIMI;HÉCTOR SOTO PARRÀ;ALESSANDRA ROMANO;VITO PAVONE;PIERO PAVONE;RAFFAELE CAMPISI;FABIO STAGNO;GIANLUCA TESTA;SARA MANTI;ALESSIO LA MANNA","18;15;14;14;11;11;11;11;11;9;9;9;8;8;7;7;7;7;6;6","MEDICINE;BIOLOGY;COMPUTER SCIENCE;ENGINEERING;PHYSICS;PSYCHOLOGY;MATHEMATICS;CHEMISTRY;SOCIOLOGY;PHILOSOPHY;ECONOMICS;BUSINESS;MATERIALS SCIENCE;POLITICAL SCIENCE;GEOGRAPHY;GEOLOGY;HISTORY;ART;ENVIRONMENTAL SCIENCE","271;63;24;24;21;18;17;14;12;7;6;5;5;5;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;CARDIOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;PEDIATRICS;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PSYCHIATRY;BIOCHEMISTRY;ONCOLOGY;ANESTHESIA;PHYSICAL THERAPY;VIROLOGY;CANCER RESEARCH;ENDOCRINOLOGY;MECHANICAL ENGINEERING","197;75;50;46;37;37;34;32;31;27;27;25;22;20;17;16;15;14;14;12","DISEASE;LUNG;POPULATION;GENE;MYOCARDIAL INFARCTION;RANDOMIZED CONTROLLED TRIAL;CANCER;COHORT;OBSERVATIONAL STUDY;CONFIDENCE INTERVAL;ADVERSE EFFECT;OUTBREAK;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;CLINICAL TRIAL;INCIDENCE (GEOMETRY);PROSPECTIVE COHORT STUDY;ASTHMA;CHEMOTHERAPY;LOGISTIC REGRESSION;PREGNANCY;RECEPTOR;STENOSIS","55;24;24;21;20;19;16;16;16;15;13;13;13;11;11;11;11;10;10;9;9;9;9","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;PERCUTANEOUS CORONARY INTERVENTION;CLINICAL ENDPOINT;HAZARD RATIO;CONVENTIONAL PCI;IDIOPATHIC PULMONARY FIBROSIS;LUNG FUNCTION;ACUTE CORONARY SYNDROME;GENOTYPE;IMMUNOGLOBULIN E;INFLAMMATORY BOWEL DISEASE;INTERSTITIAL LUNG DISEASE;BORTEZOMIB;BRONCHIECTASIS;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;IMATINIB;MULTICENTER STUDY;NEURORADIOLOGY;PROTOCOL (SCIENCE);REVASCULARIZATION","27;13;13;12;11;10;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);DIFFUSING CAPACITY;NILOTINIB;TICAGRELOR;DRUG-ELUTING STENT;ENTHESITIS;GOLIMUMAB;NIVOLUMAB;OMALIZUMAB;TARGET LESION;USUAL INTERSTITIAL PNEUMONIA;CARFILZOMIB;CONNECTIVE TISSUE DISEASE;DASATINIB;DIGITAL POLYMERASE CHAIN REACTION;EXHALED NITRIC OXIDE;HEME OXYGENASE;IMATINIB MESYLATE;KLEBSIELLA PNEUMONIAE;MACE;MEPOLIZUMAB;P2Y12;PIRFENIDONE;PRASUGREL;PROTEIN PHOSPHATASE 2;RUXOLITINIB;SECUKINUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;SOLITARY FIBROUS TUMOR;USTEKINUMAB;VEDOLIZUMAB;VENETOCLAX","26;7;5;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MALE;ITALY;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;CORONARY ARTERY DISEASE;PERCUTANEOUS CORONARY INTERVENTION;AGED, 80 AND OVER;COVID-19;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;CHILD;ADOLESCENT;REGISTRIES;RISK FACTORS;ATRIAL FIBRILLATION","164;113;69;65;55;46;35;33;27;23;22;19;19;18;18;16;15;15;15;13","MANAGEMENT OF VALVULAR HEART DISEASE;CORONAVIRUS DISEASE 2019;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;EFFICACY AND RESISTANCE IN CML TREATMENT;ASTHMA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;EPIDEMIOLOGY AND TREATMENT OF BONE FRACTURES;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MODELING THE DYNAMICS OF COVID-19 PANDEMIC;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY","13;10;9;9;7;7;6;6;5;5;4;3;3;3;3;3;3;3;3;3","2019-20 CORONAVIRUS OUTBREAK;CLINICAL ENDPOINT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;PANDEMIC;PROSTHETIC VALVES EVALUATION;TREATMENT;IDIOPATHIC PULMONARY FIBROSIS;NONINVASIVE VENTILATION;CARDIAC IMAGING;DLCO;STROKE (ENGINE);CONCOMITANT;CORONARY STENTS;DIAGNOSIS;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;NEURORADIOLOGY;POSITIVE END-EXPIRATORY PRESSURE;PRESENTATION (OBSTETRICS);BETACORONAVIRUS;CARDIOVASCULAR RISK ASSESSMENT","12;12;12;10;10;10;7;7;6;6;6;5;5;5;5;5;5;5;4;4","AORTIC VALVE;TRANSCATHETER AORTIC;IDIOPATHIC PULMONARY;MULTICENTER STUDY;MULTIPLE SCLEROSIS;PULMONARY FIBROSIS;INFLAMMATORY BOWEL;PATIENTS TREATED;ACUTE CORONARY;CHRONIC MYELOID;LUNG CANCER;MULTIPLE MYELOMA;MYELOID LEUKEMIA;VALVE IMPLANTATION;ITALIAN SOCIETY;LEFT MAIN;OBSERVATIONAL STUDY;POSITION PAPER;VALVE REPLACEMENT;BLEEDING RISK;BOTULINUM TOXIN;BOWEL DISEASE;BOWEL DISEASES;CELL LUNG;CLINICAL OUTCOMES;CML PATIENTS;CONSENSUS DOCUMENT;CORONARY INTERVENTION;CORONARY SYNDROME;CORONARY SYNDROMES","11;8;7;7;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","SPEAKERS BUREAU;ADVISORY COMMITTEES;ENTITYS BOARD;CONSULTANCY HONORARIA;RESEARCH FUNDING;COMMITTEES SPEAKERS;HR CI;PULMONARY FUNCTION;FUNCTION TESTING;HONORARIA SPEAKERS;ADVERSE EVENTS;COVID- PANDEMIC;PATIENTS TREATED;HONORARIA MEMBERSHIP;CLINICAL PRACTICE;HEALTH CARE;COMPUTED TOMOGRAPHY;CONSULTANCY MEMBERSHIP;ANAESTHESIOLOGY JOURNALS;AORTIC VALVE;HEART RATE;LUNG CANCER;LUNG FUNCTION;NOVARTIS HONORARIA;PALLIATIVE CARE;PATIENTS RECEIVING;PUBMED SCOPUS;AOU POLICLINICO-VITTORIO;BUREAU ABBVIE;CONSECUTIVE PATIENTS","80;64;64;43;32;27;27;22;17;16;15;15;15;14;13;12;11;11;10;10;10;10;10;10;10;10;10;9;9;9",120,0.43,7.1,10,2.5,1,0,2.5,1,1,1.25,11.25,0,1,10,0,3,2,4,7.5,6,0,0,48.25,49.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,5.75,282.25,1.19,3,0.75,144.5,0,0,0,0,3,0,0,1,0,4,0,0,0,0,0,0,0,4,0,0,3,0,0,1,0,0,0,0,0,0,"Italy;Japan;Switzerland;United States","2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","4;4;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;LUNG;LUNG CANCER;BRAIN DISORDERS;MENTAL HEALTH;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;PREVENTION","4;4;2;2;2;1;1;1;1;1;1","CANCER;MENTAL HEALTH;NEUROLOGICAL","2;1;1","6.1 PHARMACEUTICALS;6.6 PSYCHOLOGICAL AND BEHAVIOURAL","3;1","LUNG CANCER","2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"FRONTIERS","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY","4;2;1;1;1","CLINICAL RESEARCH;CANCER;CHRONIC PAIN;GENETICS;LUNG;LUNG CANCER;NEUROSCIENCES;PAIN RESEARCH;PATIENT SAFETY","2;1;1;1;1;1;1;1;1","CANCER","1",NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","2","LUNG CANCER","1",NA,NA
"AOUSSN_VITTORIOEMANUELE",2021,174,22.8620689655172,1.9367816091954,0.149425287356322,0.17816091954023,0.160919540229885,1.81182795698925,1,1.40909090909091,1,0.706896551724138,0,79,33,22,11,0.45,0.19,0.13,0.06,13.72,0.889608163540457,6.22535211267605,0.454022988505747,0.994252873563218,0.408,0.393,0.377,0.384,"MARCO BARBANTI;FEDERICO DE MARCO;ROSARIO FOTI;ANTONIO COLOMBO;FRANCESCO DI RAIMONDO;BERNHARD REIMERS;CORRADO TAMBURINO;LUIS NOMBELA‐FRANCO;FLORENZO IANNONE;FRANCESCO GALLO;TOBIAS ZEUS;ELISA VISALLI;STEFAN TOGGWEILER;MARIANNA ADAMO;SALVATORE BRUGALETTA;GIOVANNA CUOMO;AMELIA SPINELLA;WALTER FRIES;ELENA GENERALI;FERNÁNDO ALFONSO","13;10;10;10;9;9;9;9;8;8;7;7;7;7;7;7;6;6;6;6","FRANCESCO DI RAIMONDO;ANTONIO BASILE;CORRADO TAMBURINO;CLAUDIA CRIMI;NUNZIO CRIMI;MARCO BARBANTI;FEDERICO DE MARCO;ANTONIO COLOMBO;DAVIDE CAPODANNO;RAFFAELE FALSAPERLA;FILIPPO SANFILIPPO;BERNHARD REIMERS;VITO PAVONE;STEFANO PALMUCCI;MASSIMILIANO SORBELLO;CRISTINA RUSSO;MARIA STELLA VALLE;MATTEO CIONI;ANTONINO CASABONA;LUIS NOMBELA‐FRANCO","0.67;0.63;0.63;0.59;0.56;0.56;0.51;0.5;0.49;0.49;0.48;0.44;0.43;0.42;0.41;0.39;0.39;0.39;0.39;0.38","MARCO BARBANTI;ROSARIO FOTI;FRANCESCO DI RAIMONDO;CORRADO TAMBURINO;ELISA VISALLI;CLAUDIA CRIMI;ANTONIO MAGNANO;CARMELO GRASSO;FRANCESCO PATTI;CONCETTA FERRACANE;DAVIDE CAPODANNO;SALVATORE LEOTTA;NUNZIO CRIMI;HÉCTOR SOTO PARRÀ;ANTONIO BASILE;RAFFAELE FALSAPERLA;GIUSEPPE MILONE;CARLO VANCHERI;ALESSANDRA ROMANO;STEFANO PALMUCCI","13;10;9;9;7;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4","FRANCESCO DI RAIMONDO;ANTONIO BASILE;CORRADO TAMBURINO;CLAUDIA CRIMI;NUNZIO CRIMI;MARCO BARBANTI;DAVIDE CAPODANNO;RAFFAELE FALSAPERLA;FILIPPO SANFILIPPO;VITO PAVONE;STEFANO PALMUCCI;MASSIMILIANO SORBELLO;MATTEO CIONI;MARINELLA ASTUTO;FRANCESCO PATTI;G ZANGHÍ;CARMELO GRASSO;ALESSANDRO VASCO;LUISA TORRI;EUGENIA VASCO","0.67;0.63;0.63;0.59;0.56;0.56;0.49;0.49;0.48;0.43;0.42;0.41;0.39;0.37;0.35;0.35;0.35;0.33;0.33;0.33","ATHANASIOS CHALKIAS;CHRISTINA AGVALD‐ÖHMAN;DAVID BREWSTER;KRISTAPS BOKUMS;PHILIPPE R. BAUER;MASSIMILIANO SORBELLO;PAOLO PELOSI;A. HIGGS;AAKANKSHA CHAWLA;ABDULMUETI ALHADI;ADNAN ALGHAMDI;AGRIPPINO BELLISSIMA;ALEXANDER J. BROWNE;ALEXANDRE BOYER;ANITA ALIAS;ANNA BANDERT;ANNALISA BENINI;ANNE CHAO;ANTONIO ARTIGAS;BENOÎT CHAMPIGNEULLE","696;696;696;696;696;362;357;348;348;348;348;348;348;348;348;348;348;348;348;348","MASSIMILIANO SORBELLO;CLAUDIA CRIMI;DAVIDE CAPODANNO;CORRADO TAMBURINO;HÉCTOR SOTO PARRÀ;ROSARIO FOTI;ELISA VISALLI;MARCO BARBANTI;CARMELO GRASSO;EMMA CACCIOLA;TERESIO AVITABILE;NUNZIO CRIMI;GAETANO BERTINO;MARIA LETIZIA MUSUMECI;EVELISE FRAZZETTO;FEDERICA MARTORANA;GIANMARCO MOTTA;PAOLO VIGNERI;INES MONTE;SALVATORE LEOTTA","353;200;123;113;107;97;96;95;93;93;65;61;57;55;51;51;51;51;50;48","MARCO BARBANTI;ROSARIO FOTI;CORRADO TAMBURINO;FRANCESCO DI RAIMONDO;ELISA VISALLI;DAVIDE CAPODANNO;FRANCESCO PATTI;CLAUDIA CRIMI;ANTONIO MAGNANO;CARMELO GRASSO;ANTONIO BASILE;CONCETTA FERRACANE;GIUSEPPE MILONE;SALVATORE LEOTTA;ALESSIO LA MANNA;CARLO VANCHERI;HÉCTOR SOTO PARRÀ;VITO PAVONE;STEFANO PALMUCCI;MASSIMILIANO SORBELLO","13;10;9;8;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;COMPUTER SCIENCE;PSYCHOLOGY;CHEMISTRY;MATHEMATICS;ECONOMICS;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;POLITICAL SCIENCE;PHILOSOPHY;ART;GEOGRAPHY;GEOLOGY;HISTORY","169;39;19;13;11;9;7;7;5;5;4;3;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;IMMUNOLOGY;GENETICS;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;ONCOLOGY;ENDOCRINOLOGY;PEDIATRICS;PHYSICAL THERAPY;PSYCHIATRY;MECHANICAL ENGINEERING;BIOCHEMISTRY;OPTICS;ANESTHESIA;CANCER RESEARCH","137;53;41;26;23;21;19;18;18;18;17;14;14;14;13;12;11;11;8;8","DISEASE;COHORT;POPULATION;HEART FAILURE;GENE;CANCER;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;INCIDENCE (GEOMETRY);LUNG;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;CHEMOTHERAPY;TRANSPLANTATION;DIABETES MELLITUS;LEUKEMIA;RECEPTOR;STEM CELL","40;17;16;14;13;12;12;12;12;11;11;11;11;9;9;9;8;8;8;8","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;EJECTION FRACTION;PERCUTANEOUS CORONARY INTERVENTION;CROHN'S DISEASE;HAZARD RATIO;MITRACLIP;COLORECTAL CANCER;INFLAMMATORY BOWEL DISEASE;MUTATION;VALVE REPLACEMENT;ADALIMUMAB;AORTIC VALVE REPLACEMENT;HEMATOPOIETIC STEM CELL TRANSPLANTATION;MITRAL VALVE REPAIR;PLACEBO;AGONIST;AORTIC VALVE STENOSIS;CD34;CHRONIC LYMPHOCYTIC LEUKEMIA;CONVENTIONAL PCI;EOSINOPHIL;FOLLICULAR LYMPHOMA;HAEMATOPOIESIS;HEART RATE;IDIOPATHIC PULMONARY FIBROSIS;INTERSTITIAL LUNG DISEASE;LUNG FUNCTION;NEUROPSYCHOLOGY;PROGENITOR CELL;SEROLOGY;TYPE 2 DIABETES","14;11;7;7;7;6;6;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);DIFFUSING CAPACITY;MEPOLIZUMAB;USTEKINUMAB;COLONOSCOPY;CXCR4;DASATINIB;FUNCTIONAL MITRAL REGURGITATION;IBRUTINIB;MACE;PHILADELPHIA CHROMOSOME;TRANSCRIPTOME;VEDOLIZUMAB;ABATACEPT;ACUTE LYMPHOCYTIC LEUKEMIA;ADJUVANT CHEMOTHERAPY;ANDROGEN RECEPTOR;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;ANTIRETROVIRAL THERAPY;ARGINASE;ATRIAL TACHYCARDIA;AXIAL SPONDYLOARTHRITIS;BASDAI;BENDAMUSTINE;BLINATUMOMAB;CARDIAC INDEX;CHRONOTROPIC;CONNECTIVE TISSUE DISEASE;DARATUMUMAB;DESTINATION THERAPY;DNA FRAGMENTATION;DRUG-ELUTING STENT;DYSKINESIA;ELTROMBOPAG;ENTHESITIS;EXECUTIVE DYSFUNCTION;EXHALED NITRIC OXIDE;FEBRILE NEUTROPENIA;FORAMEN SECUNDUM;FOURNIER GANGRENE;GERMINAL CENTER;GLUCAGON-LIKE PEPTIDE 1 RECEPTOR;GRANULOMATOSIS WITH POLYANGIITIS;HAND ECZEMA;HERPESVIRIDAE;IDIOPATHIC INTERSTITIAL PNEUMONIA;IMMUNOGLOBULIN M;INTERATRIAL SEPTUM;IRRITANT CONTACT DERMATITIS;KRAS;LACTOBACILLUS RHAMNOSUS;LARYNGEAL MASKS;LEUKAPHERESIS;LEVODOPA;MALE INFERTILITY;MEDIAL MENISCUS;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;MISSENSE MUTATION;NUCLEOTIDE EXCISION REPAIR;NUMBER NEEDED TO TREAT;OBETICHOLIC ACID;PATCH TESTING;PEMBROLIZUMAB;PEMETREXED;POMALIDOMIDE;PR INTERVAL;PROBAND;PROSTATE-SPECIFIC ANTIGEN;RESPIRATORY RATE;ROS1;SANGER SEQUENCING;SCLEROSTIN;SEMEN ANALYSIS;SEROPREVALENCE;STAPHYLOCOCCAL INFECTIONS;STAPHYLOCOCCUS;STROKE VOLUME;SYSTEMIC VASCULITIS;THROMBOPOIETIN;USUAL INTERSTITIAL PNEUMONIA;VASOACTIVE INTESTINAL PEPTIDE;VENETOCLAX;VOXEL-BASED MORPHOMETRY","14;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;ITALY;MALE;FEMALE;MIDDLE AGED;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADULT;AGED;COVID-19;PROSPECTIVE STUDIES;MITRAL VALVE INSUFFICIENCY;AGED, 80 AND OVER;ANTIBODIES, MONOCLONAL, HUMANIZED;REGISTRIES;PERCUTANEOUS CORONARY INTERVENTION;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RISK FACTORS;SARS-COV-2","108;65;29;28;27;19;16;16;13;13;12;12;10;9;9;9;8;7;7;7","MANAGEMENT OF VALVULAR HEART DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;CORONAVIRUS DISEASE 2019 RESEARCH;HEMATOPOIETIC STEM CELL BIOLOGY;IMMUNOGENICITY OF BIOSIMILAR THERAPEUTICS IN DRUG DEVELOPMENT","16;6;5;4;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2","TRANSCATHETER AORTIC-VALVE REPLACEMENT;PROSTHETIC VALVES EVALUATION;CLINICAL ENDPOINT;PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;STROKE (ENGINE);TREATMENT;CARDIAC IMAGING;MITRACLIP;DISCONTINUATION;MITRAL REGURGITATION;VALVE REPLACEMENT;ECHOCARDIOGRAPHY;INTERQUARTILE RANGE;NONINVASIVE VENTILATION;REGIMEN;SURGICAL AORTIC-VALVE REPLACEMENT;BLEEDING RISK;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL PRACTICE","17;14;11;8;7;7;7;6;6;5;5;5;4;4;4;4;4;3;3;3","MULTIPLE SCLEROSIS;STEM CELL;TRANSCATHETER AORTIC;AORTIC VALVE;INFLAMMATORY BOWEL;MITRAL VALVE;MULTICENTER STUDY;OBSERVATIONAL STUDY;CELL TRANSPLANTATION;CROHNS DISEASE;VALVE REPAIR;VALVE REPLACEMENT;ACUTE LYMPHOBLASTIC;AUTOIMMUNE SYSTEMIC;BLEEDING RISK;BOWEL DISEASE;COGNITIVE IMPAIRMENT;COHERENCE TOMOGRAPHY;CONTROLLED TRIAL;CYSTIC FIBROSIS;EDGE-TO-EDGE MITRAL;ITALIAN PATIENTS;MITRAL REGURGITATION;MULTIPLE MYELOMA;OPTICAL COHERENCE;PARKINSONS DISEASE;POSITION PAPER;PROSPECTIVE OBSERVATIONAL;REAL-WORLD EXPERIENCE;RETROSPECTIVE MULTICENTER","6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","RESEARCH FUNDING;ADVISORY COMMITTEES;ENTITYS BOARD;CD CELLSKG;SPEAKERS BUREAU;SYSTEMIC SCLEROSIS;PUBMED SCOPUS;PATIENTS UNDERGOING;BRISTOL-MYERS SQUIBB;PATIENTS TREATED;ADVERSE EVENTS;CURRENT EMPLOYMENT;DEFINITE COVID-;HR CI;AORTIC VALVE;BLEEDING RISK;INCREASED RISK;MIN MAX;NOVARTIS PFIZER;AUTOIMMUNE SYSTEMIC;BUREAU ABBVIE;CLINICAL OUTCOMES;GRANTRESEARCH SUPPORT;MEDIAN FOLLOW-UP;MEDIAN MIN;SARS-COV- INFECTION;SD MEDIAN;CLINICAL PRACTICE;CONSECUTIVE PATIENTS;GILEAD SCIENCES","44;34;34;30;27;27;18;15;14;14;13;13;13;13;12;12;12;12;12;11;11;11;11;11;11;11;11;10;10;10",78,0.45,8.38,9,1,3.25,0,3,0,0,0,10.75,0,1,9,1,1,2,2,6.25,4,0,0,35,35,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,3.14,316.93,8.43,10,0.71,104.79,0,0,2,0,11,0,0,1,0,14,0,0,0,0,0,0,0,14,0,0,14,0,0,0,0,0,0,0,0,0,"United States;Italy;Japan","3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","14;9;3;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LUNG;CANCER;PATIENT SAFETY;AUTOIMMUNE DISEASE;INFECTIOUS DISEASES;LYMPHOMA;PEDIATRIC;PREVENTION;BRAIN DISORDERS;CARDIOVASCULAR;CHILDHOOD LEUKEMIA;EPILEPSY;EYE DISEASE AND DISORDERS OF VISION;HEART DISEASE;LUNG CANCER;NEURODEGENERATIVE","14;14;8;6;5;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;BLOOD;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;RESPIRATORY","4;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL","12;3;1;1;1","LEUKEMIA / LEUKAEMIA;BRAIN TUMOR;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","6;2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2022,108,21.3425925925926,1.7037037037037,0.12962962962963,0.0648148148148148,0.12962962962963,1.6,1.07692307692308,1.16666666666667,1.16666666666667,0.648148148148148,0,44,23,8,7,0.41,0.21,0.07,0.06,7.58,0.849501068924761,5.682570593963,0.481481481481481,1,0.463,0.295,0.25,0.305,"MARCO BARBANTI;CORRADO TAMBURINO;ANTONIO L. BARTORELLI;AZEEM LATIB;FEDERICO DE MARCO;ROSARIO FOTI;GIUSEPPE TARANTINI;FLORENZO IANNONE;ALESSANDRA ROMANO;ENRICO FUSARO;FRANCESCO BEDOGNI;DIDIER TCHÉTCHÉ;FLAVIO RIBICHINI;RAN KORNOWSKI;LARS SØNDERGAARD;GIUSEPPA PAGANO MARIANO;FABRIZIO CONTI;WON‐KEUN KIM;GIULIANA GUGGINO;VITO PAVONE","11;11;8;8;7;7;7;7;7;7;6;6;5;5;5;5;5;5;5;5","DAVIDE CAPODANNO;VITO PAVONE;ALESSANDRA ROMANO;FEDERICO CANAVESE;ANTONIO ANDREACCHIO;MARCO LEGNAZZI;FILIPPO MARANO;GIULIA CARUSO;CORRADO TAMBURINO;MARTINO RUGGIERI;ANTÓNIO COSTA;SERGIO FICHERA;ROBERTO ROSARIO CORSINI;VINCENZO PARRINELLO;MARCO BARBANTI;RAFFAELE FALSAPERLA;MASSIMILIANO SORBELLO;MARCO SAPIENZA;ANTONINO LO GIUDICE;AZEEM LATIB","0.73;0.68;0.58;0.52;0.52;0.5;0.5;0.5;0.49;0.47;0.45;0.45;0.45;0.45;0.41;0.4;0.38;0.38;0.29;0.29","MARCO BARBANTI;CORRADO TAMBURINO;ROSARIO FOTI;ALESSANDRA ROMANO;VITO PAVONE;FRANCESCO DI RAIMONDO;ROSAMARIA ROSSO;MARTINO RUGGIERI;CARMELO GRASSO;MASSIMILIANO SORBELLO;DAVIDE CAPODANNO;ANTONIO BASILE;NUNZIATINA LAURA PARRINELLO;RAFFAELE FALSAPERLA;FRANCESCO PATTI;SALVATORE SCANDURA;MARCO SAPIENZA;PIERO PAVONE;MAURIZIO CAMINITI;NUNZIO CRIMI","11;11;7;7;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;2","DAVIDE CAPODANNO;VITO PAVONE;ALESSANDRA ROMANO;MARCO LEGNAZZI;GIULIA CARUSO;CORRADO TAMBURINO;MARTINO RUGGIERI;VINCENZO PARRINELLO;MARCO BARBANTI;RAFFAELE FALSAPERLA;MASSIMILIANO SORBELLO;MARCO SAPIENZA;ANTONINO LO GIUDICE;ISABELLA PENNISI;SEBASTIANO PIANA;GIUSEPPE GIORDANO;VIVIANA LENTINI;PIERO PAVONE;GIANLUCA TESTA;ANDREA VESCIO","0.73;0.68;0.58;0.5;0.5;0.49;0.47;0.45;0.41;0.4;0.38;0.38;0.29;0.29;0.29;0.29;0.29;0.27;0.27;0.27","CORRADO TAMBURINO;MARIA GRAZIA VALSECCHI;ANDREA MORELLI;ANNE-LAURE FEDOUX;ANNE-MARIE WELSH;ANTHONY S. MCLEAN;ANTOINE VIEILLARD‐BARON;ARMAND MEKONTSO DESSAP;BERNARD CHOLLEY;BRUNO EVRARD;BRUNO FRANÇOIS;C. BRAULT;CYRIL CHARRON;DANIEL DE BACKER;F. CLAU-TERRÉ;FERNANDO PISCIONERI;FILIPPO SANFILIPPO;FRANÇOIS BAGATE;GISÈLE BANAUCH;GWÉNAËL PRAT","95;82;79;79;79;79;79;79;79;79;79;79;79;79;79;79;79;79;79;79","CORRADO TAMBURINO;FILIPPO SANFILIPPO;MASSIMILIANO SORBELLO;CARMELO GRASSO;ROSARIO FOTI;FRANCESCO PATTI;VITO PAVONE;MARCO BARBANTI;DARIO PLUCHINO;MASSIMILIANO VISOCCHI;GIUSEPPE MICALI;G ZANGHÍ;ANDREA VESCIO;ELISA VISALLI;GIANLUCA TESTA;GIORGIO AMATO;YLENIA DAL BOSCO;INES MONTE;CONCETTA ILENIA PALERMO;NUNZIO CRIMI","95;79;69;50;47;38;33;32;31;29;26;23;22;22;22;22;22;21;20;20","CORRADO TAMBURINO;MARCO BARBANTI;ROSARIO FOTI;ALESSANDRA ROMANO;VITO PAVONE;DAVIDE CAPODANNO;MASSIMILIANO SORBELLO;CARMELO GRASSO;FRANCESCO DI RAIMONDO;FRANCESCO PATTI;NUNZIATINA LAURA PARRINELLO;ROSAMARIA ROSSO;SALVATORE SCANDURA;ANDREA VESCIO;ANTONINO LO GIUDICE;ANTONIO BASILE;CONCETTA ILENIA PALERMO;ELISA VISALLI;EVELISE FRAZZETTO;FABIO STAGNO","10;8;7;6;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;MATHEMATICS;PSYCHOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY;ART;BUSINESS;ECONOMICS;HISTORY;PHILOSOPHY","98;19;10;9;8;7;7;4;2;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;RADIOLOGY;GENETICS;ONCOLOGY;PATHOLOGY;CANCER RESEARCH;GASTROENTEROLOGY;PEDIATRICS;PSYCHIATRY;OPTICS;ANESTHESIA;PHYSICAL THERAPY;BIOCHEMISTRY;DERMATOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;NURSING;PHARMACOLOGY","75;37;27;18;15;14;13;12;12;11;11;11;7;6;5;5;4;4;4;4;4;4;4;4","POPULATION;DISEASE;GENE;MYOCARDIAL INFARCTION;CONFIDENCE INTERVAL;ADVERSE EFFECT;CHEMOTHERAPY;COHORT;HEART FAILURE;STENOSIS;CANCER;CLINICAL TRIAL;ODDS RATIO;RETROSPECTIVE COHORT STUDY;ANTIBODY;AORTIC VALVE;INCIDENCE (GEOMETRY);INTUBATION;MITRAL REGURGITATION;THALASSEMIA","17;14;13;9;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5;5","PERCUTANEOUS CORONARY INTERVENTION;PSORIATIC ARTHRITIS;CLINICAL ENDPOINT;HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);VALVE REPLACEMENT;2019-20 CORONAVIRUS OUTBREAK;ADALIMUMAB;AORTIC VALVE REPLACEMENT;AUTOLOGOUS STEM-CELL TRANSPLANTATION;EJECTION FRACTION;MUTATION;AGONIST;BORTEZOMIB;BREAST CANCER;CONVENTIONAL PCI;CORONARY ANGIOGRAPHY;CYCLOPHOSPHAMIDE;DOWNREGULATION AND UPREGULATION;ETANERCEPT;FUSION GENE;GENE EXPRESSION;IMATINIB;INFLAMMATORY BOWEL DISEASE;INTERSTITIAL LUNG DISEASE;MITRAL VALVE REPAIR;NEUTROPENIA;PSORIASIS AREA AND SEVERITY INDEX;RESTENOSIS;REVASCULARIZATION;TRACHEAL INTUBATION;TRANSCRIPTION FACTOR;TYROSINE KINASE;ULCERATIVE COLITIS","5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CORONAVIRUS DISEASE 2019 (COVID-19);SECUKINUMAB;USTEKINUMAB;DASATINIB;DRUG-ELUTING STENT;GOLIMUMAB;NILOTINIB;OBETICHOLIC ACID;PAX5;VINCRISTINE;ABSOLUTE NEUTROPHIL COUNT;AFLIBERCEPT;AGGREGATIBACTER ACTINOMYCETEMCOMITANS;ANAPLASTIC LYMPHOMA KINASE;ANEUPLOIDY;ARGINASE;BOOSTER DOSE;BROTH MICRODILUTION;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC SKELETON;CASPOFUNGIN;CENTRAL RETINAL VEIN OCCLUSION;CENTRAL VENOUS PRESSURE;CERTOLIZUMAB PEGOL;CHEMILUMINESCENT IMMUNOASSAY;CHEMOIMMUNOTHERAPY;CHILDHOOD OBESITY;CONGENITAL NEUTROPENIA;CONTRAST-INDUCED NEPHROPATHY;DIFFUSING CAPACITY;ENTEROTOXIN;ENTHESITIS;FEBRILE NEUTROPENIA;FILGRASTIM;FINASTERIDE;FUSOBACTERIUM NUCLEATUM;GERMLINE MUTATION;HEME OXYGENASE;HONEYSUCKLE;INTRAOPERATIVE MRI;MEAN ARTERIAL PRESSURE;MICROARRAY;MISSENSE MUTATION;ONCOGENE;PEDIATRIC TRAUMA;POLY ADP RIBOSE POLYMERASE;POSACONAZOLE;PROMOTER;RAD51;RADIOIMMUNOTHERAPY;RANIBIZUMAB;RIGHT CORONARY ARTERY;SANGER SEQUENCING;SINGLE-NUCLEOTIDE POLYMORPHISM;STREPTOCOCCUS ORALIS;SUPRAGLOTTIC AIRWAY;SYSTEMIC VASCULITIS;TARGET LESION;TICAGRELOR;TRANSCRIPTOME;TRANSITIONAL CELL CARCINOMA;TREPONEMA DENTICOLA;UROTHELIAL CANCER;UROTHELIAL CARCINOMA;VEDOLIZUMAB;WINDOW PERIOD","4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;AORTIC VALVE STENOSIS;TREATMENT OUTCOME;TRANSCATHETER AORTIC VALVE REPLACEMENT;AORTIC VALVE;COVID-19;FEMALE;MALE;RETROSPECTIVE STUDIES;MITRAL VALVE INSUFFICIENCY;AORTIC VALVE INSUFFICIENCY;CORONARY ARTERY DISEASE;HEART VALVE PROSTHESIS IMPLANTATION;MITRAL VALVE;CORONARY VESSELS;MIDDLE AGED;PROSPECTIVE STUDIES;REGISTRIES;RISK FACTORS","62;46;27;20;18;17;17;13;12;12;9;8;8;8;8;7;7;7;7;7","MANAGEMENT OF VALVULAR HEART DISEASE;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;CLASSIFICATION AND TREATMENT OF SPONDYLOARTHRITIS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;LYMPHOID NEOPLASMS;CORONAVIRUS DISEASE 2019;EPIDEMIOLOGY AND TREATMENT OF CHILDHOOD LEUKEMIA;OPERATING ROOM PLANNING AND SCHEDULING IN HEALTHCARE;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;ANTERIOR CRUCIATE LIGAMENT INJURIES IN ATHLETES;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ASTHMA;ATRIAL FIBRILLATION","13;5;4;4;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1","TRANSCATHETER AORTIC-VALVE REPLACEMENT;PROSTHETIC VALVES EVALUATION;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;CLINICAL ENDPOINT;DISCONTINUATION;HEART VALVE SURGERY;LUMEN (ANATOMY);VALVE REPLACEMENT;2019-20 CORONAVIRUS OUTBREAK;AUTOLOGOUS STEM-CELL TRANSPLANTATION;CARDIAC SURGERY RISK MODELS;INTERQUARTILE RANGE;MITRAL REGURGITATION;PSORIATIC ARTHRITIS;SURGICAL AORTIC-VALVE REPLACEMENT;TRACHEAL INTUBATION;USTEKINUMAB;ABVD;AUTOANTIBODIES","15;12;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2","AORTIC VALVE;TRANSCATHETER AORTIC;VALVE IMPLANTATION;PSORIATIC ARTHRITIS;CLINICAL OUTCOMES;OBSERVATIONAL STUDY;BIOLOGIC TREATMENTS;HODGKIN LYMPHOMA;IMAGING ASSESSMENT;LONGITUDINAL STUDY;MITRAL VALVE;MULTIPLE MYELOMA;OBSERVATIONAL LONGITUDINAL;POSITION PAPER;PRE-PROCEDURAL IMAGING;THALASSEMIA MAJOR;ACUTE CORONARY;ACUTE LYMPHOBLASTIC;ASPECTS HEART;AUTOIMMUNE SYSTEMIC;AUTOLOGOUS STEM;BASIC TECHNICAL;BILIARY CHOLANGITIS;BONFILS FIBEROPTIC;BOWEL DISEASE;CARDIAC IRON;CHILDHOOD ACUTE;CIRRHOTIC PATIENTS;CLINICAL INDICATION;CLINICAL PRACTICE","9;9;7;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PATIENTS UNDERGOING;VITD LEVELS;PATIENTS TREATED;ADVERSE EVENTS;ASD PATIENTS;HUMERUS FRACTURES;SUPRACONDYLAR HUMERUS;AORTIC VALVE;BONE MARROW;IRON OVERLOAD;MEDIAN FOLLOW-UP;PATIENTS RECEIVED;QRS DURATION;ACUTE STROKE;ARGININE DEPRIVATION;BOOSTER DOSE;CARDIAC IRON;CLINICAL OUTCOMES;CLINICAL TRIAL;CSF PROTEIN;EJECTION FRACTION;INCREASED RISK;INTERSTITIAL LUNG;LOGISTIC REGRESSION;MEDIAN AGE;MITRAL REGURGITATION;PANCREATIC IO;PROPENSITY SCORE;RISK FACTOR;RISK FACTORS","14;11;10;9;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5",45,0.42,8.5,5,3,1.5,0,1.5,0,1,0,7,0,0,5.5,0,0,2,2,6.25,2,0,0,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4,384.5,1.87,1,0.5,71,0,0,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;2","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEURODEGENERATIVE;AUTOIMMUNE DISEASE;BRAIN DISORDERS;COMPARATIVE EFFECTIVENESS RESEARCH;MULTIPLE SCLEROSIS;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC","2;2;2;1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2023,61,22.6065573770492,2.01639344262295,0.0655737704918033,0.0983606557377049,0.0819672131147541,1.33695652173913,0.8,1,0.833333333333333,0.737704918032787,0,29,7,6,1,0.48,0.11,0.1,0.02,4.41,1.00610223339068,5.39514563106795,0.426229508196721,1,0.465,0.15,0.133,0.15,"CORRADO TAMBURINO;GIUSEPPE TARANTINI;ROSAMARIA ROSSO;CARMELO GRASSO;MARIANNA ADAMO;COSMO GODINO;MARCO VENTIMIGLIA;WALTER FRIES;FILIPPO CADEMARTIRI;ANTONIO POPOLO RUBBIO;ROBERTO DI MITRI;MAURO GROVA;CRISTINA GIANNINI;DARIO PLUCHINO;FABIO SALVATORE MACALUSO;CONCETTA FERRACANE;VALERIO CECINATI;ANGELO CASÀ;ANNA VIOLA;NICOLAS M. VAN MIEGHEM","6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;3","DANIELE BATTISTA;JESSICA CAMARGO MOLANO;ROSAMARIA ROSSO;CORRADO TAMBURINO;SIMONE MACRÌ;PATRIZIA CAMPOLONGO;GIANLUCA TESTA;FEDERICA PISA;C. BAREZZI;VITO PAVONE;SREERAMAN RAJAN;VINCENZO MARLETTA;LAURA TROVATO;SALVATORE BAGLIO;MARIO ZAPPIA;MADDALENA CALVO;GIOVANNI MOSTILE;VALERIA DIBILIO;BRUNO ANDÒ;ANDREA MARINO","0.5;0.5;0.29;0.28;0.25;0.25;0.25;0.25;0.25;0.25;0.24;0.24;0.24;0.24;0.24;0.24;0.24;0.24;0.24;0.24","CORRADO TAMBURINO;ROSAMARIA ROSSO;CARMELO GRASSO;ANTONIO POPOLO RUBBIO;DARIO PLUCHINO;CONCETTA FERRACANE;DAVIDE CAPODANNO;MARCO BARBANTI;ROSARIO FOTI;LAURA TROVATO;MARIO ZAPPIA;GIANLUCA TESTA;MADDALENA CALVO;DAVIDE CAMPAGNA;GIOVANNI MOSTILE;VALERIA DIBILIO;MICHELE VECCHIO;ANTONIO MAGNANO;YLENIA DAL BOSCO;ALESSIO LA MANNA","6;5;5;4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2","JESSICA CAMARGO MOLANO;ROSAMARIA ROSSO;CORRADO TAMBURINO;PATRIZIA CAMPOLONGO;GIANLUCA TESTA;VITO PAVONE;LAURA TROVATO;MARIO ZAPPIA;MADDALENA CALVO;GIOVANNI MOSTILE;VALERIA DIBILIO;DAVIDE CAPODANNO;CARMELO GRASSO;MICHELE VECCHIO;DAVIDE CAMPAGNA;EDMONDO GRILLI;CONCETTA FERRACANE;DARIO PLUCHINO;GIUSEPPE SESSA;CLAUDIA DE CRISTO","0.5;0.29;0.28;0.25;0.25;0.25;0.24;0.24;0.24;0.24;0.24;0.23;0.21;0.21;0.2;0.2;0.2;0.17;0.17;0.17","MARINE GOUDELIN;JEAN-BAPTISTE LASCARROU;MATTEO PAROTTO;ANDREA MORELLI;ANNE-LAURE FEDOU;ANNE-MARIE WELSH;ANTHONY S. MCLEAN;ANTOINE VIEILLARD‐BARON;ARMAND MEKONTSO DESSAP;ARNAUD DESACHY;BERNARD CHOLLEY;BRUNO EVRARD;BRUNO FRANÇOIS;C. BRAULT;CYRIL CHARRON;DANIEL DE BACKER;F. CLAU-TERRÉ;FERNANDO PISCIONERI;FILIPPO SANFILIPPO;FRANÇOIS BAGATE","68;52;52;34;34;34;34;34;34;34;34;34;34;34;34;34;34;34;34;34","FILIPPO SANFILIPPO;S. BANAUCH-MAYER;S. CLAVIER;S. GIGLIORI;ROSAMARIA ROSSO;MASSIMILIANO SORBELLO;CORRADO TAMBURINO;CARMELO GRASSO;PAOLO VIGNERI;GIANLUCA TESTA;VITO PAVONE;CONCETTA FERRACANE;GAETANO MAGRO;GIUSEPPE BROGGI;LUCIA SALVATORELLI;TOMMASO DI BELLA;DARIO PLUCHINO;MARCO BARBANTI;MARILENA MAGLIA;PASQUALE CAPONNETTO","34;34;34;34;29;26;21;20;15;14;14;13;13;13;13;13;11;11;11;11","ROSAMARIA ROSSO;CARMELO GRASSO;CORRADO TAMBURINO;CONCETTA FERRACANE;DARIO PLUCHINO;DAVIDE CAPODANNO;ALESSIO LA MANNA;FABIO STAGNO;GIANLUCA TESTA;GIOVANNA RUSSO;GIOVANNI MOSTILE;MADDALENA CALVO;MARCO BARBANTI;MARIO ZAPPIA;ROSARIO FOTI;VALERIA DIBILIO;VITO PAVONE;ANTONIO BASILE;ANTONIO MAGNANO;ANTONIO POPOLO RUBBIO","5;5;5;4;4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MEDICINE;PHYSICS;CHEMISTRY;BIOLOGY;COMPUTER SCIENCE;ECONOMICS;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;HISTORY;POLITICAL SCIENCE","57;8;6;5;5;3;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;IMMUNOLOGY;PEDIATRICS;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;PATHOLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;ONCOLOGY;ANESTHESIA;NURSING;OPTICS;CANCER RESEARCH;DERMATOLOGY;PHYSICAL THERAPY;PSYCHIATRY;ARTIFICIAL INTELLIGENCE;CELL BIOLOGY;EMBEDDED SYSTEM;EMERGENCY MEDICINE;ENDOCRINOLOGY;FINANCE;GENETICS;MACHINE LEARNING;QUANTUM MECHANICS","50;20;14;10;10;9;8;7;7;6;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","DISEASE;COHORT;ADVERSE EFFECT;POPULATION;RANDOMIZED CONTROLLED TRIAL;CANCER;OBSERVATIONAL STUDY;DISCONTINUATION;THALASSEMIA;CONFIDENCE INTERVAL;CLINICAL TRIAL;GENE;HEART FAILURE;MITRAL REGURGITATION;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;ANTIBODY;INCIDENCE (GEOMETRY);INTERQUARTILE RANGE;LYMPHOMA;MYELOID LEUKEMIA;MYOCARDIAL INFARCTION;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY;RHEUMATOID ARTHRITIS;TRANSPLANTATION;VACCINATION","13;11;10;9;8;7;7;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;INFECTIOUS DISEASE (MEDICAL SPECIALTY);COLORECTAL CANCER;HAZARD RATIO;RITUXIMAB;ARGON PLASMA COAGULATION;CROHN'S DISEASE;EJECTION FRACTION;HEART TRANSPLANTATION;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;INFLAMMATORY BOWEL DISEASE;INFLIXIMAB;MITRACLIP;PLACEBO;RELIABILITY (SEMICONDUCTOR);ROBUSTNESS (EVOLUTION);TOFACITINIB;TOLERABILITY;ULCERATIVE COLITIS","9;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);USTEKINUMAB;ACUTE CHEST SYNDROME;ADAPTIVE NEURO FUZZY INFERENCE SYSTEM;AORTIC VALVULOPLASTY;BRIDGE TO TRANSPLANTATION;CHIMERIC ANTIGEN RECEPTOR;DASATINIB;ELTROMBOPAG;FUNCTIONAL MITRAL REGURGITATION;LIRAGLUTIDE;MAMMOGRAPHY;MITOPHAGY;OBINUTUZUMAB;OPPORTUNISTIC INFECTION;PARASITEMIA;POSTURAL INSTABILITY;RADIOIMMUNOTHERAPY;RIBAVIRIN;RIVAROXABAN;VENETOCLAX;VITAMIN K ANTAGONIST","4;4;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;TREATMENT OUTCOME;MALE;COVID-19;AGED;AORTIC VALVE STENOSIS;BETA-THALASSEMIA;HEART FAILURE;HEART VALVE PROSTHESIS IMPLANTATION;MITRAL VALVE INSUFFICIENCY;ADULT;AORTIC VALVE;PROSPECTIVE STUDIES;CHILD;GLIOBLASTOMA;MIDDLE AGED;QUALITY OF LIFE;AORTIC VALVE INSUFFICIENCY","32;28;12;12;10;7;6;6;6;6;6;6;5;5;5;4;4;4;4;3","GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;MANAGEMENT OF VALVULAR HEART DISEASE;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND RESISTANCE IN CML TREATMENT;GAIT ANALYSIS AND FALL PREVENTION IN ELDERLY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;LYMPHOID NEOPLASMS;ORGAN TRANSPLANTATION AND REJECTION;ADVANCES IN ULTRASOUND ELASTOGRAPHY IMAGING TECHNIQUES;ATOPIC DERMATITIS AND SKIN MICROBIOME;AUTOMATED DETECTION OF HATE SPEECH AND OFFENSIVE LANGUAGE;BORON NEUTRON CAPTURE THERAPY;CANCER STEM CELLS AND TUMOR METASTASIS;CLINICAL AND PATHOLOGICAL ASPECTS OF URACHAL CARCINOMA;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND MANAGEMENT OF CONGENITAL DIAPHRAGMATIC HERNIA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION","7;6;4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;DISCONTINUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;MITRAL REGURGITATION;PANDEMIC;TRANSFUSION THERAPY;ULCERATIVE COLITIS;INTERQUARTILE RANGE;TREATMENT;MITRACLIP;POSTURAL STABILITY;RISK STRATIFICATION;ROBUSTNESS (EVOLUTION);TOLERABILITY;TREATMENT DISCONTINUATION;USTEKINUMAB;VACCINES;2019-20 CORONAVIRUS OUTBREAK;ACUTE CHEST SYNDROME;ANASTOMOTIC LEAKAGE","9;6;5;4;4;4;4;3;3;2;2;2;2;2;2;2;2;1;1;1","POLYETHYLENE GLYCOL;MITRAL REGURGITATION;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;ADVERSE EFFECTS;ASCORBATE VERSUS;COLONOSCOPY CLEANSING;CROHNS DISEASE;DISCONTINUATION FINAL;FINAL ANALYSIS;FONDAZIONE ITALIANA;FUNCTIONAL MITRAL;HEART TRANSPLANTATION;INHIBITOR DISCONTINUATION;IRON OVERLOAD;ITALIANA LINFOMI;KINASE INHIBITOR;LEUKEMIA PATIENTS;MULTICENTRE RANDOMIZED;PATIENTS ELIGIBLE;POSTOPERATIVE RECURRENCE;PROMISING OPTION;SN-IBD STUDY;THALASSEMIA MAJOR;TRANSCATHETER EDGE-TO-EDGE;TYROSINE KINASE;ULCERATIVE COLITIS;ACUTE CHEST;ADULT ATOPIC;ADVERSE EVENTS","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","ADVISORY ROLE;RR CI;WIREBASED ADR;OBSERVATIONAL STUDY;REFERENCE COHORT;EDUCATIONAL GRANTS;FXI INHIBITORS;MEDIAN AGE;PRIMARY ENDPOINT;TAKEDA ROCHE;ADVERSE EVENTS;IRON OVERLOAD;RUTGEERTS SCORE;STATISTICALLY SIGNIFICANT;CLINICAL PRACTICE;HR CI;MULTICENTER OBSERVATIONAL;PATIENTS TREATED;VAPING CESSATION;ADULT PATIENTS;ASCT VERSUS;CLINICAL FAILURE;DISCONTINUATION COHORT;EFFICACY ENDPOINT;EJECTION FRACTION;ELECTIVE HTX;EMP FALCIPARUMEM;ENDOSCOPIC SUCCESS;GENDER DIFFERENCES;GRANTS TAKEDA","9;9;9;8;8;7;7;7;7;7;6;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",31,0.51,7.12,6,1.5,1,0,2,0,0,0,7,0,0,7,0,0,2,4.5,6.75,4,0,0,8,8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,2.75,223.5,4.55,1,0.25,50.25,0,0,2,0,1,0,0,1,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3203 DENTISTRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AUTOIMMUNE DISEASE;LUNG;RARE DISEASES;AGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;ORPHAN DRUG;PATIENT SAFETY;SCLERODERMA","3;3;2;2;2;1;1;1;1;1","INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY","1;1","6.1 PHARMACEUTICALS","3","LUNG CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOUSSN_VITTORIOEMANUELE",2024,31,32.5806451612903,1.93548387096774,0,0.032258064516129,0,1.33333333333333,0,0.5,0,0.580645161290323,0,10,10,2,4,0.32,0.32,0.06,0.13,0.77,0.810076257100205,4.40876656472986,0.354838709677419,1,0.402,0,0,0,"GIUSEPPE TARANTINI;ANTONIO L. BARTORELLI;MATTEO MONTORFANO;ANTONIO POPOLO RUBBIO;PAOLO DENTI;CORRADO TAMBURINO;FRANCESCO DE FELICE;ANNALISA MONGIARDO;FRANCESCO BEDOGNI;ARTURO GIORDANO;EMMANUEL VILLA;CESARE BALDI;GAETANO BERTINO;IDA MONTEFORTE;MAURIZIO RUSSELLO;MARIANNA ADAMO;PIETRO POZZONI;ALESSANDRA ROMANO;PAOLO FERRARO;LUCHINO CHESSA","5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;3;3;3;3","KHALID AL‐RASADI;ALESSANDRA ROMANO;GIUSEPPE TARANTINI;ANTONIO L. BARTORELLI;MATTEO MONTORFANO;ANTONIO POPOLO RUBBIO;PAOLO DENTI;CORRADO TAMBURINO;FRANCESCO DE FELICE;ANNALISA MONGIARDO;FRANCESCO BEDOGNI;ARTURO GIORDANO;EMMANUEL VILLA;DESIREE BRANCATO;FRANCESCA BRUNO;CONCETTA FEDERICO;SALVATORE SACCONE;DAIANA GALVANO;MARIELLA CARUSO;GIUSEPPE MUSUMECI","0.25;0.19;0.18;0.18;0.18;0.18;0.18;0.18;0.18;0.18;0.18;0.18;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.16","CORRADO TAMBURINO;GAETANO BERTINO;ALESSANDRA ROMANO;PASQUA BETTA;SALVATORE LEOTTA;FRANCESCO DI RAIMONDO;ROSAMARIA ROSSO;CARMELO GRASSO;E. FRAZZETTO;CARMINE MATTIA;ROSARIO FOTI;ANDREA SPADARO;ALESSANDRA QUOTA;MARIA CONVERSANO;M. TURCHETTA;HÉCTOR SOTO PARRÀ;ANGELO MARIA PATTI;MICHELE VECCHIO;GIULIA GIUFFRIDA;OMETTO FRANCESCA","5;4;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","ALESSANDRA ROMANO;CORRADO TAMBURINO;DAIANA GALVANO;MARIELLA CARUSO;ROSAMARIA ROSSO;FRANCESCO DI RAIMONDO;M. TURCHETTA;ANGELO MARIA PATTI;MARIO FALSAPERLA;SALVATORE LEOTTA;MARIA ANNA CONIGLIO;ALESSANDRA QUOTA;M. PETTINATO;PIERO PAVONE;MARIA TERESA CANNIZZARO;CARMELO MINARDI;ANDREA SPADARO;HÉCTOR SOTO PARRÀ;GIULIA GIUFFRIDA;GIUSEPPE MILONE","0.19;0.18;0.17;0.17;0.16;0.15;0.14;0.12;0.12;0.12;0.11;0.1;0.1;0.1;0.09;0.08;0.07;0.07;0.07;0.07","ALESSIA PEPE;ANNA SPASIANO;ANTONELLA MELONI;ANTONINO VALLONE;EMILIO QUAIA;FILIPPO CADEMARTIRI;GIUSEPPE PERITORE;KHALID AL‐RASADI;LAURA PISTOIA;LIANA CUCCIA;MARIA CATERINA PUTTI;MARIA RITA GAMBERINI;MASSIMO ALLÒ;PAOLO RICCHI;RICCARDO RIGHI;ROSAMARIA ROSSO;STEFANIA RENNE;VALERIO CECINATI;VINCENZO POSITANO;A SLESARCHUK OLGA","6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;6;3","ROSAMARIA ROSSO;ALESSANDRA ROMANO;AMATO GIORGIO;ANGELO MARIA PATTI;DAL BOSCO YLENIA;FOTI ROBERTA;FOTI ROSARIO;FRANCESCO DE LUCIA;FUSARO ENRICO;MARCHETTA ANTONIO;MARIA ANNA CONIGLIO;OMETTO FRANCESCA;ROVERA GUIDO;VISALLI ELISA;VITETTA ROSETTA;VOLPE ALESSANDRO;CORRADO TAMBURINO;MARIO FALSAPERLA;SALVATORE LEOTTA;CARMELO GRASSO","6;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;1","CORRADO TAMBURINO;PASQUA BETTA;ALESSANDRA ROMANO;CARMELO GRASSO;CARMINE MATTIA;FRANCESCO DI RAIMONDO;SALVATORE LEOTTA;AMATO GIORGIO;ANGELO MARIA PATTI;CARMELO MINARDI;DAL BOSCO YLENIA;FOTI ROBERTA;FOTI ROSARIO;FRANCESCO DE LUCIA;FUSARO ENRICO;MARCHETTA ANTONIO;MARIA ANNA CONIGLIO;MARIO FALSAPERLA;OMETTO FRANCESCA;ROSAMARIA ROSSO","5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PHILOSOPHY;SOCIOLOGY;CHEMISTRY;ENVIRONMENTAL SCIENCE;POLITICAL SCIENCE;PSYCHOLOGY","27;10;5;4;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;CARDIOLOGY;GASTROENTEROLOGY;ANESTHESIA;BIOCHEMISTRY;IMMUNOLOGY;ONCOLOGY;PATHOLOGY;PEDIATRICS;CANCER RESEARCH;CELL BIOLOGY;INTENSIVE CARE MEDICINE;LINGUISTICS;MECHANICAL ENGINEERING;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;QUANTUM MECHANICS;STATISTICS","20;11;6;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","MITRAL REGURGITATION;CONFIDENCE INTERVAL;DISEASE;GENE;HEART FAILURE;MECHANICAL VENTILATION;MITRAL VALVE;OBSTRUCTIVE SLEEP APNEA;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;ADVERSE EFFECT;CEREBRAL PALSY;FLOW CYTOMETRY;INTENSIVE CARE;NEONATAL INTENSIVE CARE UNIT;ODDS RATIO;PREGNANCY;PROSPECTIVE COHORT STUDY;RESPIRATORY DISTRESS;TRANSPLANTATION","5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","AGONIST;CONTINUOUS POSITIVE AIRWAY PRESSURE;MITRACLIP;MITRAL VALVE REPAIR;CHROMOSOME;EJECTION FRACTION;GESTATIONAL AGE;ALKALINE PHOSPHATASE;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AVASCULAR NECROSIS;BIRTH WEIGHT;BREAST CANCER;CHROMOSOMAL TRANSLOCATION;CROHN'S DISEASE;DEFERASIROX;DEFERIPRONE;DERMOEPIDERMAL JUNCTION;EZETIMIBE;FATTY LIVER;FRACTION OF INSPIRED OXYGEN;GENODERMATOSIS;GRANULATION TISSUE;HAEMATOPOIESIS;IMATINIB;IMMUNOPHENOTYPING;INFLAMMATORY BOWEL DISEASE;INSULIN RESISTANCE;INTRA-RATER RELIABILITY;INTRACLASS CORRELATION;K562 CELLS;LAMININ;LEGIONELLA;LEGIONELLA PNEUMOPHILA;LIVER TRANSPLANTATION;LOOP-MEDIATED ISOTHERMAL AMPLIFICATION;LOW BIRTH WEIGHT;MOVEMENT DISORDERS;NEPHRECTOMY;NEUROLOGICAL DISORDER;OPEN LABEL;PATIENT-REPORTED OUTCOME;PHENOTYPE;PLASMACYTOMA;RELIABILITY (SEMICONDUCTOR);ROBUSTNESS (EVOLUTION);SALVAGE THERAPY;SICKLE CELL ANEMIA;SPASTIC;TYPE 2 DIABETES;TYPE 2 DIABETES MELLITUS;TYROSINE KINASE;VIABILITY ASSAY","3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","OBETICHOLIC ACID;BRONCHOPULMONARY DYSPLASIA;FUNCTIONAL MITRAL REGURGITATION;CHROMOSOME ENGINEERING;CROHN DISEASE;CYTOGENETICS;DASATINIB;DIRECT BILIRUBIN;HEMATOPOIETIC STEM CELL;INFLAMMATORY BOWEL DISEASES;INTRAVENTRICULAR HEMORRHAGE;JUNCTIONAL EPIDERMOLYSIS BULLOSA (VETERINARY MEDICINE);KARYOTYPE;METASTATIC BREAST CANCER;MISSENSE MUTATION;NONALCOHOLIC FATTY LIVER DISEASE;PERIVENTRICULAR LEUKOMALACIA;RETINOPATHY OF PREMATURITY;SURFACTANT THERAPY;TRIPLE-NEGATIVE BREAST CANCER","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;TREATMENT OUTCOME;AGED;ITALY;ADULT;AGED, 80 AND OVER;CARDIAC CATHETERIZATION;HEART VALVE PROSTHESIS IMPLANTATION;INFANT, NEWBORN;MITRAL VALVE;MITRAL VALVE INSUFFICIENCY;PROSPECTIVE STUDIES;PULMONARY SURFACTANTS;RESPIRATORY DISTRESS SYNDROME, NEWBORN;CHILD, PRESCHOOL;CONTINUOUS POSITIVE AIRWAY PRESSURE;FOLLOW-UP STUDIES","19;12;7;6;6;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2","MANAGEMENT OF VALVULAR HEART DISEASE;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;ANESTHESIA AND SEDATION MANAGEMENT;ANKLE INJURIES AND DISORDERS IN SPORTS MEDICINE;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;GENOME EVOLUTION AND POLYPLOIDY IN PLANTS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATOCELLULAR CARCINOMA;IMPACT OF SPINAL DEFORMITY ON HEALTH AND FUNCTION;LYMPHOID NEOPLASMS;METASTATIC CARCINOMAS FROM LUNG AND BREAST;PAPER-BASED DIAGNOSTIC DEVICES;PATHOGENESIS AND TREATMENT OF OSTEONECROSIS","5;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TRANSCATHETER AORTIC-VALVE REPLACEMENT;MITRAL REGURGITATION;MITRACLIP;OBETICHOLIC ACID;PRIMARY SCLEROSING CHOLANGITIS;PROSTHETIC VALVES EVALUATION;BRONCHOPULMONARY DYSPLASIA;FUNCTIONAL MITRAL REGURGITATION;NONINVASIVE VENTILATION;POSITIVE END-EXPIRATORY PRESSURE;TREATMENT;ANKLE INJURIES;AUTOLOGOUS STEM-CELL TRANSPLANTATION;AVASCULAR NECROSIS;CARDIAC SURGERY RISK MODELS;CHROMOSOMAL REARRANGEMENT;CHROMOSOME DUPLICATION;CHROMOSOME ENGINEERING;CHRONIC INSTABILITY;CLIPPING (MORPHOLOGY)","5;4;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","VALVE REPAIR;MITRAL VALVE;BILIARY CHOLANGITIS;PRIMARY BILIARY;TRANSCATHETER MITRAL;OBETICHOLIC ACID;PRETERM NEONATES;RANDOMIZED CONTROLLED;REAL-WORLD DATA;STEM CELL;SURFACTANT ADMINISTRATION;TRANSCATHETER EDGE-TO-EDGE;UNDERGOING TRANSCATHETER;ABSTRACT PO--;ACID DRIVES;ACID-TREATED PATIENTS;ADVANCEDMETASTATIC TRIPLE-NEGATIVE;ALTERED GRANULATION;AMPLIFICATION FINAL;AMPLIFICATION-BASED KIT;ANALGESIA RESUSCITATION;ANESTHESIA ANALGESIA;ANKLE INSTABILITY;ANTITUMOR ACTIVITY;ARTHRITIS PATIENTS;AUTOLOGOUS STEM;AVASCULAR NECROSIS;BIOCHEMICAL ASPECTS;BIOCHEMICAL RESPONSE;BOWEL DISEASES","5;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SPASTIC PARESIS;MOVEMENT DISORDER;MOVEMENT DISORDERS;ADVANCED HF;MOTOR COMMAND;MOTOR NEURONAL;PATIENTS UNDERGOING;SPASTIC DYSTONIA;SURFACTANT ADMINISTRATION;HONG KONG;PRETERM INFANTS;SIGNIFICANT DIFFERENCES;SPASTIC MOVEMENT;SPASTIC MYOPATHY;SPINAL CORD;BOTULINUM TOXIN;EXCITATORY BRAINSTEM;HR CI;LEGIONELLA PNEUMOPHILA;MITRAL VALVE;MUSCLE EXTENSIBILITY;NEURONAL OVERACTIVITY;SPASTIC CO-CONTRACTION;STRETCH REFLEXES;SURVIVAL RATE;UNSTRETCHED POSITION;ANKLE INSTABILITY;ANTHROPOMETRIC MEASUREMENTS;BRAINSTEM DESCENDING;CONSULTING HONORARIA","15;11;11;6;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3",1,0.03,2,3,0,0,0,0,0,0,0,4,0,0,3,0,0,0,0,3,0,0,0,2,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
